#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Altered functional connectivity between sub-regions in the thalamus and cortex in schizophrenia patients measured by resting state BOLD fMRI at 7T
#Text=The thalamus is a small brain structure that relays neuronal signals between subcortical and cortical regions.
1-1	0-7	Altered	_	
1-2	8-18	functional	_	
1-3	19-31	connectivity	_	
1-4	32-39	between	_	
1-5	40-51	sub-regions	_	
1-6	52-54	in	_	
1-7	55-58	the	_	
1-8	59-67	thalamus	_	
1-9	68-71	and	_	
1-10	72-78	cortex	_	
1-11	79-81	in	_	
1-12	82-95	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-13	96-104	patients	_	
1-14	105-113	measured	_	
1-15	114-116	by	_	
1-16	117-124	resting	_	
1-17	125-130	state	_	
1-18	131-135	BOLD	_	
1-19	136-140	fMRI	_	
1-20	141-143	at	_	
1-21	144-146	7T	_	
1-22	147-150	The	_	
1-23	151-159	thalamus	_	
1-24	160-162	is	_	
1-25	163-164	a	_	
1-26	165-170	small	_	
1-27	171-176	brain	_	
1-28	177-186	structure	_	
1-29	187-191	that	_	
1-30	192-198	relays	_	
1-31	199-207	neuronal	_	
1-32	208-215	signals	_	
1-33	216-223	between	_	
1-34	224-235	subcortical	_	
1-35	236-239	and	_	
1-36	240-248	cortical	_	
1-37	249-256	regions	_	
1-38	256-257	.	_	

#Text=Abnormal thalamocortical connectivity in schizophrenia has been reported in previous studies using blood-oxygenation-level-dependent (BOLD) functional MRI (fMRI) performed at 3T.
2-1	258-266	Abnormal	_	
2-2	267-282	thalamocortical	_	
2-3	283-295	connectivity	_	
2-4	296-298	in	_	
2-5	299-312	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-6	313-316	has	_	
2-7	317-321	been	_	
2-8	322-330	reported	_	
2-9	331-333	in	_	
2-10	334-342	previous	_	
2-11	343-350	studies	_	
2-12	351-356	using	_	
2-13	357-390	blood-oxygenation-level-dependent	_	
2-14	391-392	(	_	
2-15	392-396	BOLD	_	
2-16	396-397	)	_	
2-17	398-408	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-18	409-412	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-19	413-414	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-20	414-418	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-21	418-419	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-22	420-429	performed	_	
2-23	430-432	at	_	
2-24	433-435	3T	_	
2-25	435-436	.	_	

#Text=However, anatomically the thalamus is not a single entity, but is subdivided into multiple distinct nuclei with different connections to various cortical regions.
3-1	437-444	However	_	
3-2	444-445	,	_	
3-3	446-458	anatomically	_	
3-4	459-462	the	_	
3-5	463-471	thalamus	_	
3-6	472-474	is	_	
3-7	475-478	not	_	
3-8	479-480	a	_	
3-9	481-487	single	_	
3-10	488-494	entity	_	
3-11	494-495	,	_	
3-12	496-499	but	_	
3-13	500-502	is	_	
3-14	503-513	subdivided	_	
3-15	514-518	into	_	
3-16	519-527	multiple	_	
3-17	528-536	distinct	_	
3-18	537-543	nuclei	_	
3-19	544-548	with	_	
3-20	549-558	different	_	
3-21	559-570	connections	_	
3-22	571-573	to	_	
3-23	574-581	various	_	
3-24	582-590	cortical	_	
3-25	591-598	regions	_	
3-26	598-599	.	_	

#Text=We sought to determine the potential benefit of using the enhanced sensitivity of BOLD fMRI at ultra-high magnetic field (7T) in exploring thalamo-cortical connectivity in schizophrenia based on subregions in the thalamus.
4-1	600-602	We	_	
4-2	603-609	sought	_	
4-3	610-612	to	_	
4-4	613-622	determine	_	
4-5	623-626	the	_	
4-6	627-636	potential	_	
4-7	637-644	benefit	_	
4-8	645-647	of	_	
4-9	648-653	using	_	
4-10	654-657	the	_	
4-11	658-666	enhanced	_	
4-12	667-678	sensitivity	_	
4-13	679-681	of	_	
4-14	682-686	BOLD	_	
4-15	687-691	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
4-16	692-694	at	_	
4-17	695-705	ultra-high	_	
4-18	706-714	magnetic	_	
4-19	715-720	field	_	
4-20	721-722	(	_	
4-21	722-724	7T	_	
4-22	724-725	)	_	
4-23	726-728	in	_	
4-24	729-738	exploring	_	
4-25	739-755	thalamo-cortical	_	
4-26	756-768	connectivity	_	
4-27	769-771	in	_	
4-28	772-785	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-29	786-791	based	_	
4-30	792-794	on	_	
4-31	795-805	subregions	_	
4-32	806-808	in	_	
4-33	809-812	the	_	
4-34	813-821	thalamus	_	
4-35	821-822	.	_	

#Text=Seeds placed in thalamic subregions of 14 patients and 14 matched controls were used to calculate whole-brain functional connectivity.
5-1	823-828	Seeds	_	
5-2	829-835	placed	_	
5-3	836-838	in	_	
5-4	839-847	thalamic	_	
5-5	848-858	subregions	_	
5-6	859-861	of	_	
5-7	862-864	14	_	
5-8	865-873	patients	_	
5-9	874-877	and	_	
5-10	878-880	14	_	
5-11	881-888	matched	_	
5-12	889-897	controls	_	
5-13	898-902	were	_	
5-14	903-907	used	_	
5-15	908-910	to	_	
5-16	911-920	calculate	_	
5-17	921-932	whole-brain	_	
5-18	933-943	functional	_	
5-19	944-956	connectivity	_	
5-20	956-957	.	_	

#Text=Our results demonstrate impaired thalamic connectivity to the prefrontal cortex and the cerebellum, but enhanced thalamic connectivity to the motor/sensory cortex in schizophrenia.
6-1	958-961	Our	_	
6-2	962-969	results	_	
6-3	970-981	demonstrate	_	
6-4	982-990	impaired	_	
6-5	991-999	thalamic	_	
6-6	1000-1012	connectivity	_	
6-7	1013-1015	to	_	
6-8	1016-1019	the	_	
6-9	1020-1030	prefrontal	_	
6-10	1031-1037	cortex	_	
6-11	1038-1041	and	_	
6-12	1042-1045	the	_	
6-13	1046-1056	cerebellum	_	
6-14	1056-1057	,	_	
6-15	1058-1061	but	_	
6-16	1062-1070	enhanced	_	
6-17	1071-1079	thalamic	_	
6-18	1080-1092	connectivity	_	
6-19	1093-1095	to	_	
6-20	1096-1099	the	_	
6-21	1100-1105	motor	_	
6-22	1105-1106	/	_	
6-23	1106-1113	sensory	_	
6-24	1114-1120	cortex	_	
6-25	1121-1123	in	_	
6-26	1124-1137	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
6-27	1137-1138	.	_	

#Text=This altered functional connectivity significantly correlated with disease duration in the patients.
7-1	1139-1143	This	_	
7-2	1144-1151	altered	_	
7-3	1152-1162	functional	_	
7-4	1163-1175	connectivity	_	
7-5	1176-1189	significantly	_	
7-6	1190-1200	correlated	_	
7-7	1201-1205	with	_	
7-8	1206-1213	disease	_	
7-9	1214-1222	duration	_	
7-10	1223-1225	in	_	
7-11	1226-1229	the	_	
7-12	1230-1238	patients	_	
7-13	1238-1239	.	_	

#Text=Remarkably, comparable effect sizes observed in previous 3T studies were detected in the current 7T study with a heterogeneous and much smaller cohort, providing evidence that ultra-high field fMRI may be a powerful tool for measuring functional connectivity abnormalities in schizophrenia.
8-1	1240-1250	Remarkably	_	
8-2	1250-1251	,	_	
8-3	1252-1262	comparable	_	
8-4	1263-1269	effect	_	
8-5	1270-1275	sizes	_	
8-6	1276-1284	observed	_	
8-7	1285-1287	in	_	
8-8	1288-1296	previous	_	
8-9	1297-1299	3T	_	
8-10	1300-1307	studies	_	
8-11	1308-1312	were	_	
8-12	1313-1321	detected	_	
8-13	1322-1324	in	_	
8-14	1325-1328	the	_	
8-15	1329-1336	current	_	
8-16	1337-1339	7T	_	
8-17	1340-1345	study	_	
8-18	1346-1350	with	_	
8-19	1351-1352	a	_	
8-20	1353-1366	heterogeneous	_	
8-21	1367-1370	and	_	
8-22	1371-1375	much	_	
8-23	1376-1383	smaller	_	
8-24	1384-1390	cohort	_	
8-25	1390-1391	,	_	
8-26	1392-1401	providing	_	
8-27	1402-1410	evidence	_	
8-28	1411-1415	that	_	
8-29	1416-1426	ultra-high	_	
8-30	1427-1432	field	_	
8-31	1433-1437	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
8-32	1438-1441	may	_	
8-33	1442-1444	be	_	
8-34	1445-1446	a	_	
8-35	1447-1455	powerful	_	
8-36	1456-1460	tool	_	
8-37	1461-1464	for	_	
8-38	1465-1474	measuring	_	
8-39	1475-1485	functional	_	
8-40	1486-1498	connectivity	_	
8-41	1499-1512	abnormalities	_	
8-42	1513-1515	in	_	
8-43	1516-1529	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
8-44	1529-1530	.	_	

#Text=Further investigation with a larger cohort is merited to validate the current findings.
9-1	1531-1538	Further	_	
9-2	1539-1552	investigation	_	
9-3	1553-1557	with	_	
9-4	1558-1559	a	_	
9-5	1560-1566	larger	_	
9-6	1567-1573	cohort	_	
9-7	1574-1576	is	_	
9-8	1577-1584	merited	_	
9-9	1585-1587	to	_	
9-10	1588-1596	validate	_	
9-11	1597-1600	the	_	
9-12	1601-1608	current	_	
9-13	1609-1617	findings	_	
9-14	1617-1618	.	_	

#Text=Introduction
#Text=The thalamus is an important deep gray matter structure that relays information between subcortical and cortical regions.
10-1	1619-1631	Introduction	_	
10-2	1632-1635	The	_	
10-3	1636-1644	thalamus	_	
10-4	1645-1647	is	_	
10-5	1648-1650	an	_	
10-6	1651-1660	important	_	
10-7	1661-1665	deep	_	
10-8	1666-1670	gray	_	
10-9	1671-1677	matter	_	
10-10	1678-1687	structure	_	
10-11	1688-1692	that	_	
10-12	1693-1699	relays	_	
10-13	1700-1711	information	_	
10-14	1712-1719	between	_	
10-15	1720-1731	subcortical	_	
10-16	1732-1735	and	_	
10-17	1736-1744	cortical	_	
10-18	1745-1752	regions	_	
10-19	1752-1753	.	_	

#Text=Altered thalamocortical connectivity has been reported in schizophrenia (SCZ).
11-1	1754-1761	Altered	_	
11-2	1762-1777	thalamocortical	_	
11-3	1778-1790	connectivity	_	
11-4	1791-1794	has	_	
11-5	1795-1799	been	_	
11-6	1800-1808	reported	_	
11-7	1809-1811	in	_	
11-8	1812-1825	schizophrenia	_	
11-9	1826-1827	(	_	
11-10	1827-1830	SCZ	_	
11-11	1830-1831	)	_	
11-12	1831-1832	.	_	

#Text=The thalamus can be subdivided into multiple distinct nuclei with different anatomical connections to various cortical regions.
12-1	1833-1836	The	_	
12-2	1837-1845	thalamus	_	
12-3	1846-1849	can	_	
12-4	1850-1852	be	_	
12-5	1853-1863	subdivided	_	
12-6	1864-1868	into	_	
12-7	1869-1877	multiple	_	
12-8	1878-1886	distinct	_	
12-9	1887-1893	nuclei	_	
12-10	1894-1898	with	_	
12-11	1899-1908	different	_	
12-12	1909-1919	anatomical	_	
12-13	1920-1931	connections	_	
12-14	1932-1934	to	_	
12-15	1935-1942	various	_	
12-16	1943-1951	cortical	_	
12-17	1952-1959	regions	_	
12-18	1959-1960	.	_	

#Text=To better assess the relationship between schizophrenia and thalamocortical connectivity, it is therefore critical to investigate the functional connectivity between sub-regions in the thalamus and the cortex, rather than averaging connectivity across the entire thalamus.
13-1	1961-1963	To	_	
13-2	1964-1970	better	_	
13-3	1971-1977	assess	_	
13-4	1978-1981	the	_	
13-5	1982-1994	relationship	_	
13-6	1995-2002	between	_	
13-7	2003-2016	schizophrenia	_	
13-8	2017-2020	and	_	
13-9	2021-2036	thalamocortical	_	
13-10	2037-2049	connectivity	_	
13-11	2049-2050	,	_	
13-12	2051-2053	it	_	
13-13	2054-2056	is	_	
13-14	2057-2066	therefore	_	
13-15	2067-2075	critical	_	
13-16	2076-2078	to	_	
13-17	2079-2090	investigate	_	
13-18	2091-2094	the	_	
13-19	2095-2105	functional	_	
13-20	2106-2118	connectivity	_	
13-21	2119-2126	between	_	
13-22	2127-2138	sub-regions	_	
13-23	2139-2141	in	_	
13-24	2142-2145	the	_	
13-25	2146-2154	thalamus	_	
13-26	2155-2158	and	_	
13-27	2159-2162	the	_	
13-28	2163-2169	cortex	_	
13-29	2169-2170	,	_	
13-30	2171-2177	rather	_	
13-31	2178-2182	than	_	
13-32	2183-2192	averaging	_	
13-33	2193-2205	connectivity	_	
13-34	2206-2212	across	_	
13-35	2213-2216	the	_	
13-36	2217-2223	entire	_	
13-37	2224-2232	thalamus	_	
13-38	2232-2233	.	_	

#Text=Indeed, findings using 3.0 Tesla (3T) MRI support a differential connectivity between specific subregions and the cortex.
14-1	2234-2240	Indeed	_	
14-2	2240-2241	,	_	
14-3	2242-2250	findings	_	
14-4	2251-2256	using	_	
14-5	2257-2260	3.0	_	
14-6	2261-2266	Tesla	_	
14-7	2267-2268	(	_	
14-8	2268-2270	3T	_	
14-9	2270-2271	)	_	
14-10	2272-2275	MRI	_	
14-11	2276-2283	support	_	
14-12	2284-2285	a	_	
14-13	2286-2298	differential	_	
14-14	2299-2311	connectivity	_	
14-15	2312-2319	between	_	
14-16	2320-2328	specific	_	
14-17	2329-2339	subregions	_	
14-18	2340-2343	and	_	
14-19	2344-2347	the	_	
14-20	2348-2354	cortex	_	
14-21	2354-2355	.	_	

#Text=As the sensitivity of blood-oxygenation-level dependent (BOLD) functional MRI (fMRI) is expected to show a supra-linear enhancement with field strength, ultra-high field (7.0 Tesla, or 7T, and beyond) BOLD fMRI provides a powerful tool for the investigation of the functional connectivity of these small sub-thalamic regions, potentially using much smaller sample sizes than are needed at 3T.
15-1	2356-2358	As	_	
15-2	2359-2362	the	_	
15-3	2363-2374	sensitivity	_	
15-4	2375-2377	of	_	
15-5	2378-2401	blood-oxygenation-level	_	
15-6	2402-2411	dependent	_	
15-7	2412-2413	(	_	
15-8	2413-2417	BOLD	_	
15-9	2417-2418	)	_	
15-10	2419-2429	functional	_	
15-11	2430-2433	MRI	_	
15-12	2434-2435	(	_	
15-13	2435-2439	fMRI	_	
15-14	2439-2440	)	_	
15-15	2441-2443	is	_	
15-16	2444-2452	expected	_	
15-17	2453-2455	to	_	
15-18	2456-2460	show	_	
15-19	2461-2462	a	_	
15-20	2463-2475	supra-linear	_	
15-21	2476-2487	enhancement	_	
15-22	2488-2492	with	_	
15-23	2493-2498	field	_	
15-24	2499-2507	strength	_	
15-25	2507-2508	,	_	
15-26	2509-2519	ultra-high	_	
15-27	2520-2525	field	_	
15-28	2526-2527	(	_	
15-29	2527-2530	7.0	_	
15-30	2531-2536	Tesla	_	
15-31	2536-2537	,	_	
15-32	2538-2540	or	_	
15-33	2541-2543	7T	_	
15-34	2543-2544	,	_	
15-35	2545-2548	and	_	
15-36	2549-2555	beyond	_	
15-37	2555-2556	)	_	
15-38	2557-2561	BOLD	_	
15-39	2562-2566	fMRI	_	
15-40	2567-2575	provides	_	
15-41	2576-2577	a	_	
15-42	2578-2586	powerful	_	
15-43	2587-2591	tool	_	
15-44	2592-2595	for	_	
15-45	2596-2599	the	_	
15-46	2600-2613	investigation	_	
15-47	2614-2616	of	_	
15-48	2617-2620	the	_	
15-49	2621-2631	functional	_	
15-50	2632-2644	connectivity	_	
15-51	2645-2647	of	_	
15-52	2648-2653	these	_	
15-53	2654-2659	small	_	
15-54	2660-2672	sub-thalamic	_	
15-55	2673-2680	regions	_	
15-56	2680-2681	,	_	
15-57	2682-2693	potentially	_	
15-58	2694-2699	using	_	
15-59	2700-2704	much	_	
15-60	2705-2712	smaller	_	
15-61	2713-2719	sample	_	
15-62	2720-2725	sizes	_	
15-63	2726-2730	than	_	
15-64	2731-2734	are	_	
15-65	2735-2741	needed	_	
15-66	2742-2744	at	_	
15-67	2745-2747	3T	_	
15-68	2747-2748	.	_	

#Text=Here, we test this hypothesis by using resting state BOLD fMRI at 7T in a group of schizophrenia patients and matched controls to measure functional connectivity between sub-regions in the thalamus defined by the Oxford thalamic connectivity atlas and the whole brain on a voxel-by-voxel basis.
16-1	2749-2753	Here	_	
16-2	2753-2754	,	_	
16-3	2755-2757	we	_	
16-4	2758-2762	test	_	
16-5	2763-2767	this	_	
16-6	2768-2778	hypothesis	_	
16-7	2779-2781	by	_	
16-8	2782-2787	using	_	
16-9	2788-2795	resting	_	
16-10	2796-2801	state	_	
16-11	2802-2806	BOLD	_	
16-12	2807-2811	fMRI	_	
16-13	2812-2814	at	_	
16-14	2815-2817	7T	_	
16-15	2818-2820	in	_	
16-16	2821-2822	a	_	
16-17	2823-2828	group	_	
16-18	2829-2831	of	_	
16-19	2832-2845	schizophrenia	_	
16-20	2846-2854	patients	_	
16-21	2855-2858	and	_	
16-22	2859-2866	matched	_	
16-23	2867-2875	controls	_	
16-24	2876-2878	to	_	
16-25	2879-2886	measure	_	
16-26	2887-2897	functional	_	
16-27	2898-2910	connectivity	_	
16-28	2911-2918	between	_	
16-29	2919-2930	sub-regions	_	
16-30	2931-2933	in	_	
16-31	2934-2937	the	_	
16-32	2938-2946	thalamus	_	
16-33	2947-2954	defined	_	
16-34	2955-2957	by	_	
16-35	2958-2961	the	_	
16-36	2962-2968	Oxford	_	
16-37	2969-2977	thalamic	_	
16-38	2978-2990	connectivity	_	
16-39	2991-2996	atlas	_	
16-40	2997-3000	and	_	
16-41	3001-3004	the	_	
16-42	3005-3010	whole	_	
16-43	3011-3016	brain	_	
16-44	3017-3019	on	_	
16-45	3020-3021	a	_	
16-46	3022-3036	voxel-by-voxel	_	
16-47	3037-3042	basis	_	
16-48	3042-3043	.	_	

#Text=Methods
#Text=Participants
#Text=Fourteen patients with a diagnosis of schizophrenia (n = 12) or schizoaffective (n = 2) disorder and fourteen age and sex matched normal controls were recruited and scanned following a Johns Hopkins Medicine Institutional Review Board approved protocol.
17-1	3044-3051	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
17-2	3052-3064	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-3	3065-3073	Fourteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-4	3074-3082	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-5	3083-3087	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-6	3088-3089	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-7	3090-3099	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-8	3100-3102	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-9	3103-3116	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
17-10	3117-3118	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-11	3118-3119	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-12	3120-3121	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-13	3122-3124	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-14	3124-3125	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-15	3126-3128	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-16	3129-3144	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[4]	
17-17	3145-3146	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-18	3146-3147	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-19	3148-3149	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-20	3150-3151	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-21	3151-3152	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-22	3153-3161	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-23	3162-3165	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-24	3166-3174	fourteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-25	3175-3178	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-26	3179-3182	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-27	3183-3186	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-28	3187-3194	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-29	3195-3201	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-30	3202-3210	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
17-31	3211-3215	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-32	3216-3225	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-33	3226-3229	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-34	3230-3237	scanned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-35	3238-3247	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-36	3248-3249	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-37	3250-3255	Johns	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-38	3256-3263	Hopkins	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-39	3264-3272	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-40	3273-3286	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-41	3287-3293	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-42	3294-3299	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-43	3300-3308	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-44	3309-3317	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
17-45	3317-3318	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=All participants gave written informed consent before scanning.
18-1	3319-3322	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
18-2	3323-3335	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
18-3	3336-3340	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
18-4	3341-3348	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
18-5	3349-3357	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
18-6	3358-3365	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
18-7	3366-3372	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
18-8	3373-3381	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
18-9	3381-3382	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=None of the subjects had other neurologic history or neurological signs on exam, or a history of vascular diseases.
19-1	3383-3387	None	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-2	3388-3390	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-3	3391-3394	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-4	3395-3403	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-5	3404-3407	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-6	3408-3413	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-7	3414-3424	neurologic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-8	3425-3432	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-9	3433-3435	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-10	3436-3448	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-11	3449-3454	signs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-12	3455-3457	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-13	3458-3462	exam	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-14	3462-3463	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-15	3464-3466	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-16	3467-3468	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-17	3469-3476	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-18	3477-3479	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-19	3480-3488	vascular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-20	3489-3497	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
19-21	3497-3498	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=As tobacco smoking could potentially affect baseline brain perfusion and thus the BOLD effect, current smoking status (cigarettes smoked per day) was determined for patients and controls.
20-1	3499-3501	As	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-2	3502-3509	tobacco	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-3	3510-3517	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-4	3518-3523	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-5	3524-3535	potentially	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-6	3536-3542	affect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-7	3543-3551	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-8	3552-3557	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-9	3558-3567	perfusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-10	3568-3571	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-11	3572-3576	thus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-12	3577-3580	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-13	3581-3585	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-14	3586-3592	effect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-15	3592-3593	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-16	3594-3601	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-17	3602-3609	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-18	3610-3616	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-19	3617-3618	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-20	3618-3628	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-21	3629-3635	smoked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-22	3636-3639	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-23	3640-3643	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-24	3643-3644	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-25	3645-3648	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-26	3649-3659	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-27	3660-3663	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-28	3664-3672	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-29	3673-3676	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-30	3677-3685	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
20-31	3685-3686	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=Current schizophrenia symptom severity was assessed with the Brief Psychiatric Rating Scale (BPRS).
21-1	3687-3694	Current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
21-2	3695-3708	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
21-3	3709-3716	symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
21-4	3717-3725	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
21-5	3726-3729	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
21-6	3730-3738	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
21-7	3739-3743	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
21-8	3744-3747	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
21-9	3748-3753	Brief	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[7]	
21-10	3754-3765	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[7]	
21-11	3766-3772	Rating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[7]	
21-12	3773-3778	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[7]	
21-13	3779-3780	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[7]	
21-14	3780-3784	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[7]	
21-15	3784-3785	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[7]	
21-16	3785-3786	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=Diagnosis was based on clinical records and clinical referrals at the point of ascertainment, and was confirmed by symptom evaluation on entry into the study.
22-1	3787-3796	Diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-2	3797-3800	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-3	3801-3806	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-4	3807-3809	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-5	3810-3818	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-6	3819-3826	records	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-7	3827-3830	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-8	3831-3839	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-9	3840-3849	referrals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-10	3850-3852	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-11	3853-3856	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-12	3857-3862	point	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-13	3863-3865	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-14	3866-3879	ascertainment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-15	3879-3880	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-16	3881-3884	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-17	3885-3888	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-18	3889-3898	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-19	3899-3901	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-20	3902-3909	symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-21	3910-3920	evaluation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-22	3921-3923	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-23	3924-3929	entry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-24	3930-3934	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-25	3935-3938	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-26	3939-3944	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
22-27	3944-3945	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=All patients, but none of the controls, were receiving antipsychotic medicines.
23-1	3946-3949	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-2	3950-3958	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-3	3958-3959	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-4	3960-3963	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-5	3964-3968	none	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-6	3969-3971	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-7	3972-3975	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-8	3976-3984	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-9	3984-3985	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-10	3986-3990	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-11	3991-4000	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-12	4001-4014	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-13	4015-4024	medicines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
23-14	4024-4025	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=Current chlorpromazine (CPZ) equivalents were used as a proxy for lifetime antipsychotic exposure.
24-1	4026-4033	Current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-2	4034-4048	chlorpromazine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-3	4049-4050	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-4	4050-4053	CPZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-5	4053-4054	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-6	4055-4066	equivalents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-7	4067-4071	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-8	4072-4076	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-9	4077-4079	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-10	4080-4081	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-11	4082-4087	proxy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-12	4088-4091	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-13	4092-4100	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-14	4101-4114	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-15	4115-4123	exposure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
24-16	4123-4124	.	_	

#Text=The Montreal Cognitive Assessment (MoCA) was performed on each participant on the day of scanning.
25-1	4125-4128	The	_	
25-2	4129-4137	Montreal	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[8]	
25-3	4138-4147	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[8]	
25-4	4148-4158	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[8]	
25-5	4159-4160	(	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[8]	
25-6	4160-4164	MoCA	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[8]	
25-7	4164-4165	)	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[8]	
25-8	4166-4169	was	_	
25-9	4170-4179	performed	_	
25-10	4180-4182	on	_	
25-11	4183-4187	each	_	
25-12	4188-4199	participant	_	
25-13	4200-4202	on	_	
25-14	4203-4206	the	_	
25-15	4207-4210	day	_	
25-16	4211-4213	of	_	
25-17	4214-4222	scanning	_	
25-18	4222-4223	.	_	

#Text=MRI
#Text=All scans were performed on a 7T Philips MRI scanner (Philips Healthcare, Best, The Netherlands).
26-1	4224-4227	MRI	_	
26-2	4228-4231	All	_	
26-3	4232-4237	scans	_	
26-4	4238-4242	were	_	
26-5	4243-4252	performed	_	
26-6	4253-4255	on	_	
26-7	4256-4257	a	_	
26-8	4258-4260	7T	_	
26-9	4261-4268	Philips	_	
26-10	4269-4272	MRI	_	
26-11	4273-4280	scanner	_	
26-12	4281-4282	(	_	
26-13	4282-4289	Philips	_	
26-14	4290-4300	Healthcare	_	
26-15	4300-4301	,	_	
26-16	4302-4306	Best	_	
26-17	4306-4307	,	_	
26-18	4308-4311	The	_	
26-19	4312-4323	Netherlands	_	
26-20	4323-4324	)	_	
26-21	4324-4325	.	_	

#Text=A 32-channel phased-array head coil (Nova Medical, Wilmington, MA) was used for RF reception and a head-only quadrature coil for transmit.
27-1	4326-4327	A	_	
27-2	4328-4330	32	_	
27-3	4330-4331	-	_	
27-4	4331-4338	channel	_	
27-5	4339-4351	phased-array	_	
27-6	4352-4356	head	_	
27-7	4357-4361	coil	_	
27-8	4362-4363	(	_	
27-9	4363-4367	Nova	_	
27-10	4368-4375	Medical	_	
27-11	4375-4376	,	_	
27-12	4377-4387	Wilmington	_	
27-13	4387-4388	,	_	
27-14	4389-4391	MA	_	
27-15	4391-4392	)	_	
27-16	4393-4396	was	_	
27-17	4397-4401	used	_	
27-18	4402-4405	for	_	
27-19	4406-4408	RF	_	
27-20	4409-4418	reception	_	
27-21	4419-4422	and	_	
27-22	4423-4424	a	_	
27-23	4425-4434	head-only	_	
27-24	4435-4445	quadrature	_	
27-25	4446-4450	coil	_	
27-26	4451-4454	for	_	
27-27	4455-4463	transmit	_	
27-28	4463-4464	.	_	

#Text=High-resolution anatomical images were acquired with a 3D magnetization prepared 2 rapid acquisition gradient echoes (MP2RAGE) sequence (voxel = 0.65 mm isotropic) to minimize B1 field inhomogeneity induced artifacts at 7T.
28-1	4465-4480	High-resolution	_	
28-2	4481-4491	anatomical	_	
28-3	4492-4498	images	_	
28-4	4499-4503	were	_	
28-5	4504-4512	acquired	_	
28-6	4513-4517	with	_	
28-7	4518-4519	a	_	
28-8	4520-4522	3D	_	
28-9	4523-4536	magnetization	_	
28-10	4537-4545	prepared	_	
28-11	4546-4547	2	_	
28-12	4548-4553	rapid	_	
28-13	4554-4565	acquisition	_	
28-14	4566-4574	gradient	_	
28-15	4575-4581	echoes	_	
28-16	4582-4583	(	_	
28-17	4583-4590	MP2RAGE	_	
28-18	4590-4591	)	_	
28-19	4592-4600	sequence	_	
28-20	4601-4602	(	_	
28-21	4602-4607	voxel	_	
28-22	4608-4609	=	_	
28-23	4610-4614	0.65	_	
28-24	4615-4617	mm	_	
28-25	4618-4627	isotropic	_	
28-26	4627-4628	)	_	
28-27	4629-4631	to	_	
28-28	4632-4640	minimize	_	
28-29	4641-4643	B1	_	
28-30	4644-4649	field	_	
28-31	4650-4663	inhomogeneity	_	
28-32	4664-4671	induced	_	
28-33	4672-4681	artifacts	_	
28-34	4682-4684	at	_	
28-35	4685-4687	7T	_	
28-36	4687-4688	.	_	

#Text=A resting state fMRI scan was performed with gradient echo (GRE) echo-planar imaging (EPI) (TR/TE/FA=2000/22ms/60°, voxel=2.5mm isotropic, 54 slices, 7 minutes) for each participant.
29-1	4689-4690	A	_	
29-2	4691-4698	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[9]	
29-3	4699-4704	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[9]	
29-4	4705-4709	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[9]	
29-5	4710-4714	scan	_	
29-6	4715-4718	was	_	
29-7	4719-4728	performed	_	
29-8	4729-4733	with	_	
29-9	4734-4742	gradient	_	
29-10	4743-4747	echo	_	
29-11	4748-4749	(	_	
29-12	4749-4752	GRE	_	
29-13	4752-4753	)	_	
29-14	4754-4765	echo-planar	_	
29-15	4766-4773	imaging	_	
29-16	4774-4775	(	_	
29-17	4775-4778	EPI	_	
29-18	4778-4779	)	_	
29-19	4780-4781	(	_	
29-20	4781-4783	TR	_	
29-21	4783-4784	/	_	
29-22	4784-4786	TE	_	
29-23	4786-4787	/	_	
29-24	4787-4789	FA	_	
29-25	4789-4790	=	_	
29-26	4790-4794	2000	_	
29-27	4794-4795	/	_	
29-28	4795-4799	22ms	_	
29-29	4799-4800	/	_	
29-30	4800-4802	60	_	
29-31	4802-4803	°	_	
29-32	4803-4804	,	_	
29-33	4805-4810	voxel	_	
29-34	4810-4811	=	_	
29-35	4811-4816	2.5mm	_	
29-36	4817-4826	isotropic	_	
29-37	4826-4827	,	_	
29-38	4828-4830	54	_	
29-39	4831-4837	slices	_	
29-40	4837-4838	,	_	
29-41	4839-4840	7	_	
29-42	4841-4848	minutes	_	
29-43	4848-4849	)	_	
29-44	4850-4853	for	_	
29-45	4854-4858	each	_	
29-46	4859-4870	participant	_	
29-47	4870-4871	.	_	

#Text=Data analysis
#Text=The statistical parametric mapping (SPM) software package (Version 8, Wellcome Trust Centre for Neuroimaging, London, United Kingdom; http://www.fil.ion.ucl.ac.uk/spm/) and in-house code programmed in Matlab (MathWorks, Natick, MA, USA) were used for image analysis.
30-1	4872-4876	Data	_	
30-2	4877-4885	analysis	_	
30-3	4886-4889	The	_	
30-4	4890-4901	statistical	_	
30-5	4902-4912	parametric	_	
30-6	4913-4920	mapping	_	
30-7	4921-4922	(	_	
30-8	4922-4925	SPM	_	
30-9	4925-4926	)	_	
30-10	4927-4935	software	_	
30-11	4936-4943	package	_	
30-12	4944-4945	(	_	
30-13	4945-4952	Version	_	
30-14	4953-4954	8	_	
30-15	4954-4955	,	_	
30-16	4956-4964	Wellcome	_	
30-17	4965-4970	Trust	_	
30-18	4971-4977	Centre	_	
30-19	4978-4981	for	_	
30-20	4982-4994	Neuroimaging	_	
30-21	4994-4995	,	_	
30-22	4996-5002	London	_	
30-23	5002-5003	,	_	
30-24	5004-5010	United	_	
30-25	5011-5018	Kingdom	_	
30-26	5018-5019	;	_	
30-27	5020-5024	http	_	
30-28	5024-5025	:	_	
30-29	5025-5026	/	_	
30-30	5026-5027	/	_	
30-31	5027-5048	www.fil.ion.ucl.ac.uk	_	
30-32	5048-5049	/	_	
30-33	5049-5052	spm	_	
30-34	5052-5053	/	_	
30-35	5053-5054	)	_	
30-36	5055-5058	and	_	
30-37	5059-5067	in-house	_	
30-38	5068-5072	code	_	
30-39	5073-5083	programmed	_	
30-40	5084-5086	in	_	
30-41	5087-5093	Matlab	_	
30-42	5094-5095	(	_	
30-43	5095-5104	MathWorks	_	
30-44	5104-5105	,	_	
30-45	5106-5112	Natick	_	
30-46	5112-5113	,	_	
30-47	5114-5116	MA	_	
30-48	5116-5117	,	_	
30-49	5118-5121	USA	_	
30-50	5121-5122	)	_	
30-51	5123-5127	were	_	
30-52	5128-5132	used	_	
30-53	5133-5136	for	_	
30-54	5137-5142	image	_	
30-55	5143-5151	analysis	_	
30-56	5151-5152	.	_	

#Text=Preprocessing included realignment, slice time correction, co-registration, segmentation, normalization; nuisance removal (CompCor), regression of global mean and motion parameters (6 rigid body motion correction parameters computed from the SPM realignment routine, and the first derivative of each parameter); and temporal filtering (0.01–0.1Hz).
31-1	5153-5166	Preprocessing	_	
31-2	5167-5175	included	_	
31-3	5176-5187	realignment	_	
31-4	5187-5188	,	_	
31-5	5189-5194	slice	_	
31-6	5195-5199	time	_	
31-7	5200-5210	correction	_	
31-8	5210-5211	,	_	
31-9	5212-5227	co-registration	_	
31-10	5227-5228	,	_	
31-11	5229-5241	segmentation	_	
31-12	5241-5242	,	_	
31-13	5243-5256	normalization	_	
31-14	5256-5257	;	_	
31-15	5258-5266	nuisance	_	
31-16	5267-5274	removal	_	
31-17	5275-5276	(	_	
31-18	5276-5283	CompCor	_	
31-19	5283-5284	)	_	
31-20	5284-5285	,	_	
31-21	5286-5296	regression	_	
31-22	5297-5299	of	_	
31-23	5300-5306	global	_	
31-24	5307-5311	mean	_	
31-25	5312-5315	and	_	
31-26	5316-5322	motion	_	
31-27	5323-5333	parameters	_	
31-28	5334-5335	(	_	
31-29	5335-5336	6	_	
31-30	5337-5342	rigid	_	
31-31	5343-5347	body	_	
31-32	5348-5354	motion	_	
31-33	5355-5365	correction	_	
31-34	5366-5376	parameters	_	
31-35	5377-5385	computed	_	
31-36	5386-5390	from	_	
31-37	5391-5394	the	_	
31-38	5395-5398	SPM	_	
31-39	5399-5410	realignment	_	
31-40	5411-5418	routine	_	
31-41	5418-5419	,	_	
31-42	5420-5423	and	_	
31-43	5424-5427	the	_	
31-44	5428-5433	first	_	
31-45	5434-5444	derivative	_	
31-46	5445-5447	of	_	
31-47	5448-5452	each	_	
31-48	5453-5462	parameter	_	
31-49	5462-5463	)	_	
31-50	5463-5464	;	_	
31-51	5465-5468	and	_	
31-52	5469-5477	temporal	_	
31-53	5478-5487	filtering	_	
31-54	5488-5489	(	_	
31-55	5489-5493	0.01	_	
31-56	5493-5494	–	_	
31-57	5494-5499	0.1Hz	_	
31-58	5499-5500	)	_	
31-59	5500-5501	.	_	

#Text=Given the emerging concerns that micro movements can affect between group differences in functional connectivity data even after standard motion correction procedures, we applied an additional “scrubbing” procedure described in previous works.
32-1	5502-5507	Given	_	
32-2	5508-5511	the	_	
32-3	5512-5520	emerging	_	
32-4	5521-5529	concerns	_	
32-5	5530-5534	that	_	
32-6	5535-5540	micro	_	
32-7	5541-5550	movements	_	
32-8	5551-5554	can	_	
32-9	5555-5561	affect	_	
32-10	5562-5569	between	_	
32-11	5570-5575	group	_	
32-12	5576-5587	differences	_	
32-13	5588-5590	in	_	
32-14	5591-5601	functional	_	
32-15	5602-5614	connectivity	_	
32-16	5615-5619	data	_	
32-17	5620-5624	even	_	
32-18	5625-5630	after	_	
32-19	5631-5639	standard	_	
32-20	5640-5646	motion	_	
32-21	5647-5657	correction	_	
32-22	5658-5668	procedures	_	
32-23	5668-5669	,	_	
32-24	5670-5672	we	_	
32-25	5673-5680	applied	_	
32-26	5681-5683	an	_	
32-27	5684-5694	additional	_	
32-28	5695-5696	“	_	
32-29	5696-5705	scrubbing	_	
32-30	5705-5706	”	_	
32-31	5707-5716	procedure	_	
32-32	5717-5726	described	_	
32-33	5727-5729	in	_	
32-34	5730-5738	previous	_	
32-35	5739-5744	works	_	
32-36	5744-5745	.	_	

#Text=Briefly, the 6 rigid body motion correction parameters were converted into the Framewise Displacement (FD) by summing the absolute value of the 3 differenced translational parameters and the 3 differenced rotational parameters.
33-1	5746-5753	Briefly	_	
33-2	5753-5754	,	_	
33-3	5755-5758	the	_	
33-4	5759-5760	6	_	
33-5	5761-5766	rigid	_	
33-6	5767-5771	body	_	
33-7	5772-5778	motion	_	
33-8	5779-5789	correction	_	
33-9	5790-5800	parameters	_	
33-10	5801-5805	were	_	
33-11	5806-5815	converted	_	
33-12	5816-5820	into	_	
33-13	5821-5824	the	_	
33-14	5825-5834	Framewise	_	
33-15	5835-5847	Displacement	_	
33-16	5848-5849	(	_	
33-17	5849-5851	FD	_	
33-18	5851-5852	)	_	
33-19	5853-5855	by	_	
33-20	5856-5863	summing	_	
33-21	5864-5867	the	_	
33-22	5868-5876	absolute	_	
33-23	5877-5882	value	_	
33-24	5883-5885	of	_	
33-25	5886-5889	the	_	
33-26	5890-5891	3	_	
33-27	5892-5903	differenced	_	
33-28	5904-5917	translational	_	
33-29	5918-5928	parameters	_	
33-30	5929-5932	and	_	
33-31	5933-5936	the	_	
33-32	5937-5938	3	_	
33-33	5939-5950	differenced	_	
33-34	5951-5961	rotational	_	
33-35	5962-5972	parameters	_	
33-36	5972-5973	.	_	

#Text=An FD threshold of .5 mm was used to identify potentially motion-contaminated scans, and one scan before and 2 scans after each of these scans above the FD threshold were excluded from further analysis.
34-1	5974-5976	An	_	
34-2	5977-5979	FD	_	
34-3	5980-5989	threshold	_	
34-4	5990-5992	of	_	
34-5	5993-5995	.5	_	
34-6	5996-5998	mm	_	
34-7	5999-6002	was	_	
34-8	6003-6007	used	_	
34-9	6008-6010	to	_	
34-10	6011-6019	identify	_	
34-11	6020-6031	potentially	_	
34-12	6032-6051	motion-contaminated	_	
34-13	6052-6057	scans	_	
34-14	6057-6058	,	_	
34-15	6059-6062	and	_	
34-16	6063-6066	one	_	
34-17	6067-6071	scan	_	
34-18	6072-6078	before	_	
34-19	6079-6082	and	_	
34-20	6083-6084	2	_	
34-21	6085-6090	scans	_	
34-22	6091-6096	after	_	
34-23	6097-6101	each	_	
34-24	6102-6104	of	_	
34-25	6105-6110	these	_	
34-26	6111-6116	scans	_	
34-27	6117-6122	above	_	
34-28	6123-6126	the	_	
34-29	6127-6129	FD	_	
34-30	6130-6139	threshold	_	
34-31	6140-6144	were	_	
34-32	6145-6153	excluded	_	
34-33	6154-6158	from	_	
34-34	6159-6166	further	_	
34-35	6167-6175	analysis	_	
34-36	6175-6176	.	_	

#Text=All analysis was also repeated without the global signal regression (GSR) step.
35-1	6177-6180	All	_	
35-2	6181-6189	analysis	_	
35-3	6190-6193	was	_	
35-4	6194-6198	also	_	
35-5	6199-6207	repeated	_	
35-6	6208-6215	without	_	
35-7	6216-6219	the	_	
35-8	6220-6226	global	_	
35-9	6227-6233	signal	_	
35-10	6234-6244	regression	_	
35-11	6245-6246	(	_	
35-12	6246-6249	GSR	_	
35-13	6249-6250	)	_	
35-14	6251-6255	step	_	
35-15	6255-6256	.	_	

#Text=To perform seed-based functional connectivity analysis between sub-thalamic regions and the brain, the Oxford thalamic connectivity atlas was employed.
36-1	6257-6259	To	_	
36-2	6260-6267	perform	_	
36-3	6268-6278	seed-based	_	
36-4	6279-6289	functional	_	
36-5	6290-6302	connectivity	_	
36-6	6303-6311	analysis	_	
36-7	6312-6319	between	_	
36-8	6320-6332	sub-thalamic	_	
36-9	6333-6340	regions	_	
36-10	6341-6344	and	_	
36-11	6345-6348	the	_	
36-12	6349-6354	brain	_	
36-13	6354-6355	,	_	
36-14	6356-6359	the	_	
36-15	6360-6366	Oxford	_	
36-16	6367-6375	thalamic	_	
36-17	6376-6388	connectivity	_	
36-18	6389-6394	atlas	_	
36-19	6395-6398	was	_	
36-20	6399-6407	employed	_	
36-21	6407-6408	.	_	

#Text=This atlas was generated using diffusion based structural connectivity in white matter between the thalamus and cortex, which segments the thalamus into seven sub-regions, with >25% probability of connection to seven exclusive cortical areas, respectively (Figure 1).
37-1	6409-6413	This	_	
37-2	6414-6419	atlas	_	
37-3	6420-6423	was	_	
37-4	6424-6433	generated	_	
37-5	6434-6439	using	_	
37-6	6440-6449	diffusion	_	
37-7	6450-6455	based	_	
37-8	6456-6466	structural	_	
37-9	6467-6479	connectivity	_	
37-10	6480-6482	in	_	
37-11	6483-6488	white	_	
37-12	6489-6495	matter	_	
37-13	6496-6503	between	_	
37-14	6504-6507	the	_	
37-15	6508-6516	thalamus	_	
37-16	6517-6520	and	_	
37-17	6521-6527	cortex	_	
37-18	6527-6528	,	_	
37-19	6529-6534	which	_	
37-20	6535-6543	segments	_	
37-21	6544-6547	the	_	
37-22	6548-6556	thalamus	_	
37-23	6557-6561	into	_	
37-24	6562-6567	seven	_	
37-25	6568-6579	sub-regions	_	
37-26	6579-6580	,	_	
37-27	6581-6585	with	_	
37-28	6586-6587	>	_	
37-29	6587-6590	25%	_	
37-30	6591-6602	probability	_	
37-31	6603-6605	of	_	
37-32	6606-6616	connection	_	
37-33	6617-6619	to	_	
37-34	6620-6625	seven	_	
37-35	6626-6635	exclusive	_	
37-36	6636-6644	cortical	_	
37-37	6645-6650	areas	_	
37-38	6650-6651	,	_	
37-39	6652-6664	respectively	_	
37-40	6665-6666	(	_	
37-41	6666-6672	Figure	_	
37-42	6673-6674	1	_	
37-43	6674-6675	)	_	
37-44	6675-6676	.	_	

#Text=Seed-based analysis was carried out using each thalamic sub-region as a seed, and whole brain connectivity maps (z values) to each seed were calculated.
38-1	6677-6687	Seed-based	_	
38-2	6688-6696	analysis	_	
38-3	6697-6700	was	_	
38-4	6701-6708	carried	_	
38-5	6709-6712	out	_	
38-6	6713-6718	using	_	
38-7	6719-6723	each	_	
38-8	6724-6732	thalamic	_	
38-9	6733-6743	sub-region	_	
38-10	6744-6746	as	_	
38-11	6747-6748	a	_	
38-12	6749-6753	seed	_	
38-13	6753-6754	,	_	
38-14	6755-6758	and	_	
38-15	6759-6764	whole	_	
38-16	6765-6770	brain	_	
38-17	6771-6783	connectivity	_	
38-18	6784-6788	maps	_	
38-19	6789-6790	(	_	
38-20	6790-6791	z	_	
38-21	6792-6798	values	_	
38-22	6798-6799	)	_	
38-23	6800-6802	to	_	
38-24	6803-6807	each	_	
38-25	6808-6812	seed	_	
38-26	6813-6817	were	_	
38-27	6818-6828	calculated	_	
38-28	6828-6829	.	_	

#Text=Second-level t-tests were performed to examine differential connectivity between schizophrenia patients and controls in the whole brain.
39-1	6830-6842	Second-level	_	
39-2	6843-6850	t-tests	_	
39-3	6851-6855	were	_	
39-4	6856-6865	performed	_	
39-5	6866-6868	to	_	
39-6	6869-6876	examine	_	
39-7	6877-6889	differential	_	
39-8	6890-6902	connectivity	_	
39-9	6903-6910	between	_	
39-10	6911-6924	schizophrenia	_	
39-11	6925-6933	patients	_	
39-12	6934-6937	and	_	
39-13	6938-6946	controls	_	
39-14	6947-6949	in	_	
39-15	6950-6953	the	_	
39-16	6954-6959	whole	_	
39-17	6960-6965	brain	_	
39-18	6965-6966	.	_	

#Text=Age, sex, smoking status, regional gray matter volume from anatomical scans, motion and differential motion parameters were all accounted for as covariates in the analysis.
40-1	6967-6970	Age	_	
40-2	6970-6971	,	_	
40-3	6972-6975	sex	_	
40-4	6975-6976	,	_	
40-5	6977-6984	smoking	_	
40-6	6985-6991	status	_	
40-7	6991-6992	,	_	
40-8	6993-7001	regional	_	
40-9	7002-7006	gray	_	
40-10	7007-7013	matter	_	
40-11	7014-7020	volume	_	
40-12	7021-7025	from	_	
40-13	7026-7036	anatomical	_	
40-14	7037-7042	scans	_	
40-15	7042-7043	,	_	
40-16	7044-7050	motion	_	
40-17	7051-7054	and	_	
40-18	7055-7067	differential	_	
40-19	7068-7074	motion	_	
40-20	7075-7085	parameters	_	
40-21	7086-7090	were	_	
40-22	7091-7094	all	_	
40-23	7095-7104	accounted	_	
40-24	7105-7108	for	_	
40-25	7109-7111	as	_	
40-26	7112-7122	covariates	_	
40-27	7123-7125	in	_	
40-28	7126-7129	the	_	
40-29	7130-7138	analysis	_	
40-30	7138-7139	.	_	

#Text=Significant clusters of decreased or increased thalamic connectivity were identified using threshold-free cluster enhancement.
41-1	7140-7151	Significant	_	
41-2	7152-7160	clusters	_	
41-3	7161-7163	of	_	
41-4	7164-7173	decreased	_	
41-5	7174-7176	or	_	
41-6	7177-7186	increased	_	
41-7	7187-7195	thalamic	_	
41-8	7196-7208	connectivity	_	
41-9	7209-7213	were	_	
41-10	7214-7224	identified	_	
41-11	7225-7230	using	_	
41-12	7231-7245	threshold-free	_	
41-13	7246-7253	cluster	_	
41-14	7254-7265	enhancement	_	
41-15	7265-7266	.	_	

#Text=The IBASPM116 atlas (PickAtlas software, Wake Forest University, North Carolina, USA) was used to identify anatomical regions within the significant clusters (note that an anatomical region from the atlas may have both decreased or increased connectivity clusters in its sub-regions).
42-1	7267-7270	The	_	
42-2	7271-7280	IBASPM116	_	
42-3	7281-7286	atlas	_	
42-4	7287-7288	(	_	
42-5	7288-7297	PickAtlas	_	
42-6	7298-7306	software	_	
42-7	7306-7307	,	_	
42-8	7308-7312	Wake	_	
42-9	7313-7319	Forest	_	
42-10	7320-7330	University	_	
42-11	7330-7331	,	_	
42-12	7332-7337	North	_	
42-13	7338-7346	Carolina	_	
42-14	7346-7347	,	_	
42-15	7348-7351	USA	_	
42-16	7351-7352	)	_	
42-17	7353-7356	was	_	
42-18	7357-7361	used	_	
42-19	7362-7364	to	_	
42-20	7365-7373	identify	_	
42-21	7374-7384	anatomical	_	
42-22	7385-7392	regions	_	
42-23	7393-7399	within	_	
42-24	7400-7403	the	_	
42-25	7404-7415	significant	_	
42-26	7416-7424	clusters	_	
42-27	7425-7426	(	_	
42-28	7426-7430	note	_	
42-29	7431-7435	that	_	
42-30	7436-7438	an	_	
42-31	7439-7449	anatomical	_	
42-32	7450-7456	region	_	
42-33	7457-7461	from	_	
42-34	7462-7465	the	_	
42-35	7466-7471	atlas	_	
42-36	7472-7475	may	_	
42-37	7476-7480	have	_	
42-38	7481-7485	both	_	
42-39	7486-7495	decreased	_	
42-40	7496-7498	or	_	
42-41	7499-7508	increased	_	
42-42	7509-7521	connectivity	_	
42-43	7522-7530	clusters	_	
42-44	7531-7533	in	_	
42-45	7534-7537	its	_	
42-46	7538-7549	sub-regions	_	
42-47	7549-7550	)	_	
42-48	7550-7551	.	_	

#Text=Effect size was estimated with Cohen’s d.
43-1	7552-7558	Effect	_	
43-2	7559-7563	size	_	
43-3	7564-7567	was	_	
43-4	7568-7577	estimated	_	
43-5	7578-7582	with	_	
43-6	7583-7588	Cohen	_	
43-7	7588-7589	’	_	
43-8	7589-7590	s	_	
43-9	7591-7592	d	_	
43-10	7592-7593	.	_	

#Text=Correlations between thalamic connectivity and disease duration, antipsychotic medication dosage, BPRS and MoCA scores (including the total score and subscales for both BPRS and MoCA) were evaluated using adjusted R2 from linear regression.
44-1	7594-7606	Correlations	_	
44-2	7607-7614	between	_	
44-3	7615-7623	thalamic	_	
44-4	7624-7636	connectivity	_	
44-5	7637-7640	and	_	
44-6	7641-7648	disease	_	
44-7	7649-7657	duration	_	
44-8	7657-7658	,	_	
44-9	7659-7672	antipsychotic	_	
44-10	7673-7683	medication	_	
44-11	7684-7690	dosage	_	
44-12	7690-7691	,	_	
44-13	7692-7696	BPRS	_	
44-14	7697-7700	and	_	
44-15	7701-7705	MoCA	_	
44-16	7706-7712	scores	_	
44-17	7713-7714	(	_	
44-18	7714-7723	including	_	
44-19	7724-7727	the	_	
44-20	7728-7733	total	_	
44-21	7734-7739	score	_	
44-22	7740-7743	and	_	
44-23	7744-7753	subscales	_	
44-24	7754-7757	for	_	
44-25	7758-7762	both	_	
44-26	7763-7767	BPRS	_	
44-27	7768-7771	and	_	
44-28	7772-7776	MoCA	_	
44-29	7776-7777	)	_	
44-30	7778-7782	were	_	
44-31	7783-7792	evaluated	_	
44-32	7793-7798	using	_	
44-33	7799-7807	adjusted	_	
44-34	7808-7810	R2	_	
44-35	7811-7815	from	_	
44-36	7816-7822	linear	_	
44-37	7823-7833	regression	_	
44-38	7833-7834	.	_	

#Text=Note that for correlations between thalamic connectivity and disease duration, BPRS and MoCA scores, partial correlations were calculated with age, smoking status and medication dosage as covariates.
45-1	7835-7839	Note	_	
45-2	7840-7844	that	_	
45-3	7845-7848	for	_	
45-4	7849-7861	correlations	_	
45-5	7862-7869	between	_	
45-6	7870-7878	thalamic	_	
45-7	7879-7891	connectivity	_	
45-8	7892-7895	and	_	
45-9	7896-7903	disease	_	
45-10	7904-7912	duration	_	
45-11	7912-7913	,	_	
45-12	7914-7918	BPRS	_	
45-13	7919-7922	and	_	
45-14	7923-7927	MoCA	_	
45-15	7928-7934	scores	_	
45-16	7934-7935	,	_	
45-17	7936-7943	partial	_	
45-18	7944-7956	correlations	_	
45-19	7957-7961	were	_	
45-20	7962-7972	calculated	_	
45-21	7973-7977	with	_	
45-22	7978-7981	age	_	
45-23	7981-7982	,	_	
45-24	7983-7990	smoking	_	
45-25	7991-7997	status	_	
45-26	7998-8001	and	_	
45-27	8002-8012	medication	_	
45-28	8013-8019	dosage	_	
45-29	8020-8022	as	_	
45-30	8023-8033	covariates	_	
45-31	8033-8034	.	_	

#Text=Multiple comparisons in the correlation analysis (functional connectivity between the thalamus and multiple cortical regions) were corrected for with the false-discovery rate (adjusted P < 0.05).
46-1	8035-8043	Multiple	_	
46-2	8044-8055	comparisons	_	
46-3	8056-8058	in	_	
46-4	8059-8062	the	_	
46-5	8063-8074	correlation	_	
46-6	8075-8083	analysis	_	
46-7	8084-8085	(	_	
46-8	8085-8095	functional	_	
46-9	8096-8108	connectivity	_	
46-10	8109-8116	between	_	
46-11	8117-8120	the	_	
46-12	8121-8129	thalamus	_	
46-13	8130-8133	and	_	
46-14	8134-8142	multiple	_	
46-15	8143-8151	cortical	_	
46-16	8152-8159	regions	_	
46-17	8159-8160	)	_	
46-18	8161-8165	were	_	
46-19	8166-8175	corrected	_	
46-20	8176-8179	for	_	
46-21	8180-8184	with	_	
46-22	8185-8188	the	_	
46-23	8189-8204	false-discovery	_	
46-24	8205-8209	rate	_	
46-25	8210-8211	(	_	
46-26	8211-8219	adjusted	_	
46-27	8220-8221	P	_	
46-28	8222-8223	<	_	
46-29	8224-8228	0.05	_	
46-30	8228-8229	)	_	
46-31	8229-8230	.	_	

#Text=Results
#Text=Demographic information and clinical measures are shown in Table 1.
47-1	8231-8238	Results	_	
47-2	8239-8250	Demographic	_	
47-3	8251-8262	information	_	
47-4	8263-8266	and	_	
47-5	8267-8275	clinical	_	
47-6	8276-8284	measures	_	
47-7	8285-8288	are	_	
47-8	8289-8294	shown	_	
47-9	8295-8297	in	_	
47-10	8298-8303	Table	_	
47-11	8304-8305	1	_	
47-12	8305-8306	.	_	

#Text=Age and sex were matched between schizophrenia patients and control subjects (P > 0.1).
48-1	8307-8310	Age	_	
48-2	8311-8314	and	_	
48-3	8315-8318	sex	_	
48-4	8319-8323	were	_	
48-5	8324-8331	matched	_	
48-6	8332-8339	between	_	
48-7	8340-8353	schizophrenia	_	
48-8	8354-8362	patients	_	
48-9	8363-8366	and	_	
48-10	8367-8374	control	_	
48-11	8375-8383	subjects	_	
48-12	8384-8385	(	_	
48-13	8385-8386	P	_	
48-14	8387-8388	>	_	
48-15	8389-8392	0.1	_	
48-16	8392-8393	)	_	
48-17	8393-8394	.	_	

#Text=The average numbers of cigarettes smoked per day were comparable between the two groups.
49-1	8395-8398	The	_	
49-2	8399-8406	average	_	
49-3	8407-8414	numbers	_	
49-4	8415-8417	of	_	
49-5	8418-8428	cigarettes	_	
49-6	8429-8435	smoked	_	
49-7	8436-8439	per	_	
49-8	8440-8443	day	_	
49-9	8444-8448	were	_	
49-10	8449-8459	comparable	_	
49-11	8460-8467	between	_	
49-12	8468-8471	the	_	
49-13	8472-8475	two	_	
49-14	8476-8482	groups	_	
49-15	8482-8483	.	_	

#Text=Schizophrenia patients had significantly higher BPRS scores (P < 0.001), and slightly lower total MoCA scores (P < 0.05) compared to control subjects.
50-1	8484-8497	Schizophrenia	_	
50-2	8498-8506	patients	_	
50-3	8507-8510	had	_	
50-4	8511-8524	significantly	_	
50-5	8525-8531	higher	_	
50-6	8532-8536	BPRS	_	
50-7	8537-8543	scores	_	
50-8	8544-8545	(	_	
50-9	8545-8546	P	_	
50-10	8547-8548	<	_	
50-11	8549-8554	0.001	_	
50-12	8554-8555	)	_	
50-13	8555-8556	,	_	
50-14	8557-8560	and	_	
50-15	8561-8569	slightly	_	
50-16	8570-8575	lower	_	
50-17	8576-8581	total	_	
50-18	8582-8586	MoCA	_	
50-19	8587-8593	scores	_	
50-20	8594-8595	(	_	
50-21	8595-8596	P	_	
50-22	8597-8598	<	_	
50-23	8599-8603	0.05	_	
50-24	8603-8604	)	_	
50-25	8605-8613	compared	_	
50-26	8614-8616	to	_	
50-27	8617-8624	control	_	
50-28	8625-8633	subjects	_	
50-29	8633-8634	.	_	

#Text=No significant differences were found in motion parameters derived from the SPM realignment routine between the two groups (data not shown).
51-1	8635-8637	No	_	
51-2	8638-8649	significant	_	
51-3	8650-8661	differences	_	
51-4	8662-8666	were	_	
51-5	8667-8672	found	_	
51-6	8673-8675	in	_	
51-7	8676-8682	motion	_	
51-8	8683-8693	parameters	_	
51-9	8694-8701	derived	_	
51-10	8702-8706	from	_	
51-11	8707-8710	the	_	
51-12	8711-8714	SPM	_	
51-13	8715-8726	realignment	_	
51-14	8727-8734	routine	_	
51-15	8735-8742	between	_	
51-16	8743-8746	the	_	
51-17	8747-8750	two	_	
51-18	8751-8757	groups	_	
51-19	8758-8759	(	_	
51-20	8759-8763	data	_	
51-21	8764-8767	not	_	
51-22	8768-8773	shown	_	
51-23	8773-8774	)	_	
51-24	8774-8775	.	_	

#Text=Tables 2 and 3 summarize the main findings in the group comparisons.
52-1	8776-8782	Tables	_	
52-2	8783-8784	2	_	
52-3	8785-8788	and	_	
52-4	8789-8790	3	_	
52-5	8791-8800	summarize	_	
52-6	8801-8804	the	_	
52-7	8805-8809	main	_	
52-8	8810-8818	findings	_	
52-9	8819-8821	in	_	
52-10	8822-8825	the	_	
52-11	8826-8831	group	_	
52-12	8832-8843	comparisons	_	
52-13	8843-8844	.	_	

#Text=Hyper-connectivity (Table 2) and hypo-connectivity (Table 3) between thalamic sub-regions and various cortical areas were detected in schizophrenia patients compared to controls, which include both primary targets and other regions (non-primary, shaded in Tables 2 and 3) of each seed.
53-1	8845-8863	Hyper-connectivity	_	
53-2	8864-8865	(	_	
53-3	8865-8870	Table	_	
53-4	8871-8872	2	_	
53-5	8872-8873	)	_	
53-6	8874-8877	and	_	
53-7	8878-8895	hypo-connectivity	_	
53-8	8896-8897	(	_	
53-9	8897-8902	Table	_	
53-10	8903-8904	3	_	
53-11	8904-8905	)	_	
53-12	8906-8913	between	_	
53-13	8914-8922	thalamic	_	
53-14	8923-8934	sub-regions	_	
53-15	8935-8938	and	_	
53-16	8939-8946	various	_	
53-17	8947-8955	cortical	_	
53-18	8956-8961	areas	_	
53-19	8962-8966	were	_	
53-20	8967-8975	detected	_	
53-21	8976-8978	in	_	
53-22	8979-8992	schizophrenia	_	
53-23	8993-9001	patients	_	
53-24	9002-9010	compared	_	
53-25	9011-9013	to	_	
53-26	9014-9022	controls	_	
53-27	9022-9023	,	_	
53-28	9024-9029	which	_	
53-29	9030-9037	include	_	
53-30	9038-9042	both	_	
53-31	9043-9050	primary	_	
53-32	9051-9058	targets	_	
53-33	9059-9062	and	_	
53-34	9063-9068	other	_	
53-35	9069-9076	regions	_	
53-36	9077-9078	(	_	
53-37	9078-9089	non-primary	_	
53-38	9089-9090	,	_	
53-39	9091-9097	shaded	_	
53-40	9098-9100	in	_	
53-41	9101-9107	Tables	_	
53-42	9108-9109	2	_	
53-43	9110-9113	and	_	
53-44	9114-9115	3	_	
53-45	9115-9116	)	_	
53-46	9117-9119	of	_	
53-47	9120-9124	each	_	
53-48	9125-9129	seed	_	
53-49	9129-9130	.	_	

#Text=Hyper-connectivity was observed between all thalamic sub-regions and the sensory/motor cortex and the temporal cortex.
54-1	9131-9149	Hyper-connectivity	_	
54-2	9150-9153	was	_	
54-3	9154-9162	observed	_	
54-4	9163-9170	between	_	
54-5	9171-9174	all	_	
54-6	9175-9183	thalamic	_	
54-7	9184-9195	sub-regions	_	
54-8	9196-9199	and	_	
54-9	9200-9203	the	_	
54-10	9204-9211	sensory	_	
54-11	9211-9212	/	_	
54-12	9212-9217	motor	_	
54-13	9218-9224	cortex	_	
54-14	9225-9228	and	_	
54-15	9229-9232	the	_	
54-16	9233-9241	temporal	_	
54-17	9242-9248	cortex	_	
54-18	9248-9249	.	_	

#Text=Hyper-connectivity to some regions in the parietal cortex was also detected from several thalamic sub-regions.
55-1	9250-9268	Hyper-connectivity	_	
55-2	9269-9271	to	_	
55-3	9272-9276	some	_	
55-4	9277-9284	regions	_	
55-5	9285-9287	in	_	
55-6	9288-9291	the	_	
55-7	9292-9300	parietal	_	
55-8	9301-9307	cortex	_	
55-9	9308-9311	was	_	
55-10	9312-9316	also	_	
55-11	9317-9325	detected	_	
55-12	9326-9330	from	_	
55-13	9331-9338	several	_	
55-14	9339-9347	thalamic	_	
55-15	9348-9359	sub-regions	_	
55-16	9359-9360	.	_	

#Text=Hypo-connectivity in schizophrenia patients was found between thalamic sub-regions and the frontal cortex, the cingulate cortex, the caudate and putamen, and the cerebellum.
56-1	9361-9378	Hypo-connectivity	_	
56-2	9379-9381	in	_	
56-3	9382-9395	schizophrenia	_	
56-4	9396-9404	patients	_	
56-5	9405-9408	was	_	
56-6	9409-9414	found	_	
56-7	9415-9422	between	_	
56-8	9423-9431	thalamic	_	
56-9	9432-9443	sub-regions	_	
56-10	9444-9447	and	_	
56-11	9448-9451	the	_	
56-12	9452-9459	frontal	_	
56-13	9460-9466	cortex	_	
56-14	9466-9467	,	_	
56-15	9468-9471	the	_	
56-16	9472-9481	cingulate	_	
56-17	9482-9488	cortex	_	
56-18	9488-9489	,	_	
56-19	9490-9493	the	_	
56-20	9494-9501	caudate	_	
56-21	9502-9505	and	_	
56-22	9506-9513	putamen	_	
56-23	9513-9514	,	_	
56-24	9515-9518	and	_	
56-25	9519-9522	the	_	
56-26	9523-9533	cerebellum	_	
56-27	9533-9534	.	_	

#Text=Most of these changes were detected in both hemispheres in corresponding regions, although the cluster sizes varied between the left and right hemispheres in some regions.
57-1	9535-9539	Most	_	
57-2	9540-9542	of	_	
57-3	9543-9548	these	_	
57-4	9549-9556	changes	_	
57-5	9557-9561	were	_	
57-6	9562-9570	detected	_	
57-7	9571-9573	in	_	
57-8	9574-9578	both	_	
57-9	9579-9590	hemispheres	_	
57-10	9591-9593	in	_	
57-11	9594-9607	corresponding	_	
57-12	9608-9615	regions	_	
57-13	9615-9616	,	_	
57-14	9617-9625	although	_	
57-15	9626-9629	the	_	
57-16	9630-9637	cluster	_	
57-17	9638-9643	sizes	_	
57-18	9644-9650	varied	_	
57-19	9651-9658	between	_	
57-20	9659-9662	the	_	
57-21	9663-9667	left	_	
57-22	9668-9671	and	_	
57-23	9672-9677	right	_	
57-24	9678-9689	hemispheres	_	
57-25	9690-9692	in	_	
57-26	9693-9697	some	_	
57-27	9698-9705	regions	_	
57-28	9705-9706	.	_	

#Text=Figure 2 displays the regions with significantly decreased or increased thalamic functional connectivity in schizophrenia patients compared to controls on MNI normalized anatomical images (significant regions from each sub-thalamic seed combined on the same figure).
58-1	9707-9713	Figure	_	
58-2	9714-9715	2	_	
58-3	9716-9724	displays	_	
58-4	9725-9728	the	_	
58-5	9729-9736	regions	_	
58-6	9737-9741	with	_	
58-7	9742-9755	significantly	_	
58-8	9756-9765	decreased	_	
58-9	9766-9768	or	_	
58-10	9769-9778	increased	_	
58-11	9779-9787	thalamic	_	
58-12	9788-9798	functional	_	
58-13	9799-9811	connectivity	_	
58-14	9812-9814	in	_	
58-15	9815-9828	schizophrenia	_	
58-16	9829-9837	patients	_	
58-17	9838-9846	compared	_	
58-18	9847-9849	to	_	
58-19	9850-9858	controls	_	
58-20	9859-9861	on	_	
58-21	9862-9865	MNI	_	
58-22	9866-9876	normalized	_	
58-23	9877-9887	anatomical	_	
58-24	9888-9894	images	_	
58-25	9895-9896	(	_	
58-26	9896-9907	significant	_	
58-27	9908-9915	regions	_	
58-28	9916-9920	from	_	
58-29	9921-9925	each	_	
58-30	9926-9938	sub-thalamic	_	
58-31	9939-9943	seed	_	
58-32	9944-9952	combined	_	
58-33	9953-9955	on	_	
58-34	9956-9959	the	_	
58-35	9960-9964	same	_	
58-36	9965-9971	figure	_	
58-37	9971-9972	)	_	
58-38	9972-9973	.	_	

#Text=Significant positive correlation was found between disease duration in schizophrenia patients and functional connectivity between the thalamus and the sensory/motor cortex (Figure 3).
59-1	9974-9985	Significant	_	
59-2	9986-9994	positive	_	
59-3	9995-10006	correlation	_	
59-4	10007-10010	was	_	
59-5	10011-10016	found	_	
59-6	10017-10024	between	_	
59-7	10025-10032	disease	_	
59-8	10033-10041	duration	_	
59-9	10042-10044	in	_	
59-10	10045-10058	schizophrenia	_	
59-11	10059-10067	patients	_	
59-12	10068-10071	and	_	
59-13	10072-10082	functional	_	
59-14	10083-10095	connectivity	_	
59-15	10096-10103	between	_	
59-16	10104-10107	the	_	
59-17	10108-10116	thalamus	_	
59-18	10117-10120	and	_	
59-19	10121-10124	the	_	
59-20	10125-10132	sensory	_	
59-21	10132-10133	/	_	
59-22	10133-10138	motor	_	
59-23	10139-10145	cortex	_	
59-24	10146-10147	(	_	
59-25	10147-10153	Figure	_	
59-26	10154-10155	3	_	
59-27	10155-10156	)	_	
59-28	10156-10157	.	_	

#Text=Significant negative correlation was observed between disease duration and functional connectivity between the thalamus and the prefrontal cortex (Figure 3).
60-1	10158-10169	Significant	_	
60-2	10170-10178	negative	_	
60-3	10179-10190	correlation	_	
60-4	10191-10194	was	_	
60-5	10195-10203	observed	_	
60-6	10204-10211	between	_	
60-7	10212-10219	disease	_	
60-8	10220-10228	duration	_	
60-9	10229-10232	and	_	
60-10	10233-10243	functional	_	
60-11	10244-10256	connectivity	_	
60-12	10257-10264	between	_	
60-13	10265-10268	the	_	
60-14	10269-10277	thalamus	_	
60-15	10278-10281	and	_	
60-16	10282-10285	the	_	
60-17	10286-10296	prefrontal	_	
60-18	10297-10303	cortex	_	
60-19	10304-10305	(	_	
60-20	10305-10311	Figure	_	
60-21	10312-10313	3	_	
60-22	10313-10314	)	_	
60-23	10314-10315	.	_	

#Text=Age, smoking status and medication dosage were included as covariates in the correlation analysis.
61-1	10316-10319	Age	_	
61-2	10319-10320	,	_	
61-3	10321-10328	smoking	_	
61-4	10329-10335	status	_	
61-5	10336-10339	and	_	
61-6	10340-10350	medication	_	
61-7	10351-10357	dosage	_	
61-8	10358-10362	were	_	
61-9	10363-10371	included	_	
61-10	10372-10374	as	_	
61-11	10375-10385	covariates	_	
61-12	10386-10388	in	_	
61-13	10389-10392	the	_	
61-14	10393-10404	correlation	_	
61-15	10405-10413	analysis	_	
61-16	10413-10414	.	_	

#Text=Note that here all sub-thalamic regions that showed significant difference in functional connectivity with the sensory/motor or the prefrontal cortex in the group comparisons were combined (union) in the correlation analysis, as results from individual seed region did not survive the significance tests, possibly due to insufficient sensitivity.
62-1	10415-10419	Note	_	
62-2	10420-10424	that	_	
62-3	10425-10429	here	_	
62-4	10430-10433	all	_	
62-5	10434-10446	sub-thalamic	_	
62-6	10447-10454	regions	_	
62-7	10455-10459	that	_	
62-8	10460-10466	showed	_	
62-9	10467-10478	significant	_	
62-10	10479-10489	difference	_	
62-11	10490-10492	in	_	
62-12	10493-10503	functional	_	
62-13	10504-10516	connectivity	_	
62-14	10517-10521	with	_	
62-15	10522-10525	the	_	
62-16	10526-10533	sensory	_	
62-17	10533-10534	/	_	
62-18	10534-10539	motor	_	
62-19	10540-10542	or	_	
62-20	10543-10546	the	_	
62-21	10547-10557	prefrontal	_	
62-22	10558-10564	cortex	_	
62-23	10565-10567	in	_	
62-24	10568-10571	the	_	
62-25	10572-10577	group	_	
62-26	10578-10589	comparisons	_	
62-27	10590-10594	were	_	
62-28	10595-10603	combined	_	
62-29	10604-10605	(	_	
62-30	10605-10610	union	_	
62-31	10610-10611	)	_	
62-32	10612-10614	in	_	
62-33	10615-10618	the	_	
62-34	10619-10630	correlation	_	
62-35	10631-10639	analysis	_	
62-36	10639-10640	,	_	
62-37	10641-10643	as	_	
62-38	10644-10651	results	_	
62-39	10652-10656	from	_	
62-40	10657-10667	individual	_	
62-41	10668-10672	seed	_	
62-42	10673-10679	region	_	
62-43	10680-10683	did	_	
62-44	10684-10687	not	_	
62-45	10688-10695	survive	_	
62-46	10696-10699	the	_	
62-47	10700-10712	significance	_	
62-48	10713-10718	tests	_	
62-49	10718-10719	,	_	
62-50	10720-10728	possibly	_	
62-51	10729-10732	due	_	
62-52	10733-10735	to	_	
62-53	10736-10748	insufficient	_	
62-54	10749-10760	sensitivity	_	
62-55	10760-10761	.	_	

#Text=The disease durations of the fourteen patients included in this analysis can be split into two sub-groups with moderate (n = 8) or long (n = 6) disease duration.
63-1	10762-10765	The	_	
63-2	10766-10773	disease	_	
63-3	10774-10783	durations	_	
63-4	10784-10786	of	_	
63-5	10787-10790	the	_	
63-6	10791-10799	fourteen	_	
63-7	10800-10808	patients	_	
63-8	10809-10817	included	_	
63-9	10818-10820	in	_	
63-10	10821-10825	this	_	
63-11	10826-10834	analysis	_	
63-12	10835-10838	can	_	
63-13	10839-10841	be	_	
63-14	10842-10847	split	_	
63-15	10848-10852	into	_	
63-16	10853-10856	two	_	
63-17	10857-10867	sub-groups	_	
63-18	10868-10872	with	_	
63-19	10873-10881	moderate	_	
63-20	10882-10883	(	_	
63-21	10883-10884	n	_	
63-22	10885-10886	=	_	
63-23	10887-10888	8	_	
63-24	10888-10889	)	_	
63-25	10890-10892	or	_	
63-26	10893-10897	long	_	
63-27	10898-10899	(	_	
63-28	10899-10900	n	_	
63-29	10901-10902	=	_	
63-30	10903-10904	6	_	
63-31	10904-10905	)	_	
63-32	10906-10913	disease	_	
63-33	10914-10922	duration	_	
63-34	10922-10923	.	_	

#Text=However, the sample size of each sub-group was too small to detect significant differences between them.
64-1	10924-10931	However	_	
64-2	10931-10932	,	_	
64-3	10933-10936	the	_	
64-4	10937-10943	sample	_	
64-5	10944-10948	size	_	
64-6	10949-10951	of	_	
64-7	10952-10956	each	_	
64-8	10957-10966	sub-group	_	
64-9	10967-10970	was	_	
64-10	10971-10974	too	_	
64-11	10975-10980	small	_	
64-12	10981-10983	to	_	
64-13	10984-10990	detect	_	
64-14	10991-11002	significant	_	
64-15	11003-11014	differences	_	
64-16	11015-11022	between	_	
64-17	11023-11027	them	_	
64-18	11027-11028	.	_	

#Text=Functional connectivity did not significantly correlate with BPRS or MoCA scores (including subscales for both BPRS and MoCA), or antipsychotic medication dosage in schizophrenia patients.
65-1	11029-11039	Functional	_	
65-2	11040-11052	connectivity	_	
65-3	11053-11056	did	_	
65-4	11057-11060	not	_	
65-5	11061-11074	significantly	_	
65-6	11075-11084	correlate	_	
65-7	11085-11089	with	_	
65-8	11090-11094	BPRS	_	
65-9	11095-11097	or	_	
65-10	11098-11102	MoCA	_	
65-11	11103-11109	scores	_	
65-12	11110-11111	(	_	
65-13	11111-11120	including	_	
65-14	11121-11130	subscales	_	
65-15	11131-11134	for	_	
65-16	11135-11139	both	_	
65-17	11140-11144	BPRS	_	
65-18	11145-11148	and	_	
65-19	11149-11153	MoCA	_	
65-20	11153-11154	)	_	
65-21	11154-11155	,	_	
65-22	11156-11158	or	_	
65-23	11159-11172	antipsychotic	_	
65-24	11173-11183	medication	_	
65-25	11184-11190	dosage	_	
65-26	11191-11193	in	_	
65-27	11194-11207	schizophrenia	_	
65-28	11208-11216	patients	_	
65-29	11216-11217	.	_	

#Text=Functional connectivity between the thalamus and the sensory/motor cortex, and functional connectivity between the thalamus and the prefrontal cortex also showed significant negative correlation (Figure 4).
66-1	11218-11228	Functional	_	
66-2	11229-11241	connectivity	_	
66-3	11242-11249	between	_	
66-4	11250-11253	the	_	
66-5	11254-11262	thalamus	_	
66-6	11263-11266	and	_	
66-7	11267-11270	the	_	
66-8	11271-11278	sensory	_	
66-9	11278-11279	/	_	
66-10	11279-11284	motor	_	
66-11	11285-11291	cortex	_	
66-12	11291-11292	,	_	
66-13	11293-11296	and	_	
66-14	11297-11307	functional	_	
66-15	11308-11320	connectivity	_	
66-16	11321-11328	between	_	
66-17	11329-11332	the	_	
66-18	11333-11341	thalamus	_	
66-19	11342-11345	and	_	
66-20	11346-11349	the	_	
66-21	11350-11360	prefrontal	_	
66-22	11361-11367	cortex	_	
66-23	11368-11372	also	_	
66-24	11373-11379	showed	_	
66-25	11380-11391	significant	_	
66-26	11392-11400	negative	_	
66-27	11401-11412	correlation	_	
66-28	11413-11414	(	_	
66-29	11414-11420	Figure	_	
66-30	11421-11422	4	_	
66-31	11422-11423	)	_	
66-32	11423-11424	.	_	

#Text=Here, all sub-thalamic regions that showed significant difference in functional connectivity with the sensory/motor or the prefrontal cortex in the group comparisons were also combined as Figure 3.
67-1	11425-11429	Here	_	
67-2	11429-11430	,	_	
67-3	11431-11434	all	_	
67-4	11435-11447	sub-thalamic	_	
67-5	11448-11455	regions	_	
67-6	11456-11460	that	_	
67-7	11461-11467	showed	_	
67-8	11468-11479	significant	_	
67-9	11480-11490	difference	_	
67-10	11491-11493	in	_	
67-11	11494-11504	functional	_	
67-12	11505-11517	connectivity	_	
67-13	11518-11522	with	_	
67-14	11523-11526	the	_	
67-15	11527-11534	sensory	_	
67-16	11534-11535	/	_	
67-17	11535-11540	motor	_	
67-18	11541-11543	or	_	
67-19	11544-11547	the	_	
67-20	11548-11558	prefrontal	_	
67-21	11559-11565	cortex	_	
67-22	11566-11568	in	_	
67-23	11569-11572	the	_	
67-24	11573-11578	group	_	
67-25	11579-11590	comparisons	_	
67-26	11591-11595	were	_	
67-27	11596-11600	also	_	
67-28	11601-11609	combined	_	
67-29	11610-11612	as	_	
67-30	11613-11619	Figure	_	
67-31	11620-11621	3	_	
67-32	11621-11622	.	_	

#Text=The key findings including group differences and correlations remained significant when all analysis was repeated without global signal regression (GSR).
68-1	11623-11626	The	_	
68-2	11627-11630	key	_	
68-3	11631-11639	findings	_	
68-4	11640-11649	including	_	
68-5	11650-11655	group	_	
68-6	11656-11667	differences	_	
68-7	11668-11671	and	_	
68-8	11672-11684	correlations	_	
68-9	11685-11693	remained	_	
68-10	11694-11705	significant	_	
68-11	11706-11710	when	_	
68-12	11711-11714	all	_	
68-13	11715-11723	analysis	_	
68-14	11724-11727	was	_	
68-15	11728-11736	repeated	_	
68-16	11737-11744	without	_	
68-17	11745-11751	global	_	
68-18	11752-11758	signal	_	
68-19	11759-11769	regression	_	
68-20	11770-11771	(	_	
68-21	11771-11774	GSR	_	
68-22	11774-11775	)	_	
68-23	11775-11776	.	_	

#Text=The results without GSR are reported in Supplemental Tables S2 and S3.
69-1	11777-11780	The	_	
69-2	11781-11788	results	_	
69-3	11789-11796	without	_	
69-4	11797-11800	GSR	_	
69-5	11801-11804	are	_	
69-6	11805-11813	reported	_	
69-7	11814-11816	in	_	
69-8	11817-11829	Supplemental	_	
69-9	11830-11836	Tables	_	
69-10	11837-11839	S2	_	
69-11	11840-11843	and	_	
69-12	11844-11846	S3	_	
69-13	11846-11847	.	_	

#Text=Discussion
#Text=In this study, resting state BOLD fMRI was performed at 7T to examine functional connectivity between sub-thalamic regions and the other brain areas in schizophrenia patients.
70-1	11848-11858	Discussion	_	
70-2	11859-11861	In	_	
70-3	11862-11866	this	_	
70-4	11867-11872	study	_	
70-5	11872-11873	,	_	
70-6	11874-11881	resting	_	
70-7	11882-11887	state	_	
70-8	11888-11892	BOLD	_	
70-9	11893-11897	fMRI	_	
70-10	11898-11901	was	_	
70-11	11902-11911	performed	_	
70-12	11912-11914	at	_	
70-13	11915-11917	7T	_	
70-14	11918-11920	to	_	
70-15	11921-11928	examine	_	
70-16	11929-11939	functional	_	
70-17	11940-11952	connectivity	_	
70-18	11953-11960	between	_	
70-19	11961-11973	sub-thalamic	_	
70-20	11974-11981	regions	_	
70-21	11982-11985	and	_	
70-22	11986-11989	the	_	
70-23	11990-11995	other	_	
70-24	11996-12001	brain	_	
70-25	12002-12007	areas	_	
70-26	12008-12010	in	_	
70-27	12011-12024	schizophrenia	_	
70-28	12025-12033	patients	_	
70-29	12033-12034	.	_	

#Text=Our results showed impaired thalamic connectivity to the prefrontal cortex and the cerebellum, but enhanced thalamic connectivity to the motor/sensory cortex in schizophrenia.
71-1	12035-12038	Our	_	
71-2	12039-12046	results	_	
71-3	12047-12053	showed	_	
71-4	12054-12062	impaired	_	
71-5	12063-12071	thalamic	_	
71-6	12072-12084	connectivity	_	
71-7	12085-12087	to	_	
71-8	12088-12091	the	_	
71-9	12092-12102	prefrontal	_	
71-10	12103-12109	cortex	_	
71-11	12110-12113	and	_	
71-12	12114-12117	the	_	
71-13	12118-12128	cerebellum	_	
71-14	12128-12129	,	_	
71-15	12130-12133	but	_	
71-16	12134-12142	enhanced	_	
71-17	12143-12151	thalamic	_	
71-18	12152-12164	connectivity	_	
71-19	12165-12167	to	_	
71-20	12168-12171	the	_	
71-21	12172-12177	motor	_	
71-22	12177-12178	/	_	
71-23	12178-12185	sensory	_	
71-24	12186-12192	cortex	_	
71-25	12193-12195	in	_	
71-26	12196-12209	schizophrenia	_	
71-27	12209-12210	.	_	

#Text=The negative correlation between the hyper-connectivity in the thalamus-sensory/motor circuit and the hypo-connectivity in the thalamus-prefrontal circuit may imply a compensatory mechanism in the brain, where additional cortical regions are recruited to subserve functions that have been impaired due to the pathology of the disorder.
72-1	12211-12214	The	_	
72-2	12215-12223	negative	_	
72-3	12224-12235	correlation	_	
72-4	12236-12243	between	_	
72-5	12244-12247	the	_	
72-6	12248-12266	hyper-connectivity	_	
72-7	12267-12269	in	_	
72-8	12270-12273	the	_	
72-9	12274-12290	thalamus-sensory	_	
72-10	12290-12291	/	_	
72-11	12291-12296	motor	_	
72-12	12297-12304	circuit	_	
72-13	12305-12308	and	_	
72-14	12309-12312	the	_	
72-15	12313-12330	hypo-connectivity	_	
72-16	12331-12333	in	_	
72-17	12334-12337	the	_	
72-18	12338-12357	thalamus-prefrontal	_	
72-19	12358-12365	circuit	_	
72-20	12366-12369	may	_	
72-21	12370-12375	imply	_	
72-22	12376-12377	a	_	
72-23	12378-12390	compensatory	_	
72-24	12391-12400	mechanism	_	
72-25	12401-12403	in	_	
72-26	12404-12407	the	_	
72-27	12408-12413	brain	_	
72-28	12413-12414	,	_	
72-29	12415-12420	where	_	
72-30	12421-12431	additional	_	
72-31	12432-12440	cortical	_	
72-32	12441-12448	regions	_	
72-33	12449-12452	are	_	
72-34	12453-12462	recruited	_	
72-35	12463-12465	to	_	
72-36	12466-12474	subserve	_	
72-37	12475-12484	functions	_	
72-38	12485-12489	that	_	
72-39	12490-12494	have	_	
72-40	12495-12499	been	_	
72-41	12500-12508	impaired	_	
72-42	12509-12512	due	_	
72-43	12513-12515	to	_	
72-44	12516-12519	the	_	
72-45	12520-12529	pathology	_	
72-46	12530-12532	of	_	
72-47	12533-12536	the	_	
72-48	12537-12545	disorder	_	
72-49	12545-12546	.	_	

#Text=We also found significant correlations between altered functional connectivity and disease duration in the patients.
73-1	12547-12549	We	_	
73-2	12550-12554	also	_	
73-3	12555-12560	found	_	
73-4	12561-12572	significant	_	
73-5	12573-12585	correlations	_	
73-6	12586-12593	between	_	
73-7	12594-12601	altered	_	
73-8	12602-12612	functional	_	
73-9	12613-12625	connectivity	_	
73-10	12626-12629	and	_	
73-11	12630-12637	disease	_	
73-12	12638-12646	duration	_	
73-13	12647-12649	in	_	
73-14	12650-12653	the	_	
73-15	12654-12662	patients	_	
73-16	12662-12663	.	_	

#Text=Our main findings (altered thalamic connectivity to the cortex) in the current study are consistent with previous large scale studies conducted at 3T and lower fields.
74-1	12664-12667	Our	_	
74-2	12668-12672	main	_	
74-3	12673-12681	findings	_	
74-4	12682-12683	(	_	
74-5	12683-12690	altered	_	
74-6	12691-12699	thalamic	_	
74-7	12700-12712	connectivity	_	
74-8	12713-12715	to	_	
74-9	12716-12719	the	_	
74-10	12720-12726	cortex	_	
74-11	12726-12727	)	_	
74-12	12728-12730	in	_	
74-13	12731-12734	the	_	
74-14	12735-12742	current	_	
74-15	12743-12748	study	_	
74-16	12749-12752	are	_	
74-17	12753-12763	consistent	_	
74-18	12764-12768	with	_	
74-19	12769-12777	previous	_	
74-20	12778-12783	large	_	
74-21	12784-12789	scale	_	
74-22	12790-12797	studies	_	
74-23	12798-12807	conducted	_	
74-24	12808-12810	at	_	
74-25	12811-12813	3T	_	
74-26	12814-12817	and	_	
74-27	12818-12823	lower	_	
74-28	12824-12830	fields	_	
74-29	12830-12831	.	_	

#Text=In the present study, we were able to detect comparable effect sizes with a much smaller cohort (n = 14, as compared to n = 90 in and n = 222 in).
75-1	12832-12834	In	_	
75-2	12835-12838	the	_	
75-3	12839-12846	present	_	
75-4	12847-12852	study	_	
75-5	12852-12853	,	_	
75-6	12854-12856	we	_	
75-7	12857-12861	were	_	
75-8	12862-12866	able	_	
75-9	12867-12869	to	_	
75-10	12870-12876	detect	_	
75-11	12877-12887	comparable	_	
75-12	12888-12894	effect	_	
75-13	12895-12900	sizes	_	
75-14	12901-12905	with	_	
75-15	12906-12907	a	_	
75-16	12908-12912	much	_	
75-17	12913-12920	smaller	_	
75-18	12921-12927	cohort	_	
75-19	12928-12929	(	_	
75-20	12929-12930	n	_	
75-21	12931-12932	=	_	
75-22	12933-12935	14	_	
75-23	12935-12936	,	_	
75-24	12937-12939	as	_	
75-25	12940-12948	compared	_	
75-26	12949-12951	to	_	
75-27	12952-12953	n	_	
75-28	12954-12955	=	_	
75-29	12956-12958	90	_	
75-30	12959-12961	in	_	
75-31	12962-12965	and	_	
75-32	12966-12967	n	_	
75-33	12968-12969	=	_	
75-34	12970-12973	222	_	
75-35	12974-12976	in	_	
75-36	12976-12977	)	_	
75-37	12977-12978	.	_	

#Text=We attribute this primarily to the enhanced sensitivity of BOLD fMRI at higher magnetic field.
76-1	12979-12981	We	_	
76-2	12982-12991	attribute	_	
76-3	12992-12996	this	_	
76-4	12997-13006	primarily	_	
76-5	13007-13009	to	_	
76-6	13010-13013	the	_	
76-7	13014-13022	enhanced	_	
76-8	13023-13034	sensitivity	_	
76-9	13035-13037	of	_	
76-10	13038-13042	BOLD	_	
76-11	13043-13047	fMRI	_	
76-12	13048-13050	at	_	
76-13	13051-13057	higher	_	
76-14	13058-13066	magnetic	_	
76-15	13067-13072	field	_	
76-16	13072-13073	.	_	

#Text=We used the Oxford thalamic connectivity atlas to define the seed regions within the thalamus for the functional connectivity analysis in this study.
77-1	13074-13076	We	_	
77-2	13077-13081	used	_	
77-3	13082-13085	the	_	
77-4	13086-13092	Oxford	_	
77-5	13093-13101	thalamic	_	
77-6	13102-13114	connectivity	_	
77-7	13115-13120	atlas	_	
77-8	13121-13123	to	_	
77-9	13124-13130	define	_	
77-10	13131-13134	the	_	
77-11	13135-13139	seed	_	
77-12	13140-13147	regions	_	
77-13	13148-13154	within	_	
77-14	13155-13158	the	_	
77-15	13159-13167	thalamus	_	
77-16	13168-13171	for	_	
77-17	13172-13175	the	_	
77-18	13176-13186	functional	_	
77-19	13187-13199	connectivity	_	
77-20	13200-13208	analysis	_	
77-21	13209-13211	in	_	
77-22	13212-13216	this	_	
77-23	13217-13222	study	_	
77-24	13222-13223	.	_	

#Text=Each sub-region (seed) in this atlas has a primary anatomical connection based on a probability threshold of 25% calculated from diffusion MRI measures.
78-1	13224-13228	Each	_	
78-2	13229-13239	sub-region	_	
78-3	13240-13241	(	_	
78-4	13241-13245	seed	_	
78-5	13245-13246	)	_	
78-6	13247-13249	in	_	
78-7	13250-13254	this	_	
78-8	13255-13260	atlas	_	
78-9	13261-13264	has	_	
78-10	13265-13266	a	_	
78-11	13267-13274	primary	_	
78-12	13275-13285	anatomical	_	
78-13	13286-13296	connection	_	
78-14	13297-13302	based	_	
78-15	13303-13305	on	_	
78-16	13306-13307	a	_	
78-17	13308-13319	probability	_	
78-18	13320-13329	threshold	_	
78-19	13330-13332	of	_	
78-20	13333-13336	25%	_	
78-21	13337-13347	calculated	_	
78-22	13348-13352	from	_	
78-23	13353-13362	diffusion	_	
78-24	13363-13366	MRI	_	
78-25	13367-13375	measures	_	
78-26	13375-13376	.	_	

#Text=Therefore, many voxels within one sub-region can still have anatomical connections to brain regions other than their assigned primary target.
79-1	13377-13386	Therefore	_	
79-2	13386-13387	,	_	
79-3	13388-13392	many	_	
79-4	13393-13399	voxels	_	
79-5	13400-13406	within	_	
79-6	13407-13410	one	_	
79-7	13411-13421	sub-region	_	
79-8	13422-13425	can	_	
79-9	13426-13431	still	_	
79-10	13432-13436	have	_	
79-11	13437-13447	anatomical	_	
79-12	13448-13459	connections	_	
79-13	13460-13462	to	_	
79-14	13463-13468	brain	_	
79-15	13469-13476	regions	_	
79-16	13477-13482	other	_	
79-17	13483-13487	than	_	
79-18	13488-13493	their	_	
79-19	13494-13502	assigned	_	
79-20	13503-13510	primary	_	
79-21	13511-13517	target	_	
79-22	13517-13518	.	_	

#Text=This seems to be the case for functional connectivity as well.
80-1	13519-13523	This	_	
80-2	13524-13529	seems	_	
80-3	13530-13532	to	_	
80-4	13533-13535	be	_	
80-5	13536-13539	the	_	
80-6	13540-13544	case	_	
80-7	13545-13548	for	_	
80-8	13549-13559	functional	_	
80-9	13560-13572	connectivity	_	
80-10	13573-13575	as	_	
80-11	13576-13580	well	_	
80-12	13580-13581	.	_	

#Text=In our data, each thalamic sub-region also had functional connections to multiple brain areas other than its primary target.
81-1	13582-13584	In	_	
81-2	13585-13588	our	_	
81-3	13589-13593	data	_	
81-4	13593-13594	,	_	
81-5	13595-13599	each	_	
81-6	13600-13608	thalamic	_	
81-7	13609-13619	sub-region	_	
81-8	13620-13624	also	_	
81-9	13625-13628	had	_	
81-10	13629-13639	functional	_	
81-11	13640-13651	connections	_	
81-12	13652-13654	to	_	
81-13	13655-13663	multiple	_	
81-14	13664-13669	brain	_	
81-15	13670-13675	areas	_	
81-16	13676-13681	other	_	
81-17	13682-13686	than	_	
81-18	13687-13690	its	_	
81-19	13691-13698	primary	_	
81-20	13699-13705	target	_	
81-21	13705-13706	.	_	

#Text=Similar results have been reported in previous 3T studies.
82-1	13707-13714	Similar	_	
82-2	13715-13722	results	_	
82-3	13723-13727	have	_	
82-4	13728-13732	been	_	
82-5	13733-13741	reported	_	
82-6	13742-13744	in	_	
82-7	13745-13753	previous	_	
82-8	13754-13756	3T	_	
82-9	13757-13764	studies	_	
82-10	13764-13765	.	_	

#Text=Alternatively, data driven approaches can be carried out to segment the thalamus based on the functional connectivity to various brain regions.
83-1	13766-13779	Alternatively	_	
83-2	13779-13780	,	_	
83-3	13781-13785	data	_	
83-4	13786-13792	driven	_	
83-5	13793-13803	approaches	_	
83-6	13804-13807	can	_	
83-7	13808-13810	be	_	
83-8	13811-13818	carried	_	
83-9	13819-13822	out	_	
83-10	13823-13825	to	_	
83-11	13826-13833	segment	_	
83-12	13834-13837	the	_	
83-13	13838-13846	thalamus	_	
83-14	13847-13852	based	_	
83-15	13853-13855	on	_	
83-16	13856-13859	the	_	
83-17	13860-13870	functional	_	
83-18	13871-13883	connectivity	_	
83-19	13884-13886	to	_	
83-20	13887-13894	various	_	
83-21	13895-13900	brain	_	
83-22	13901-13908	regions	_	
83-23	13908-13909	.	_	

#Text=As such procedures typically require much larger sample size, they will be incorporated in our subsequent studies.
84-1	13910-13912	As	_	
84-2	13913-13917	such	_	
84-3	13918-13928	procedures	_	
84-4	13929-13938	typically	_	
84-5	13939-13946	require	_	
84-6	13947-13951	much	_	
84-7	13952-13958	larger	_	
84-8	13959-13965	sample	_	
84-9	13966-13970	size	_	
84-10	13970-13971	,	_	
84-11	13972-13976	they	_	
84-12	13977-13981	will	_	
84-13	13982-13984	be	_	
84-14	13985-13997	incorporated	_	
84-15	13998-14000	in	_	
84-16	14001-14004	our	_	
84-17	14005-14015	subsequent	_	
84-18	14016-14023	studies	_	
84-19	14023-14024	.	_	

#Text=The global signal regression (GSR) step in functional connectivity analysis may potentially confound group comparison results, as the magnitudes of the global brain signal may vary under different physiological and pathological conditions.
85-1	14025-14028	The	_	
85-2	14029-14035	global	_	
85-3	14036-14042	signal	_	
85-4	14043-14053	regression	_	
85-5	14054-14055	(	_	
85-6	14055-14058	GSR	_	
85-7	14058-14059	)	_	
85-8	14060-14064	step	_	
85-9	14065-14067	in	_	
85-10	14068-14078	functional	_	
85-11	14079-14091	connectivity	_	
85-12	14092-14100	analysis	_	
85-13	14101-14104	may	_	
85-14	14105-14116	potentially	_	
85-15	14117-14125	confound	_	
85-16	14126-14131	group	_	
85-17	14132-14142	comparison	_	
85-18	14143-14150	results	_	
85-19	14150-14151	,	_	
85-20	14152-14154	as	_	
85-21	14155-14158	the	_	
85-22	14159-14169	magnitudes	_	
85-23	14170-14172	of	_	
85-24	14173-14176	the	_	
85-25	14177-14183	global	_	
85-26	14184-14189	brain	_	
85-27	14190-14196	signal	_	
85-28	14197-14200	may	_	
85-29	14201-14205	vary	_	
85-30	14206-14211	under	_	
85-31	14212-14221	different	_	
85-32	14222-14235	physiological	_	
85-33	14236-14239	and	_	
85-34	14240-14252	pathological	_	
85-35	14253-14263	conditions	_	
85-36	14263-14264	.	_	

#Text=We therefore performed the same analysis with and without the GSR step in preprocessing.
86-1	14265-14267	We	_	
86-2	14268-14277	therefore	_	
86-3	14278-14287	performed	_	
86-4	14288-14291	the	_	
86-5	14292-14296	same	_	
86-6	14297-14305	analysis	_	
86-7	14306-14310	with	_	
86-8	14311-14314	and	_	
86-9	14315-14322	without	_	
86-10	14323-14326	the	_	
86-11	14327-14330	GSR	_	
86-12	14331-14335	step	_	
86-13	14336-14338	in	_	
86-14	14339-14352	preprocessing	_	
86-15	14352-14353	.	_	

#Text=Similar to reports in the literature, the results without GSR seemed to show somewhat less anti-correlations compared to results with GSR.
87-1	14354-14361	Similar	_	
87-2	14362-14364	to	_	
87-3	14365-14372	reports	_	
87-4	14373-14375	in	_	
87-5	14376-14379	the	_	
87-6	14380-14390	literature	_	
87-7	14390-14391	,	_	
87-8	14392-14395	the	_	
87-9	14396-14403	results	_	
87-10	14404-14411	without	_	
87-11	14412-14415	GSR	_	
87-12	14416-14422	seemed	_	
87-13	14423-14425	to	_	
87-14	14426-14430	show	_	
87-15	14431-14439	somewhat	_	
87-16	14440-14444	less	_	
87-17	14445-14462	anti-correlations	_	
87-18	14463-14471	compared	_	
87-19	14472-14474	to	_	
87-20	14475-14482	results	_	
87-21	14483-14487	with	_	
87-22	14488-14491	GSR	_	
87-23	14491-14492	.	_	

#Text=However, our main findings including the group level differences in functional connectivity and correlations were consistent between the two methods.
88-1	14493-14500	However	_	
88-2	14500-14501	,	_	
88-3	14502-14505	our	_	
88-4	14506-14510	main	_	
88-5	14511-14519	findings	_	
88-6	14520-14529	including	_	
88-7	14530-14533	the	_	
88-8	14534-14539	group	_	
88-9	14540-14545	level	_	
88-10	14546-14557	differences	_	
88-11	14558-14560	in	_	
88-12	14561-14571	functional	_	
88-13	14572-14584	connectivity	_	
88-14	14585-14588	and	_	
88-15	14589-14601	correlations	_	
88-16	14602-14606	were	_	
88-17	14607-14617	consistent	_	
88-18	14618-14625	between	_	
88-19	14626-14629	the	_	
88-20	14630-14633	two	_	
88-21	14634-14641	methods	_	
88-22	14641-14642	.	_	

#Text=Regional brain atrophy, which has been documented in schizophrenia, may be another potential confounding effect for the functional connectivity measures.
89-1	14643-14651	Regional	_	
89-2	14652-14657	brain	_	
89-3	14658-14665	atrophy	_	
89-4	14665-14666	,	_	
89-5	14667-14672	which	_	
89-6	14673-14676	has	_	
89-7	14677-14681	been	_	
89-8	14682-14692	documented	_	
89-9	14693-14695	in	_	
89-10	14696-14709	schizophrenia	_	
89-11	14709-14710	,	_	
89-12	14711-14714	may	_	
89-13	14715-14717	be	_	
89-14	14718-14725	another	_	
89-15	14726-14735	potential	_	
89-16	14736-14747	confounding	_	
89-17	14748-14754	effect	_	
89-18	14755-14758	for	_	
89-19	14759-14762	the	_	
89-20	14763-14773	functional	_	
89-21	14774-14786	connectivity	_	
89-22	14787-14795	measures	_	
89-23	14795-14796	.	_	

#Text=To rule out this confounding factor, we included gray matter volume derived from high resolution anatomical images as a covariate in group comparisons and correlation analyses in this study.
90-1	14797-14799	To	_	
90-2	14800-14804	rule	_	
90-3	14805-14808	out	_	
90-4	14809-14813	this	_	
90-5	14814-14825	confounding	_	
90-6	14826-14832	factor	_	
90-7	14832-14833	,	_	
90-8	14834-14836	we	_	
90-9	14837-14845	included	_	
90-10	14846-14850	gray	_	
90-11	14851-14857	matter	_	
90-12	14858-14864	volume	_	
90-13	14865-14872	derived	_	
90-14	14873-14877	from	_	
90-15	14878-14882	high	_	
90-16	14883-14893	resolution	_	
90-17	14894-14904	anatomical	_	
90-18	14905-14911	images	_	
90-19	14912-14914	as	_	
90-20	14915-14916	a	_	
90-21	14917-14926	covariate	_	
90-22	14927-14929	in	_	
90-23	14930-14935	group	_	
90-24	14936-14947	comparisons	_	
90-25	14948-14951	and	_	
90-26	14952-14963	correlation	_	
90-27	14964-14972	analyses	_	
90-28	14973-14975	in	_	
90-29	14976-14980	this	_	
90-30	14981-14986	study	_	
90-31	14986-14987	.	_	

#Text=Tobacco use is always more prevalent in schizophrenia patients than the general population, and chronic smoking may significantly alter brain functions.
91-1	14988-14995	Tobacco	_	
91-2	14996-14999	use	_	
91-3	15000-15002	is	_	
91-4	15003-15009	always	_	
91-5	15010-15014	more	_	
91-6	15015-15024	prevalent	_	
91-7	15025-15027	in	_	
91-8	15028-15041	schizophrenia	_	
91-9	15042-15050	patients	_	
91-10	15051-15055	than	_	
91-11	15056-15059	the	_	
91-12	15060-15067	general	_	
91-13	15068-15078	population	_	
91-14	15078-15079	,	_	
91-15	15080-15083	and	_	
91-16	15084-15091	chronic	_	
91-17	15092-15099	smoking	_	
91-18	15100-15103	may	_	
91-19	15104-15117	significantly	_	
91-20	15118-15123	alter	_	
91-21	15124-15129	brain	_	
91-22	15130-15139	functions	_	
91-23	15139-15140	.	_	

#Text=Therefore, most control subjects recruited for this study were regular smokers, in order to group match the schizophrenia patients.
92-1	15141-15150	Therefore	_	
92-2	15150-15151	,	_	
92-3	15152-15156	most	_	
92-4	15157-15164	control	_	
92-5	15165-15173	subjects	_	
92-6	15174-15183	recruited	_	
92-7	15184-15187	for	_	
92-8	15188-15192	this	_	
92-9	15193-15198	study	_	
92-10	15199-15203	were	_	
92-11	15204-15211	regular	_	
92-12	15212-15219	smokers	_	
92-13	15219-15220	,	_	
92-14	15221-15223	in	_	
92-15	15224-15229	order	_	
92-16	15230-15232	to	_	
92-17	15233-15238	group	_	
92-18	15239-15244	match	_	
92-19	15245-15248	the	_	
92-20	15249-15262	schizophrenia	_	
92-21	15263-15271	patients	_	
92-22	15271-15272	.	_	

#Text=The current smoking status of each study participant was recorded in cigarettes smoked per day, and the average numbers were comparable between controls and patients.
93-1	15273-15276	The	_	
93-2	15277-15284	current	_	
93-3	15285-15292	smoking	_	
93-4	15293-15299	status	_	
93-5	15300-15302	of	_	
93-6	15303-15307	each	_	
93-7	15308-15313	study	_	
93-8	15314-15325	participant	_	
93-9	15326-15329	was	_	
93-10	15330-15338	recorded	_	
93-11	15339-15341	in	_	
93-12	15342-15352	cigarettes	_	
93-13	15353-15359	smoked	_	
93-14	15360-15363	per	_	
93-15	15364-15367	day	_	
93-16	15367-15368	,	_	
93-17	15369-15372	and	_	
93-18	15373-15376	the	_	
93-19	15377-15384	average	_	
93-20	15385-15392	numbers	_	
93-21	15393-15397	were	_	
93-22	15398-15408	comparable	_	
93-23	15409-15416	between	_	
93-24	15417-15425	controls	_	
93-25	15426-15429	and	_	
93-26	15430-15438	patients	_	
93-27	15438-15439	.	_	

#Text=Moreover, smoking status was included as a covariate for all statistical analyses here.
94-1	15440-15448	Moreover	_	
94-2	15448-15449	,	_	
94-3	15450-15457	smoking	_	
94-4	15458-15464	status	_	
94-5	15465-15468	was	_	
94-6	15469-15477	included	_	
94-7	15478-15480	as	_	
94-8	15481-15482	a	_	
94-9	15483-15492	covariate	_	
94-10	15493-15496	for	_	
94-11	15497-15500	all	_	
94-12	15501-15512	statistical	_	
94-13	15513-15521	analyses	_	
94-14	15522-15526	here	_	
94-15	15526-15527	.	_	

#Text=Full exploration of the effects of smoking on functional connectivity will require a more detailed investigation, including more refined measures of cigarette exposure and a sample size sufficient to search for a dose-response relationship between smoking and measures of connectivity.
95-1	15528-15532	Full	_	
95-2	15533-15544	exploration	_	
95-3	15545-15547	of	_	
95-4	15548-15551	the	_	
95-5	15552-15559	effects	_	
95-6	15560-15562	of	_	
95-7	15563-15570	smoking	_	
95-8	15571-15573	on	_	
95-9	15574-15584	functional	_	
95-10	15585-15597	connectivity	_	
95-11	15598-15602	will	_	
95-12	15603-15610	require	_	
95-13	15611-15612	a	_	
95-14	15613-15617	more	_	
95-15	15618-15626	detailed	_	
95-16	15627-15640	investigation	_	
95-17	15640-15641	,	_	
95-18	15642-15651	including	_	
95-19	15652-15656	more	_	
95-20	15657-15664	refined	_	
95-21	15665-15673	measures	_	
95-22	15674-15676	of	_	
95-23	15677-15686	cigarette	_	
95-24	15687-15695	exposure	_	
95-25	15696-15699	and	_	
95-26	15700-15701	a	_	
95-27	15702-15708	sample	_	
95-28	15709-15713	size	_	
95-29	15714-15724	sufficient	_	
95-30	15725-15727	to	_	
95-31	15728-15734	search	_	
95-32	15735-15738	for	_	
95-33	15739-15740	a	_	
95-34	15741-15754	dose-response	_	
95-35	15755-15767	relationship	_	
95-36	15768-15775	between	_	
95-37	15776-15783	smoking	_	
95-38	15784-15787	and	_	
95-39	15788-15796	measures	_	
95-40	15797-15799	of	_	
95-41	15800-15812	connectivity	_	
95-42	15812-15813	.	_	

#Text=Note that the functional connectivity data in controls in the current study may also be different from normal subjects in other studies due to tobacco use.
96-1	15814-15818	Note	_	
96-2	15819-15823	that	_	
96-3	15824-15827	the	_	
96-4	15828-15838	functional	_	
96-5	15839-15851	connectivity	_	
96-6	15852-15856	data	_	
96-7	15857-15859	in	_	
96-8	15860-15868	controls	_	
96-9	15869-15871	in	_	
96-10	15872-15875	the	_	
96-11	15876-15883	current	_	
96-12	15884-15889	study	_	
96-13	15890-15893	may	_	
96-14	15894-15898	also	_	
96-15	15899-15901	be	_	
96-16	15902-15911	different	_	
96-17	15912-15916	from	_	
96-18	15917-15923	normal	_	
96-19	15924-15932	subjects	_	
96-20	15933-15935	in	_	
96-21	15936-15941	other	_	
96-22	15942-15949	studies	_	
96-23	15950-15953	due	_	
96-24	15954-15956	to	_	
96-25	15957-15964	tobacco	_	
96-26	15965-15968	use	_	
96-27	15968-15969	.	_	

#Text=Finally, an important caveat is that the patients, not controls, in this study were all receiving antipsychotic medicines.
97-1	15970-15977	Finally	_	
97-2	15977-15978	,	_	
97-3	15979-15981	an	_	
97-4	15982-15991	important	_	
97-5	15992-15998	caveat	_	
97-6	15999-16001	is	_	
97-7	16002-16006	that	_	
97-8	16007-16010	the	_	
97-9	16011-16019	patients	_	
97-10	16019-16020	,	_	
97-11	16021-16024	not	_	
97-12	16025-16033	controls	_	
97-13	16033-16034	,	_	
97-14	16035-16037	in	_	
97-15	16038-16042	this	_	
97-16	16043-16048	study	_	
97-17	16049-16053	were	_	
97-18	16054-16057	all	_	
97-19	16058-16067	receiving	_	
97-20	16068-16081	antipsychotic	_	
97-21	16082-16091	medicines	_	
97-22	16091-16092	.	_	

#Text=Several studies have shown that antipsychotic drugs and their therapeutic effect can restore and increase functional connectivity in the ventral tegmental area (midbrain), striatum, dorsal attention network, and hippocampus in schizophrenia patients.
98-1	16093-16100	Several	_	
98-2	16101-16108	studies	_	
98-3	16109-16113	have	_	
98-4	16114-16119	shown	_	
98-5	16120-16124	that	_	
98-6	16125-16138	antipsychotic	_	
98-7	16139-16144	drugs	_	
98-8	16145-16148	and	_	
98-9	16149-16154	their	_	
98-10	16155-16166	therapeutic	_	
98-11	16167-16173	effect	_	
98-12	16174-16177	can	_	
98-13	16178-16185	restore	_	
98-14	16186-16189	and	_	
98-15	16190-16198	increase	_	
98-16	16199-16209	functional	_	
98-17	16210-16222	connectivity	_	
98-18	16223-16225	in	_	
98-19	16226-16229	the	_	
98-20	16230-16237	ventral	_	
98-21	16238-16247	tegmental	_	
98-22	16248-16252	area	_	
98-23	16253-16254	(	_	
98-24	16254-16262	midbrain	_	
98-25	16262-16263	)	_	
98-26	16263-16264	,	_	
98-27	16265-16273	striatum	_	
98-28	16273-16274	,	_	
98-29	16275-16281	dorsal	_	
98-30	16282-16291	attention	_	
98-31	16292-16299	network	_	
98-32	16299-16300	,	_	
98-33	16301-16304	and	_	
98-34	16305-16316	hippocampus	_	
98-35	16317-16319	in	_	
98-36	16320-16333	schizophrenia	_	
98-37	16334-16342	patients	_	
98-38	16342-16343	.	_	

#Text=A further complication is that different pharmacological classes of antipsychotics may have different effects on brain function.
99-1	16344-16345	A	_	
99-2	16346-16353	further	_	
99-3	16354-16366	complication	_	
99-4	16367-16369	is	_	
99-5	16370-16374	that	_	
99-6	16375-16384	different	_	
99-7	16385-16400	pharmacological	_	
99-8	16401-16408	classes	_	
99-9	16409-16411	of	_	
99-10	16412-16426	antipsychotics	_	
99-11	16427-16430	may	_	
99-12	16431-16435	have	_	
99-13	16436-16445	different	_	
99-14	16446-16453	effects	_	
99-15	16454-16456	on	_	
99-16	16457-16462	brain	_	
99-17	16463-16471	function	_	
99-18	16471-16472	.	_	

#Text=In our data, no significant correlation was found between functional connectivity and medication dosage in patients; and medication dosage was included as a covariate when assessing correlations between functional connectivity and disease duration, BPRS and MOCA scores (including subscales).
100-1	16473-16475	In	_	
100-2	16476-16479	our	_	
100-3	16480-16484	data	_	
100-4	16484-16485	,	_	
100-5	16486-16488	no	_	
100-6	16489-16500	significant	_	
100-7	16501-16512	correlation	_	
100-8	16513-16516	was	_	
100-9	16517-16522	found	_	
100-10	16523-16530	between	_	
100-11	16531-16541	functional	_	
100-12	16542-16554	connectivity	_	
100-13	16555-16558	and	_	
100-14	16559-16569	medication	_	
100-15	16570-16576	dosage	_	
100-16	16577-16579	in	_	
100-17	16580-16588	patients	_	
100-18	16588-16589	;	_	
100-19	16590-16593	and	_	
100-20	16594-16604	medication	_	
100-21	16605-16611	dosage	_	
100-22	16612-16615	was	_	
100-23	16616-16624	included	_	
100-24	16625-16627	as	_	
100-25	16628-16629	a	_	
100-26	16630-16639	covariate	_	
100-27	16640-16644	when	_	
100-28	16645-16654	assessing	_	
100-29	16655-16667	correlations	_	
100-30	16668-16675	between	_	
100-31	16676-16686	functional	_	
100-32	16687-16699	connectivity	_	
100-33	16700-16703	and	_	
100-34	16704-16711	disease	_	
100-35	16712-16720	duration	_	
100-36	16720-16721	,	_	
100-37	16722-16726	BPRS	_	
100-38	16727-16730	and	_	
100-39	16731-16735	MOCA	_	
100-40	16736-16742	scores	_	
100-41	16743-16744	(	_	
100-42	16744-16753	including	_	
100-43	16754-16763	subscales	_	
100-44	16763-16764	)	_	
100-45	16764-16765	.	_	

#Text=Besides, decreased functional connectivity was found between the thalamus and the prefrontal cortex, and the cerebellum, whereas the studies mentioned above showed increased functional connectivity after antipsychotic drug administration.
101-1	16766-16773	Besides	_	
101-2	16773-16774	,	_	
101-3	16775-16784	decreased	_	
101-4	16785-16795	functional	_	
101-5	16796-16808	connectivity	_	
101-6	16809-16812	was	_	
101-7	16813-16818	found	_	
101-8	16819-16826	between	_	
101-9	16827-16830	the	_	
101-10	16831-16839	thalamus	_	
101-11	16840-16843	and	_	
101-12	16844-16847	the	_	
101-13	16848-16858	prefrontal	_	
101-14	16859-16865	cortex	_	
101-15	16865-16866	,	_	
101-16	16867-16870	and	_	
101-17	16871-16874	the	_	
101-18	16875-16885	cerebellum	_	
101-19	16885-16886	,	_	
101-20	16887-16894	whereas	_	
101-21	16895-16898	the	_	
101-22	16899-16906	studies	_	
101-23	16907-16916	mentioned	_	
101-24	16917-16922	above	_	
101-25	16923-16929	showed	_	
101-26	16930-16939	increased	_	
101-27	16940-16950	functional	_	
101-28	16951-16963	connectivity	_	
101-29	16964-16969	after	_	
101-30	16970-16983	antipsychotic	_	
101-31	16984-16988	drug	_	
101-32	16989-17003	administration	_	
101-33	17003-17004	.	_	

#Text=Future study is warranted to determine if abnormalities in functional connectivity are also presenting in unmedicated patients, and if antipsychotics differentially affect connectivity of specific brain regions.
102-1	17005-17011	Future	_	
102-2	17012-17017	study	_	
102-3	17018-17020	is	_	
102-4	17021-17030	warranted	_	
102-5	17031-17033	to	_	
102-6	17034-17043	determine	_	
102-7	17044-17046	if	_	
102-8	17047-17060	abnormalities	_	
102-9	17061-17063	in	_	
102-10	17064-17074	functional	_	
102-11	17075-17087	connectivity	_	
102-12	17088-17091	are	_	
102-13	17092-17096	also	_	
102-14	17097-17107	presenting	_	
102-15	17108-17110	in	_	
102-16	17111-17122	unmedicated	_	
102-17	17123-17131	patients	_	
102-18	17131-17132	,	_	
102-19	17133-17136	and	_	
102-20	17137-17139	if	_	
102-21	17140-17154	antipsychotics	_	
102-22	17155-17169	differentially	_	
102-23	17170-17176	affect	_	
102-24	17177-17189	connectivity	_	
102-25	17190-17192	of	_	
102-26	17193-17201	specific	_	
102-27	17202-17207	brain	_	
102-28	17208-17215	regions	_	
102-29	17215-17216	.	_	

#Text=The small sample size is a fundamental limitation of the current study.
103-1	17217-17220	The	_	
103-2	17221-17226	small	_	
103-3	17227-17233	sample	_	
103-4	17234-17238	size	_	
103-5	17239-17241	is	_	
103-6	17242-17243	a	_	
103-7	17244-17255	fundamental	_	
103-8	17256-17266	limitation	_	
103-9	17267-17269	of	_	
103-10	17270-17273	the	_	
103-11	17274-17281	current	_	
103-12	17282-17287	study	_	
103-13	17287-17288	.	_	

#Text=The heterogeneity of the study population (the patients can be split into two sub-groups with moderate (n = 8) or long (n = 6) disease duration) and differential effects of acute and chronic substance abuse other than tobacco may also confound the results of group comparisons and correlation analysis.
104-1	17289-17292	The	_	
104-2	17293-17306	heterogeneity	_	
104-3	17307-17309	of	_	
104-4	17310-17313	the	_	
104-5	17314-17319	study	_	
104-6	17320-17330	population	_	
104-7	17331-17332	(	_	
104-8	17332-17335	the	_	
104-9	17336-17344	patients	_	
104-10	17345-17348	can	_	
104-11	17349-17351	be	_	
104-12	17352-17357	split	_	
104-13	17358-17362	into	_	
104-14	17363-17366	two	_	
104-15	17367-17377	sub-groups	_	
104-16	17378-17382	with	_	
104-17	17383-17391	moderate	_	
104-18	17392-17393	(	_	
104-19	17393-17394	n	_	
104-20	17395-17396	=	_	
104-21	17397-17398	8	_	
104-22	17398-17399	)	_	
104-23	17400-17402	or	_	
104-24	17403-17407	long	_	
104-25	17408-17409	(	_	
104-26	17409-17410	n	_	
104-27	17411-17412	=	_	
104-28	17413-17414	6	_	
104-29	17414-17415	)	_	
104-30	17416-17423	disease	_	
104-31	17424-17432	duration	_	
104-32	17432-17433	)	_	
104-33	17434-17437	and	_	
104-34	17438-17450	differential	_	
104-35	17451-17458	effects	_	
104-36	17459-17461	of	_	
104-37	17462-17467	acute	_	
104-38	17468-17471	and	_	
104-39	17472-17479	chronic	_	
104-40	17480-17489	substance	_	
104-41	17490-17495	abuse	_	
104-42	17496-17501	other	_	
104-43	17502-17506	than	_	
104-44	17507-17514	tobacco	_	
104-45	17515-17518	may	_	
104-46	17519-17523	also	_	
104-47	17524-17532	confound	_	
104-48	17533-17536	the	_	
104-49	17537-17544	results	_	
104-50	17545-17547	of	_	
104-51	17548-17553	group	_	
104-52	17554-17565	comparisons	_	
104-53	17566-17569	and	_	
104-54	17570-17581	correlation	_	
104-55	17582-17590	analysis	_	
104-56	17590-17591	.	_	

#Text=Future studies with larger samples will be necessary to validate our findings, analyze additional clinical variables, and explore the relationship of thalamic anatomy and connectivity in further detail.
105-1	17592-17598	Future	_	
105-2	17599-17606	studies	_	
105-3	17607-17611	with	_	
105-4	17612-17618	larger	_	
105-5	17619-17626	samples	_	
105-6	17627-17631	will	_	
105-7	17632-17634	be	_	
105-8	17635-17644	necessary	_	
105-9	17645-17647	to	_	
105-10	17648-17656	validate	_	
105-11	17657-17660	our	_	
105-12	17661-17669	findings	_	
105-13	17669-17670	,	_	
105-14	17671-17678	analyze	_	
105-15	17679-17689	additional	_	
105-16	17690-17698	clinical	_	
105-17	17699-17708	variables	_	
105-18	17708-17709	,	_	
105-19	17710-17713	and	_	
105-20	17714-17721	explore	_	
105-21	17722-17725	the	_	
105-22	17726-17738	relationship	_	
105-23	17739-17741	of	_	
105-24	17742-17750	thalamic	_	
105-25	17751-17758	anatomy	_	
105-26	17759-17762	and	_	
105-27	17763-17775	connectivity	_	
105-28	17776-17778	in	_	
105-29	17779-17786	further	_	
105-30	17787-17793	detail	_	
105-31	17793-17794	.	_	

#Text=Conclusion
#Text=The enhanced sensitivity of BOLD fMRI at ultra-high field (7T) allowed the detection of altered functional connectivity between sub-regions in the thalamus and cortex in schizophrenia patients from a cohort much smaller compared to previous 3T studies.
106-1	17795-17805	Conclusion	_	
106-2	17806-17809	The	_	
106-3	17810-17818	enhanced	_	
106-4	17819-17830	sensitivity	_	
106-5	17831-17833	of	_	
106-6	17834-17838	BOLD	_	
106-7	17839-17843	fMRI	_	
106-8	17844-17846	at	_	
106-9	17847-17857	ultra-high	_	
106-10	17858-17863	field	_	
106-11	17864-17865	(	_	
106-12	17865-17867	7T	_	
106-13	17867-17868	)	_	
106-14	17869-17876	allowed	_	
106-15	17877-17880	the	_	
106-16	17881-17890	detection	_	
106-17	17891-17893	of	_	
106-18	17894-17901	altered	_	
106-19	17902-17912	functional	_	
106-20	17913-17925	connectivity	_	
106-21	17926-17933	between	_	
106-22	17934-17945	sub-regions	_	
106-23	17946-17948	in	_	
106-24	17949-17952	the	_	
106-25	17953-17961	thalamus	_	
106-26	17962-17965	and	_	
106-27	17966-17972	cortex	_	
106-28	17973-17975	in	_	
106-29	17976-17989	schizophrenia	_	
106-30	17990-17998	patients	_	
106-31	17999-18003	from	_	
106-32	18004-18005	a	_	
106-33	18006-18012	cohort	_	
106-34	18013-18017	much	_	
106-35	18018-18025	smaller	_	
106-36	18026-18034	compared	_	
106-37	18035-18037	to	_	
106-38	18038-18046	previous	_	
106-39	18047-18049	3T	_	
106-40	18050-18057	studies	_	
106-41	18057-18058	.	_	

#Text=Our results therefore support the further development of ultra-high field functional connectivity measures as biomarkers for therapeutic trials in schizophrenia, which could greatly benefit from the capacity to detect functional changes with fewer subjects.
107-1	18059-18062	Our	_	
107-2	18063-18070	results	_	
107-3	18071-18080	therefore	_	
107-4	18081-18088	support	_	
107-5	18089-18092	the	_	
107-6	18093-18100	further	_	
107-7	18101-18112	development	_	
107-8	18113-18115	of	_	
107-9	18116-18126	ultra-high	_	
107-10	18127-18132	field	_	
107-11	18133-18143	functional	_	
107-12	18144-18156	connectivity	_	
107-13	18157-18165	measures	_	
107-14	18166-18168	as	_	
107-15	18169-18179	biomarkers	_	
107-16	18180-18183	for	_	
107-17	18184-18195	therapeutic	_	
107-18	18196-18202	trials	_	
107-19	18203-18205	in	_	
107-20	18206-18219	schizophrenia	_	
107-21	18219-18220	,	_	
107-22	18221-18226	which	_	
107-23	18227-18232	could	_	
107-24	18233-18240	greatly	_	
107-25	18241-18248	benefit	_	
107-26	18249-18253	from	_	
107-27	18254-18257	the	_	
107-28	18258-18266	capacity	_	
107-29	18267-18269	to	_	
107-30	18270-18276	detect	_	
107-31	18277-18287	functional	_	
107-32	18288-18295	changes	_	
107-33	18296-18300	with	_	
107-34	18301-18306	fewer	_	
107-35	18307-18315	subjects	_	
107-36	18315-18316	.	_	

#Text=In addition, our data support further investigation into the potential value of using functional connectivity, as determined by ultra-high field methods, to track disease progression and evaluate therapeutic interventions at the level of individual patients.
108-1	18317-18319	In	_	
108-2	18320-18328	addition	_	
108-3	18328-18329	,	_	
108-4	18330-18333	our	_	
108-5	18334-18338	data	_	
108-6	18339-18346	support	_	
108-7	18347-18354	further	_	
108-8	18355-18368	investigation	_	
108-9	18369-18373	into	_	
108-10	18374-18377	the	_	
108-11	18378-18387	potential	_	
108-12	18388-18393	value	_	
108-13	18394-18396	of	_	
108-14	18397-18402	using	_	
108-15	18403-18413	functional	_	
108-16	18414-18426	connectivity	_	
108-17	18426-18427	,	_	
108-18	18428-18430	as	_	
108-19	18431-18441	determined	_	
108-20	18442-18444	by	_	
108-21	18445-18455	ultra-high	_	
108-22	18456-18461	field	_	
108-23	18462-18469	methods	_	
108-24	18469-18470	,	_	
108-25	18471-18473	to	_	
108-26	18474-18479	track	_	
108-27	18480-18487	disease	_	
108-28	18488-18499	progression	_	
108-29	18500-18503	and	_	
108-30	18504-18512	evaluate	_	
108-31	18513-18524	therapeutic	_	
108-32	18525-18538	interventions	_	
108-33	18539-18541	at	_	
108-34	18542-18545	the	_	
108-35	18546-18551	level	_	
108-36	18552-18554	of	_	
108-37	18555-18565	individual	_	
108-38	18566-18574	patients	_	
108-39	18574-18575	.	_	

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
109-1	18576-18589	Supplementary	_	
109-2	18590-18598	Material	_	
109-3	18599-18603	This	_	
109-4	18604-18606	is	_	
109-5	18607-18608	a	_	
109-6	18609-18612	PDF	_	
109-7	18613-18617	file	_	
109-8	18618-18620	of	_	
109-9	18621-18623	an	_	
109-10	18624-18632	unedited	_	
109-11	18633-18643	manuscript	_	
109-12	18644-18648	that	_	
109-13	18649-18652	has	_	
109-14	18653-18657	been	_	
109-15	18658-18666	accepted	_	
109-16	18667-18670	for	_	
109-17	18671-18682	publication	_	
109-18	18682-18683	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
110-1	18684-18686	As	_	
110-2	18687-18688	a	_	
110-3	18689-18696	service	_	
110-4	18697-18699	to	_	
110-5	18700-18703	our	_	
110-6	18704-18713	customers	_	
110-7	18714-18716	we	_	
110-8	18717-18720	are	_	
110-9	18721-18730	providing	_	
110-10	18731-18735	this	_	
110-11	18736-18741	early	_	
110-12	18742-18749	version	_	
110-13	18750-18752	of	_	
110-14	18753-18756	the	_	
110-15	18757-18767	manuscript	_	
110-16	18767-18768	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
111-1	18769-18772	The	_	
111-2	18773-18783	manuscript	_	
111-3	18784-18788	will	_	
111-4	18789-18796	undergo	_	
111-5	18797-18808	copyediting	_	
111-6	18808-18809	,	_	
111-7	18810-18821	typesetting	_	
111-8	18821-18822	,	_	
111-9	18823-18826	and	_	
111-10	18827-18833	review	_	
111-11	18834-18836	of	_	
111-12	18837-18840	the	_	
111-13	18841-18850	resulting	_	
111-14	18851-18856	proof	_	
111-15	18857-18863	before	_	
111-16	18864-18866	it	_	
111-17	18867-18869	is	_	
111-18	18870-18879	published	_	
111-19	18880-18882	in	_	
111-20	18883-18886	its	_	
111-21	18887-18892	final	_	
111-22	18893-18900	citable	_	
111-23	18901-18905	form	_	
111-24	18905-18906	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
112-1	18907-18913	Please	_	
112-2	18914-18918	note	_	
112-3	18919-18923	that	_	
112-4	18924-18930	during	_	
112-5	18931-18934	the	_	
112-6	18935-18945	production	_	
112-7	18946-18953	process	_	
112-8	18954-18960	errors	_	
112-9	18961-18964	may	_	
112-10	18965-18967	be	_	
112-11	18968-18978	discovered	_	
112-12	18979-18984	which	_	
112-13	18985-18990	could	_	
112-14	18991-18997	affect	_	
112-15	18998-19001	the	_	
112-16	19002-19009	content	_	
112-17	19009-19010	,	_	
112-18	19011-19014	and	_	
112-19	19015-19018	all	_	
112-20	19019-19024	legal	_	
112-21	19025-19036	disclaimers	_	
112-22	19037-19041	that	_	
112-23	19042-19047	apply	_	
112-24	19048-19050	to	_	
112-25	19051-19054	the	_	
112-26	19055-19062	journal	_	
112-27	19063-19070	pertain	_	
112-28	19070-19071	.	_	

#Text=Conflict of interest
#Text=Equipment used in the study was manufactured by Philips.
113-1	19072-19080	Conflict	_	
113-2	19081-19083	of	_	
113-3	19084-19092	interest	_	
113-4	19093-19102	Equipment	_	
113-5	19103-19107	used	_	
113-6	19108-19110	in	_	
113-7	19111-19114	the	_	
113-8	19115-19120	study	_	
113-9	19121-19124	was	_	
113-10	19125-19137	manufactured	_	
113-11	19138-19140	by	_	
113-12	19141-19148	Philips	_	
113-13	19148-19149	.	_	

#Text=Peter C.M. van Zijl receives grant support from Philips, is a paid lecturer for Philips, and is the inventor of technology that is licensed to Philips.
114-1	19150-19155	Peter	_	
114-2	19156-19159	C.M	_	
114-3	19159-19160	.	_	
114-4	19161-19164	van	_	
114-5	19165-19169	Zijl	_	
114-6	19170-19178	receives	_	
114-7	19179-19184	grant	_	
114-8	19185-19192	support	_	
114-9	19193-19197	from	_	
114-10	19198-19205	Philips	_	
114-11	19205-19206	,	_	
114-12	19207-19209	is	_	
114-13	19210-19211	a	_	
114-14	19212-19216	paid	_	
114-15	19217-19225	lecturer	_	
114-16	19226-19229	for	_	
114-17	19230-19237	Philips	_	
114-18	19237-19238	,	_	
114-19	19239-19242	and	_	
114-20	19243-19245	is	_	
114-21	19246-19249	the	_	
114-22	19250-19258	inventor	_	
114-23	19259-19261	of	_	
114-24	19262-19272	technology	_	
114-25	19273-19277	that	_	
114-26	19278-19280	is	_	
114-27	19281-19289	licensed	_	
114-28	19290-19292	to	_	
114-29	19293-19300	Philips	_	
114-30	19300-19301	.	_	

#Text=This arrangement has been approved by Johns Hopkins in accordance with its conflict of interest policies.
115-1	19302-19306	This	_	
115-2	19307-19318	arrangement	_	
115-3	19319-19322	has	_	
115-4	19323-19327	been	_	
115-5	19328-19336	approved	_	
115-6	19337-19339	by	_	
115-7	19340-19345	Johns	_	
115-8	19346-19353	Hopkins	_	
115-9	19354-19356	in	_	
115-10	19357-19367	accordance	_	
115-11	19368-19372	with	_	
115-12	19373-19376	its	_	
115-13	19377-19385	conflict	_	
115-14	19386-19388	of	_	
115-15	19389-19397	interest	_	
115-16	19398-19406	policies	_	
115-17	19406-19407	.	_	

#Text=Abbreviations:
#Text=3T
#Text=3.0 Tesla
#Text=7T
#Text=7.0 Tesla
#Text=SCZ
#Text=Schizophrenia
#Text=BOLD
#Text=Blood-oxygenation-level dependent
#Text=fMRI
#Text=Functional MRI
#Text=BPRS
#Text=Brief Psychiatric Rating Scale
#Text=MoCA
#Text=Montreal Cognitive Assessment
#Text=GRE
#Text=Gradient-echo
#Text=EPI
#Text=Echo-planar imaging
#Text=SPM
#Text=Statistical Parametric Mapping
#Text=GSR
#Text=Global signal regression
#Text=References
#Text=Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.
116-1	19408-19421	Abbreviations	_	
116-2	19421-19422	:	_	
116-3	19423-19425	3T	_	
116-4	19426-19429	3.0	_	
116-5	19430-19435	Tesla	_	
116-6	19436-19438	7T	_	
116-7	19439-19442	7.0	_	
116-8	19443-19448	Tesla	_	
116-9	19449-19452	SCZ	_	
116-10	19453-19466	Schizophrenia	_	
116-11	19467-19471	BOLD	_	
116-12	19472-19495	Blood-oxygenation-level	_	
116-13	19496-19505	dependent	_	
116-14	19506-19510	fMRI	_	
116-15	19511-19521	Functional	_	
116-16	19522-19525	MRI	_	
116-17	19526-19530	BPRS	_	
116-18	19531-19536	Brief	_	
116-19	19537-19548	Psychiatric	_	
116-20	19549-19555	Rating	_	
116-21	19556-19561	Scale	_	
116-22	19562-19566	MoCA	_	
116-23	19567-19575	Montreal	_	
116-24	19576-19585	Cognitive	_	
116-25	19586-19596	Assessment	_	
116-26	19597-19600	GRE	_	
116-27	19601-19614	Gradient-echo	_	
116-28	19615-19618	EPI	_	
116-29	19619-19630	Echo-planar	_	
116-30	19631-19638	imaging	_	
116-31	19639-19642	SPM	_	
116-32	19643-19654	Statistical	_	
116-33	19655-19665	Parametric	_	
116-34	19666-19673	Mapping	_	
116-35	19674-19677	GSR	_	
116-36	19678-19684	Global	_	
116-37	19685-19691	signal	_	
116-38	19692-19702	regression	_	
116-39	19703-19713	References	_	
116-40	19714-19727	Antipsychotic	_	
116-41	19728-19732	dose	_	
116-42	19733-19744	equivalents	_	
116-43	19745-19748	and	_	
116-44	19749-19759	dose-years	_	
116-45	19759-19760	:	_	
116-46	19761-19762	a	_	
116-47	19763-19775	standardized	_	
116-48	19776-19782	method	_	
116-49	19783-19786	for	_	
116-50	19787-19796	comparing	_	
116-51	19797-19805	exposure	_	
116-52	19806-19808	to	_	
116-53	19809-19818	different	_	
116-54	19819-19824	drugs	_	
116-55	19824-19825	.	_	

#Text=Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness.
117-1	19826-19840	Characterizing	_	
117-2	19841-19857	thalamo-cortical	_	
117-3	19858-19870	disturbances	_	
117-4	19871-19873	in	_	
117-5	19874-19887	schizophrenia	_	
117-6	19888-19891	and	_	
117-7	19892-19899	bipolar	_	
117-8	19900-19907	illness	_	
117-9	19907-19908	.	_	

#Text=Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk.
118-1	19909-19920	Association	_	
118-2	19921-19923	of	_	
118-3	19924-19932	Thalamic	_	
118-4	19933-19948	Dysconnectivity	_	
118-5	19949-19952	and	_	
118-6	19953-19963	Conversion	_	
118-7	19964-19966	to	_	
118-8	19967-19976	Psychosis	_	
118-9	19977-19979	in	_	
118-10	19980-19985	Youth	_	
118-11	19986-19989	and	_	
118-12	19990-19995	Young	_	
118-13	19996-20002	Adults	_	
118-14	20003-20005	at	_	
118-15	20006-20014	Elevated	_	
118-16	20015-20023	Clinical	_	
118-17	20024-20028	Risk	_	
118-18	20028-20029	.	_	

#Text=Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging.
119-1	20030-20042	Non-invasive	_	
119-2	20043-20050	mapping	_	
119-3	20051-20053	of	_	
119-4	20054-20065	connections	_	
119-5	20066-20073	between	_	
119-6	20074-20079	human	_	
119-7	20080-20088	thalamus	_	
119-8	20089-20092	and	_	
119-9	20093-20099	cortex	_	
119-10	20100-20105	using	_	
119-11	20106-20115	diffusion	_	
119-12	20116-20123	imaging	_	
119-13	20123-20124	.	_	

#Text=Characterization and propagation of uncertainty in diffusion-weighted MR imaging.
120-1	20125-20141	Characterization	_	
120-2	20142-20145	and	_	
120-3	20146-20157	propagation	_	
120-4	20158-20160	of	_	
120-5	20161-20172	uncertainty	_	
120-6	20173-20175	in	_	
120-7	20176-20194	diffusion-weighted	_	
120-8	20195-20197	MR	_	
120-9	20198-20205	imaging	_	
120-10	20205-20206	.	_	

#Text=Thalamus and posterior temporal lobe show greater inter-network connectivity at rest and across sensory paradigms in schizophrenia.
121-1	20207-20215	Thalamus	_	
121-2	20216-20219	and	_	
121-3	20220-20229	posterior	_	
121-4	20230-20238	temporal	_	
121-5	20239-20243	lobe	_	
121-6	20244-20248	show	_	
121-7	20249-20256	greater	_	
121-8	20257-20270	inter-network	_	
121-9	20271-20283	connectivity	_	
121-10	20284-20286	at	_	
121-11	20287-20291	rest	_	
121-12	20292-20295	and	_	
121-13	20296-20302	across	_	
121-14	20303-20310	sensory	_	
121-15	20311-20320	paradigms	_	
121-16	20321-20323	in	_	
121-17	20324-20337	schizophrenia	_	
121-18	20337-20338	.	_	

#Text=A systematic review and meta-analysis of the effects of antipsychotic medications on regional cerebral blood flow (rCBF) in schizophrenia: association with response to treatment.
122-1	20339-20340	A	_	
122-2	20341-20351	systematic	_	
122-3	20352-20358	review	_	
122-4	20359-20362	and	_	
122-5	20363-20376	meta-analysis	_	
122-6	20377-20379	of	_	
122-7	20380-20383	the	_	
122-8	20384-20391	effects	_	
122-9	20392-20394	of	_	
122-10	20395-20408	antipsychotic	_	
122-11	20409-20420	medications	_	
122-12	20421-20423	on	_	
122-13	20424-20432	regional	_	
122-14	20433-20441	cerebral	_	
122-15	20442-20447	blood	_	
122-16	20448-20452	flow	_	
122-17	20453-20454	(	_	
122-18	20454-20458	rCBF	_	
122-19	20458-20459	)	_	
122-20	20460-20462	in	_	
122-21	20463-20476	schizophrenia	_	
122-22	20476-20477	:	_	
122-23	20478-20489	association	_	
122-24	20490-20494	with	_	
122-25	20495-20503	response	_	
122-26	20504-20506	to	_	
122-27	20507-20516	treatment	_	
122-28	20516-20517	.	_	

#Text=Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia.
123-1	20518-20525	Ventral	_	
123-2	20526-20535	tegmental	_	
123-3	20536-20540	area	_	
123-4	20540-20541	/	_	
123-5	20541-20549	midbrain	_	
123-6	20550-20560	functional	_	
123-7	20561-20573	connectivity	_	
123-8	20574-20577	and	_	
123-9	20578-20586	response	_	
123-10	20587-20589	to	_	
123-11	20590-20603	antipsychotic	_	
123-12	20604-20614	medication	_	
123-13	20615-20617	in	_	
123-14	20618-20631	schizophrenia	_	
123-15	20631-20632	.	_	

#Text=Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus.
124-1	20633-20654	Functional-anatomical	_	
124-2	20655-20665	validation	_	
124-3	20666-20669	and	_	
124-4	20670-20680	individual	_	
124-5	20681-20690	variation	_	
124-6	20691-20693	of	_	
124-7	20694-20703	diffusion	_	
124-8	20704-20722	tractography-based	_	
124-9	20723-20735	segmentation	_	
124-10	20736-20738	of	_	
124-11	20739-20742	the	_	
124-12	20743-20748	human	_	
124-13	20749-20757	thalamus	_	
124-14	20757-20758	.	_	

#Text=Thalamocortical connectivity during resting state in schizophrenia.
125-1	20759-20774	Thalamocortical	_	
125-2	20775-20787	connectivity	_	
125-3	20788-20794	during	_	
125-4	20795-20802	resting	_	
125-5	20803-20808	state	_	
125-6	20809-20811	in	_	
125-7	20812-20825	schizophrenia	_	
125-8	20825-20826	.	_	

#Text=Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone.
126-1	20827-20840	Abnormalities	_	
126-2	20841-20843	in	_	
126-3	20844-20849	large	_	
126-4	20850-20855	scale	_	
126-5	20856-20866	functional	_	
126-6	20867-20875	networks	_	
126-7	20876-20878	in	_	
126-8	20879-20890	unmedicated	_	
126-9	20891-20899	patients	_	
126-10	20900-20904	with	_	
126-11	20905-20918	schizophrenia	_	
126-12	20919-20922	and	_	
126-13	20923-20930	effects	_	
126-14	20931-20933	of	_	
126-15	20934-20945	risperidone	_	
126-16	20945-20946	.	_	

#Text=Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study.
127-1	20947-20955	Aberrant	_	
127-2	20956-20967	Hippocampal	_	
127-3	20968-20980	Connectivity	_	
127-4	20981-20983	in	_	
127-5	20984-20995	Unmedicated	_	
127-6	20996-21004	Patients	_	
127-7	21005-21009	With	_	
127-8	21010-21023	Schizophrenia	_	
127-9	21024-21027	and	_	
127-10	21028-21035	Effects	_	
127-11	21036-21038	of	_	
127-12	21039-21052	Antipsychotic	_	
127-13	21053-21063	Medication	_	
127-14	21063-21064	:	_	
127-15	21065-21066	A	_	
127-16	21067-21079	Longitudinal	_	
127-17	21080-21087	Resting	_	
127-18	21088-21093	State	_	
127-19	21094-21104	Functional	_	
127-20	21105-21108	MRI	_	
127-21	21109-21114	Study	_	
127-22	21114-21115	.	_	

#Text=Stereological studies of capillary length density in the frontal cortex of schizophrenics.
128-1	21116-21129	Stereological	_	
128-2	21130-21137	studies	_	
128-3	21138-21140	of	_	
128-4	21141-21150	capillary	_	
128-5	21151-21157	length	_	
128-6	21158-21165	density	_	
128-7	21166-21168	in	_	
128-8	21169-21172	the	_	
128-9	21173-21180	frontal	_	
128-10	21181-21187	cortex	_	
128-11	21188-21190	of	_	
128-12	21191-21205	schizophrenics	_	
128-13	21205-21206	.	_	

#Text=Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method.
129-1	21207-21216	Automated	_	
129-2	21217-21225	labeling	_	
129-3	21226-21228	of	_	
129-4	21229-21232	the	_	
129-5	21233-21238	human	_	
129-6	21239-21244	brain	_	
129-7	21244-21245	:	_	
129-8	21246-21247	a	_	
129-9	21248-21259	preliminary	_	
129-10	21260-21266	report	_	
129-11	21267-21269	on	_	
129-12	21270-21273	the	_	
129-13	21274-21285	development	_	
129-14	21286-21289	and	_	
129-15	21290-21300	evaluation	_	
129-16	21301-21303	of	_	
129-17	21304-21305	a	_	
129-18	21306-21323	forward-transform	_	
129-19	21324-21330	method	_	
129-20	21330-21331	.	_	

#Text=Automated Talairach atlas labels for functional brain mapping.
130-1	21332-21341	Automated	_	
130-2	21342-21351	Talairach	_	
130-3	21352-21357	atlas	_	
130-4	21358-21364	labels	_	
130-5	21365-21368	for	_	
130-6	21369-21379	functional	_	
130-7	21380-21385	brain	_	
130-8	21386-21393	mapping	_	
130-9	21393-21394	.	_	

#Text=Differences in cerebellar blood volume in schizophrenia and bipolar disorder.
131-1	21395-21406	Differences	_	
131-2	21407-21409	in	_	
131-3	21410-21420	cerebellar	_	
131-4	21421-21426	blood	_	
131-5	21427-21433	volume	_	
131-6	21434-21436	in	_	
131-7	21437-21450	schizophrenia	_	
131-8	21451-21454	and	_	
131-9	21455-21462	bipolar	_	
131-10	21463-21471	disorder	_	
131-11	21471-21472	.	_	

#Text=Precentral gyrus discrepancy in electronic versions of the Talairach atlas.
132-1	21473-21483	Precentral	_	
132-2	21484-21489	gyrus	_	
132-3	21490-21501	discrepancy	_	
132-4	21502-21504	in	_	
132-5	21505-21515	electronic	_	
132-6	21516-21524	versions	_	
132-7	21525-21527	of	_	
132-8	21528-21531	the	_	
132-9	21532-21541	Talairach	_	
132-10	21542-21547	atlas	_	
132-11	21547-21548	.	_	

#Text=An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.
133-1	21549-21551	An	_	
133-2	21552-21561	automated	_	
133-3	21562-21568	method	_	
133-4	21569-21572	for	_	
133-5	21573-21586	neuroanatomic	_	
133-6	21587-21590	and	_	
133-7	21591-21608	cytoarchitectonic	_	
133-8	21609-21620	atlas-based	_	
133-9	21621-21634	interrogation	_	
133-10	21635-21637	of	_	
133-11	21638-21642	fMRI	_	
133-12	21643-21647	data	_	
133-13	21648-21652	sets	_	
133-14	21652-21653	.	_	

#Text=MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field.
134-1	21654-21661	MP2RAGE	_	
134-2	21661-21662	,	_	
134-3	21663-21664	a	_	
134-4	21665-21669	self	_	
134-5	21670-21680	bias-field	_	
134-6	21681-21690	corrected	_	
134-7	21691-21699	sequence	_	
134-8	21700-21703	for	_	
134-9	21704-21712	improved	_	
134-10	21713-21725	segmentation	_	
134-11	21726-21729	and	_	
134-12	21730-21732	T1	_	
134-13	21732-21733	-	_	
134-14	21733-21740	mapping	_	
134-15	21741-21743	at	_	
134-16	21744-21748	high	_	
134-17	21749-21754	field	_	
134-18	21754-21755	.	_	

#Text=A large scale (N=400) investigation of gray matter differences in schizophrenia using optimized voxel-based morphometry.
135-1	21756-21757	A	_	
135-2	21758-21763	large	_	
135-3	21764-21769	scale	_	
135-4	21770-21771	(	_	
135-5	21771-21772	N	_	
135-6	21772-21773	=	_	
135-7	21773-21776	400	_	
135-8	21776-21777	)	_	
135-9	21778-21791	investigation	_	
135-10	21792-21794	of	_	
135-11	21795-21799	gray	_	
135-12	21800-21806	matter	_	
135-13	21807-21818	differences	_	
135-14	21819-21821	in	_	
135-15	21822-21835	schizophrenia	_	
135-16	21836-21841	using	_	
135-17	21842-21851	optimized	_	
135-18	21852-21863	voxel-based	_	
135-19	21864-21875	morphometry	_	
135-20	21875-21876	.	_	

#Text=The impact of global signal regression on resting state correlations: are anti-correlated networks introduced?
136-1	21877-21880	The	_	
136-2	21881-21887	impact	_	
136-3	21888-21890	of	_	
136-4	21891-21897	global	_	
136-5	21898-21904	signal	_	
136-6	21905-21915	regression	_	
136-7	21916-21918	on	_	
136-8	21919-21926	resting	_	
136-9	21927-21932	state	_	
136-10	21933-21945	correlations	_	
136-11	21945-21946	:	_	
136-12	21947-21950	are	_	
136-13	21951-21966	anti-correlated	_	
136-14	21967-21975	networks	_	
136-15	21976-21986	introduced	_	
136-16	21986-21987	?	_	

#Text=Reduction of motion-related artifacts in resting state fMRI using aCompCor.
137-1	21988-21997	Reduction	_	
137-2	21998-22000	of	_	
137-3	22001-22015	motion-related	_	
137-4	22016-22025	artifacts	_	
137-5	22026-22028	in	_	
137-6	22029-22036	resting	_	
137-7	22037-22042	state	_	
137-8	22043-22047	fMRI	_	
137-9	22048-22053	using	_	
137-10	22054-22062	aCompCor	_	
137-11	22062-22063	.	_	

#Text=The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.
138-1	22064-22067	The	_	
138-2	22068-22076	Montreal	_	
138-3	22077-22086	Cognitive	_	
138-4	22087-22097	Assessment	_	
138-5	22097-22098	,	_	
138-6	22099-22103	MoCA	_	
138-7	22103-22104	:	_	
138-8	22105-22106	a	_	
138-9	22107-22112	brief	_	
138-10	22113-22122	screening	_	
138-11	22123-22127	tool	_	
138-12	22128-22131	for	_	
138-13	22132-22136	mild	_	
138-14	22137-22146	cognitive	_	
138-15	22147-22157	impairment	_	
138-16	22157-22158	.	_	

#Text=Pseudo-continuous arterial spin labeling MRI study of schizophrenic patients.
139-1	22159-22176	Pseudo-continuous	_	
139-2	22177-22185	arterial	_	
139-3	22186-22190	spin	_	
139-4	22191-22199	labeling	_	
139-5	22200-22203	MRI	_	
139-6	22204-22209	study	_	
139-7	22210-22212	of	_	
139-8	22213-22226	schizophrenic	_	
139-9	22227-22235	patients	_	
139-10	22235-22236	.	_	

#Text=The Brief Psychiatric Rating Scale.
140-1	22237-22240	The	_	
140-2	22241-22246	Brief	_	
140-3	22247-22258	Psychiatric	_	
140-4	22259-22265	Rating	_	
140-5	22266-22271	Scale	_	
140-6	22271-22272	.	_	

#Text=Ziskind-Somerfeld Research Award 1996.
141-1	22273-22290	Ziskind-Somerfeld	_	
141-2	22291-22299	Research	_	
141-3	22300-22305	Award	_	
141-4	22306-22310	1996	_	
141-5	22310-22311	.	_	

#Text=Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder.
142-1	22312-22318	Medial	_	
142-2	22319-22322	and	_	
142-3	22323-22331	superior	_	
142-4	22332-22340	temporal	_	
142-5	22341-22346	gyral	_	
142-6	22347-22354	volumes	_	
142-7	22355-22358	and	_	
142-8	22359-22367	cerebral	_	
142-9	22368-22377	asymmetry	_	
142-10	22378-22380	in	_	
142-11	22381-22394	schizophrenia	_	
142-12	22395-22401	versus	_	
142-13	22402-22409	bipolar	_	
142-14	22410-22418	disorder	_	
142-15	22418-22419	.	_	

#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion.
143-1	22420-22428	Spurious	_	
143-2	22429-22432	but	_	
143-3	22433-22443	systematic	_	
143-4	22444-22456	correlations	_	
143-5	22457-22459	in	_	
143-6	22460-22470	functional	_	
143-7	22471-22483	connectivity	_	
143-8	22484-22487	MRI	_	
143-9	22488-22496	networks	_	
143-10	22497-22502	arise	_	
143-11	22503-22507	from	_	
143-12	22508-22515	subject	_	
143-13	22516-22522	motion	_	
143-14	22522-22523	.	_	

#Text=Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.
144-1	22525-22538	Antipsychotic	_	
144-2	22539-22548	treatment	_	
144-3	22549-22552	and	_	
144-4	22553-22563	functional	_	
144-5	22564-22576	connectivity	_	
144-6	22577-22579	of	_	
144-7	22580-22583	the	_	
144-8	22584-22592	striatum	_	
144-9	22593-22595	in	_	
144-10	22596-22609	first-episode	_	
144-11	22610-22623	schizophrenia	_	
144-12	22623-22624	.	_	

#Text=Impact of in-scanner head motion on multiple measures of functional connectivity: relevance for studies of neurodevelopment in youth.
145-1	22625-22631	Impact	_	
145-2	22632-22634	of	_	
145-3	22635-22645	in-scanner	_	
145-4	22646-22650	head	_	
145-5	22651-22657	motion	_	
145-6	22658-22660	on	_	
145-7	22661-22669	multiple	_	
145-8	22670-22678	measures	_	
145-9	22679-22681	of	_	
145-10	22682-22692	functional	_	
145-11	22693-22705	connectivity	_	
145-12	22705-22706	:	_	
145-13	22707-22716	relevance	_	
145-14	22717-22720	for	_	
145-15	22721-22728	studies	_	
145-16	22729-22731	of	_	
145-17	22732-22748	neurodevelopment	_	
145-18	22749-22751	in	_	
145-19	22752-22757	youth	_	
145-20	22757-22758	.	_	

#Text=Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference.
146-1	22759-22773	Threshold-free	_	
146-2	22774-22781	cluster	_	
146-3	22782-22793	enhancement	_	
146-4	22793-22794	:	_	
146-5	22795-22805	addressing	_	
146-6	22806-22814	problems	_	
146-7	22815-22817	of	_	
146-8	22818-22827	smoothing	_	
146-9	22827-22828	,	_	
146-10	22829-22838	threshold	_	
146-11	22839-22849	dependence	_	
146-12	22850-22853	and	_	
146-13	22854-22866	localisation	_	
146-14	22867-22869	in	_	
146-15	22870-22877	cluster	_	
146-16	22878-22887	inference	_	
146-17	22887-22888	.	_	

#Text=Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.
147-1	22889-22898	Automated	_	
147-2	22899-22909	anatomical	_	
147-3	22910-22918	labeling	_	
147-4	22919-22921	of	_	
147-5	22922-22933	activations	_	
147-6	22934-22936	in	_	
147-7	22937-22940	SPM	_	
147-8	22941-22946	using	_	
147-9	22947-22948	a	_	
147-10	22949-22960	macroscopic	_	
147-11	22961-22971	anatomical	_	
147-12	22972-22984	parcellation	_	
147-13	22985-22987	of	_	
147-14	22988-22991	the	_	
147-15	22992-22995	MNI	_	
147-16	22996-22999	MRI	_	
147-17	23000-23014	single-subject	_	
147-18	23015-23020	brain	_	
147-19	23020-23021	.	_	

#Text=An integrative model for neuronal activity-induced signal changes for gradient and spin echo functional imaging.
148-1	23022-23024	An	_	
148-2	23025-23036	integrative	_	
148-3	23037-23042	model	_	
148-4	23043-23046	for	_	
148-5	23047-23055	neuronal	_	
148-6	23056-23072	activity-induced	_	
148-7	23073-23079	signal	_	
148-8	23080-23087	changes	_	
148-9	23088-23091	for	_	
148-10	23092-23100	gradient	_	
148-11	23101-23104	and	_	
148-12	23105-23109	spin	_	
148-13	23110-23114	echo	_	
148-14	23115-23125	functional	_	
148-15	23126-23133	imaging	_	
148-16	23133-23134	.	_	

#Text=T1 weighted brain images at 7 Tesla unbiased for Proton Density, T2* contrast and RF coil receive B1 sensitivity with simultaneous vessel visualization.
149-1	23135-23137	T1	_	
149-2	23138-23146	weighted	_	
149-3	23147-23152	brain	_	
149-4	23153-23159	images	_	
149-5	23160-23162	at	_	
149-6	23163-23164	7	_	
149-7	23165-23170	Tesla	_	
149-8	23171-23179	unbiased	_	
149-9	23180-23183	for	_	
149-10	23184-23190	Proton	_	
149-11	23191-23198	Density	_	
149-12	23198-23199	,	_	
149-13	23200-23202	T2	_	
149-14	23202-23203	*	_	
149-15	23204-23212	contrast	_	
149-16	23213-23216	and	_	
149-17	23217-23219	RF	_	
149-18	23220-23224	coil	_	
149-19	23225-23232	receive	_	
149-20	23233-23235	B1	_	
149-21	23236-23247	sensitivity	_	
149-22	23248-23252	with	_	
149-23	23253-23265	simultaneous	_	
149-24	23266-23272	vessel	_	
149-25	23273-23286	visualization	_	
149-26	23286-23287	.	_	

#Text=The influence of head motion on intrinsic functional connectivity MRI.
150-1	23288-23291	The	_	
150-2	23292-23301	influence	_	
150-3	23302-23304	of	_	
150-4	23305-23309	head	_	
150-5	23310-23316	motion	_	
150-6	23317-23319	on	_	
150-7	23320-23329	intrinsic	_	
150-8	23330-23340	functional	_	
150-9	23341-23353	connectivity	_	
150-10	23354-23357	MRI	_	
150-11	23357-23358	.	_	

#Text=Resting state cerebral blood flow and objective motor activity reveal basal ganglia dysfunction in schizophrenia.
151-1	23359-23366	Resting	_	
151-2	23367-23372	state	_	
151-3	23373-23381	cerebral	_	
151-4	23382-23387	blood	_	
151-5	23388-23392	flow	_	
151-6	23393-23396	and	_	
151-7	23397-23406	objective	_	
151-8	23407-23412	motor	_	
151-9	23413-23421	activity	_	
151-10	23422-23428	reveal	_	
151-11	23429-23434	basal	_	
151-12	23435-23442	ganglia	_	
151-13	23443-23454	dysfunction	_	
151-14	23455-23457	in	_	
151-15	23458-23471	schizophrenia	_	
151-16	23471-23472	.	_	

#Text=Altered global brain signal in schizophrenia.
152-1	23473-23480	Altered	_	
152-2	23481-23487	global	_	
152-3	23488-23493	brain	_	
152-4	23494-23500	signal	_	
152-5	23501-23503	in	_	
152-6	23504-23517	schizophrenia	_	
152-7	23517-23518	.	_	

#Text=Oxford thalamic connectivity atlas.
153-1	23519-23525	Oxford	_	
153-2	23526-23534	thalamic	_	
153-3	23535-23547	connectivity	_	
153-4	23548-23553	atlas	_	
153-5	23553-23554	.	_	

#Text=The thalamus is segmented into seven sub-regions based on white matter diffusion tractography.
154-1	23555-23558	The	_	
154-2	23559-23567	thalamus	_	
154-3	23568-23570	is	_	
154-4	23571-23580	segmented	_	
154-5	23581-23585	into	_	
154-6	23586-23591	seven	_	
154-7	23592-23603	sub-regions	_	
154-8	23604-23609	based	_	
154-9	23610-23612	on	_	
154-10	23613-23618	white	_	
154-11	23619-23625	matter	_	
154-12	23626-23635	diffusion	_	
154-13	23636-23648	tractography	_	
154-14	23648-23649	.	_	

#Text=Each sub-region has a primary connection to a cortical area as listed in the Figure.
155-1	23650-23654	Each	_	
155-2	23655-23665	sub-region	_	
155-3	23666-23669	has	_	
155-4	23670-23671	a	_	
155-5	23672-23679	primary	_	
155-6	23680-23690	connection	_	
155-7	23691-23693	to	_	
155-8	23694-23695	a	_	
155-9	23696-23704	cortical	_	
155-10	23705-23709	area	_	
155-11	23710-23712	as	_	
155-12	23713-23719	listed	_	
155-13	23720-23722	in	_	
155-14	23723-23726	the	_	
155-15	23727-23733	Figure	_	
155-16	23733-23734	.	_	

#Text=Map of thalamic functional connectivity changes between schizophrenia patients and control subjects overlaid on MNI normalized anatomical images.
156-1	23735-23738	Map	_	
156-2	23739-23741	of	_	
156-3	23742-23750	thalamic	_	
156-4	23751-23761	functional	_	
156-5	23762-23774	connectivity	_	
156-6	23775-23782	changes	_	
156-7	23783-23790	between	_	
156-8	23791-23804	schizophrenia	_	
156-9	23805-23813	patients	_	
156-10	23814-23817	and	_	
156-11	23818-23825	control	_	
156-12	23826-23834	subjects	_	
156-13	23835-23843	overlaid	_	
156-14	23844-23846	on	_	
156-15	23847-23850	MNI	_	
156-16	23851-23861	normalized	_	
156-17	23862-23872	anatomical	_	
156-18	23873-23879	images	_	
156-19	23879-23880	.	_	

#Text=Only voxels that show significant difference between the two groups are highlighted (red: schizophrenia > control; blue: schizophrenia < control).
157-1	23881-23885	Only	_	
157-2	23886-23892	voxels	_	
157-3	23893-23897	that	_	
157-4	23898-23902	show	_	
157-5	23903-23914	significant	_	
157-6	23915-23925	difference	_	
157-7	23926-23933	between	_	
157-8	23934-23937	the	_	
157-9	23938-23941	two	_	
157-10	23942-23948	groups	_	
157-11	23949-23952	are	_	
157-12	23953-23964	highlighted	_	
157-13	23965-23966	(	_	
157-14	23966-23969	red	_	
157-15	23969-23970	:	_	
157-16	23971-23984	schizophrenia	_	
157-17	23985-23986	>	_	
157-18	23987-23994	control	_	
157-19	23994-23995	;	_	
157-20	23996-24000	blue	_	
157-21	24000-24001	:	_	
157-22	24002-24015	schizophrenia	_	
157-23	24016-24017	<	_	
157-24	24018-24025	control	_	
157-25	24025-24026	)	_	
157-26	24026-24027	.	_	

#Text=Significant results from all sub-thalamic seed regions in Tables 2 and 3 are shown on the same figure.
158-1	24028-24039	Significant	_	
158-2	24040-24047	results	_	
158-3	24048-24052	from	_	
158-4	24053-24056	all	_	
158-5	24057-24069	sub-thalamic	_	
158-6	24070-24074	seed	_	
158-7	24075-24082	regions	_	
158-8	24083-24085	in	_	
158-9	24086-24092	Tables	_	
158-10	24093-24094	2	_	
158-11	24095-24098	and	_	
158-12	24099-24100	3	_	
158-13	24101-24104	are	_	
158-14	24105-24110	shown	_	
158-15	24111-24113	on	_	
158-16	24114-24117	the	_	
158-17	24118-24122	same	_	
158-18	24123-24129	figure	_	
158-19	24129-24130	.	_	

#Text=Correlations analysis.
159-1	24131-24143	Correlations	_	
159-2	24144-24152	analysis	_	
159-3	24152-24153	.	_	

#Text=Scatter plots showing correlations between the disease duration in schizophrenia patients, and the thalamic functional connectivity to the sensory/motor cortex (a) and the prefrontal cortex (b), respectively.
160-1	24154-24161	Scatter	_	
160-2	24162-24167	plots	_	
160-3	24168-24175	showing	_	
160-4	24176-24188	correlations	_	
160-5	24189-24196	between	_	
160-6	24197-24200	the	_	
160-7	24201-24208	disease	_	
160-8	24209-24217	duration	_	
160-9	24218-24220	in	_	
160-10	24221-24234	schizophrenia	_	
160-11	24235-24243	patients	_	
160-12	24243-24244	,	_	
160-13	24245-24248	and	_	
160-14	24249-24252	the	_	
160-15	24253-24261	thalamic	_	
160-16	24262-24272	functional	_	
160-17	24273-24285	connectivity	_	
160-18	24286-24288	to	_	
160-19	24289-24292	the	_	
160-20	24293-24300	sensory	_	
160-21	24300-24301	/	_	
160-22	24301-24306	motor	_	
160-23	24307-24313	cortex	_	
160-24	24314-24315	(	_	
160-25	24315-24316	a	_	
160-26	24316-24317	)	_	
160-27	24318-24321	and	_	
160-28	24322-24325	the	_	
160-29	24326-24336	prefrontal	_	
160-30	24337-24343	cortex	_	
160-31	24344-24345	(	_	
160-32	24345-24346	b	_	
160-33	24346-24347	)	_	
160-34	24347-24348	,	_	
160-35	24349-24361	respectively	_	
160-36	24361-24362	.	_	

#Text=R2: adjusted R2 from linear regression.
161-1	24363-24365	R2	_	
161-2	24365-24366	:	_	
161-3	24367-24375	adjusted	_	
161-4	24376-24378	R2	_	
161-5	24379-24383	from	_	
161-6	24384-24390	linear	_	
161-7	24391-24401	regression	_	
161-8	24401-24402	.	_	

#Text=Age, smoking status and medication dosage were included as covariates in the correlation analysis.
162-1	24403-24406	Age	_	
162-2	24406-24407	,	_	
162-3	24408-24415	smoking	_	
162-4	24416-24422	status	_	
162-5	24423-24426	and	_	
162-6	24427-24437	medication	_	
162-7	24438-24444	dosage	_	
162-8	24445-24449	were	_	
162-9	24450-24458	included	_	
162-10	24459-24461	as	_	
162-11	24462-24472	covariates	_	
162-12	24473-24475	in	_	
162-13	24476-24479	the	_	
162-14	24480-24491	correlation	_	
162-15	24492-24500	analysis	_	
162-16	24500-24501	.	_	

#Text=All sub-thalamic regions that showed significant difference in functional connectivity with the sensory/motor or the prefrontal cortex in the group comparisons were combined in the correlation analysis.
163-1	24502-24505	All	_	
163-2	24506-24518	sub-thalamic	_	
163-3	24519-24526	regions	_	
163-4	24527-24531	that	_	
163-5	24532-24538	showed	_	
163-6	24539-24550	significant	_	
163-7	24551-24561	difference	_	
163-8	24562-24564	in	_	
163-9	24565-24575	functional	_	
163-10	24576-24588	connectivity	_	
163-11	24589-24593	with	_	
163-12	24594-24597	the	_	
163-13	24598-24605	sensory	_	
163-14	24605-24606	/	_	
163-15	24606-24611	motor	_	
163-16	24612-24614	or	_	
163-17	24615-24618	the	_	
163-18	24619-24629	prefrontal	_	
163-19	24630-24636	cortex	_	
163-20	24637-24639	in	_	
163-21	24640-24643	the	_	
163-22	24644-24649	group	_	
163-23	24650-24661	comparisons	_	
163-24	24662-24666	were	_	
163-25	24667-24675	combined	_	
163-26	24676-24678	in	_	
163-27	24679-24682	the	_	
163-28	24683-24694	correlation	_	
163-29	24695-24703	analysis	_	
163-30	24703-24704	.	_	

#Text=Correlation between thalamic functional connectivity to the sensory/motor cortex and the prefrontal cortex.
164-1	24705-24716	Correlation	_	
164-2	24717-24724	between	_	
164-3	24725-24733	thalamic	_	
164-4	24734-24744	functional	_	
164-5	24745-24757	connectivity	_	
164-6	24758-24760	to	_	
164-7	24761-24764	the	_	
164-8	24765-24772	sensory	_	
164-9	24772-24773	/	_	
164-10	24773-24778	motor	_	
164-11	24779-24785	cortex	_	
164-12	24786-24789	and	_	
164-13	24790-24793	the	_	
164-14	24794-24804	prefrontal	_	
164-15	24805-24811	cortex	_	
164-16	24811-24812	.	_	

#Text=R2: adjusted R2 from linear regression.
165-1	24813-24815	R2	_	
165-2	24815-24816	:	_	
165-3	24817-24825	adjusted	_	
165-4	24826-24828	R2	_	
165-5	24829-24833	from	_	
165-6	24834-24840	linear	_	
165-7	24841-24851	regression	_	
165-8	24851-24852	.	_	

#Text=All sub-thalamic regions that showed significant difference in functional connectivity with the sensory/motor or the prefrontal cortex in the group comparisons were combined in the correlation analysis.
166-1	24853-24856	All	_	
166-2	24857-24869	sub-thalamic	_	
166-3	24870-24877	regions	_	
166-4	24878-24882	that	_	
166-5	24883-24889	showed	_	
166-6	24890-24901	significant	_	
166-7	24902-24912	difference	_	
166-8	24913-24915	in	_	
166-9	24916-24926	functional	_	
166-10	24927-24939	connectivity	_	
166-11	24940-24944	with	_	
166-12	24945-24948	the	_	
166-13	24949-24956	sensory	_	
166-14	24956-24957	/	_	
166-15	24957-24962	motor	_	
166-16	24963-24965	or	_	
166-17	24966-24969	the	_	
166-18	24970-24980	prefrontal	_	
166-19	24981-24987	cortex	_	
166-20	24988-24990	in	_	
166-21	24991-24994	the	_	
166-22	24995-25000	group	_	
166-23	25001-25012	comparisons	_	
166-24	25013-25017	were	_	
166-25	25018-25026	combined	_	
166-26	25027-25029	in	_	
166-27	25030-25033	the	_	
166-28	25034-25045	correlation	_	
166-29	25046-25054	analysis	_	
166-30	25054-25055	.	_	

#Text=Demographic and clinical data for the study participants.
167-1	25056-25067	Demographic	_	
167-2	25068-25071	and	_	
167-3	25072-25080	clinical	_	
167-4	25081-25085	data	_	
167-5	25086-25089	for	_	
167-6	25090-25093	the	_	
167-7	25094-25099	study	_	
167-8	25100-25112	participants	_	
167-9	25112-25113	.	_	

#Text=Controlsubjects\tSchizophreniapatients\tP value a\t \tN\t14\t14\tN/A\t \tSex (Male)\t75%\t75%\t1\t \tRace (Caucasian/AfricanAmerican)\t7/7\t7/7\t1\t \tAge (year)\t37.3±16.7 b\t39.5±18.5\t0.71\t \tDisease duration (year)\tN/A\t19.1±17.7\tN/A\t \tSmoking status (cig/day)\t1.7±3.1\t2.3±2.4\t0.55\t \tBPRS scorec\t23.1±3.4\t38.1±8.4\t<0.00001\t \tMedicationd\tN/A\t93.9±130.7\tN/A\t \tMoCAescore\t25.5±3.0\t22.8±3.8\t0.04\t \t
#Text=P values from two-sample t-tests between the two groups for age, smoking status, BPRS and MoCA scores; or from χ2-test for the categorical variable sex.
#Text=mean ± standard deviation
#Text=Brief Psychiatric Rating Scale (BPRS); please see Methods section for references.
168-1	25115-25130	Controlsubjects	_	
168-2	25131-25152	Schizophreniapatients	_	
168-3	25153-25154	P	_	
168-4	25155-25160	value	_	
168-5	25161-25162	a	_	
168-6	25165-25166	N	_	
168-7	25167-25169	14	_	
168-8	25170-25172	14	_	
168-9	25173-25174	N	_	
168-10	25174-25175	/	_	
168-11	25175-25176	A	_	
168-12	25179-25182	Sex	_	
168-13	25183-25184	(	_	
168-14	25184-25188	Male	_	
168-15	25188-25189	)	_	
168-16	25190-25193	75%	_	
168-17	25194-25197	75%	_	
168-18	25198-25199	1	_	
168-19	25202-25206	Race	_	
168-20	25207-25208	(	_	
168-21	25208-25217	Caucasian	_	
168-22	25217-25218	/	_	
168-23	25218-25233	AfricanAmerican	_	
168-24	25233-25234	)	_	
168-25	25235-25236	7	_	
168-26	25236-25237	/	_	
168-27	25237-25238	7	_	
168-28	25239-25240	7	_	
168-29	25240-25241	/	_	
168-30	25241-25242	7	_	
168-31	25243-25244	1	_	
168-32	25247-25250	Age	_	
168-33	25251-25252	(	_	
168-34	25252-25256	year	_	
168-35	25256-25257	)	_	
168-36	25258-25262	37.3	_	
168-37	25262-25263	±	_	
168-38	25263-25267	16.7	_	
168-39	25268-25269	b	_	
168-40	25270-25274	39.5	_	
168-41	25274-25275	±	_	
168-42	25275-25279	18.5	_	
168-43	25280-25284	0.71	_	
168-44	25287-25294	Disease	_	
168-45	25295-25303	duration	_	
168-46	25304-25305	(	_	
168-47	25305-25309	year	_	
168-48	25309-25310	)	_	
168-49	25311-25312	N	_	
168-50	25312-25313	/	_	
168-51	25313-25314	A	_	
168-52	25315-25319	19.1	_	
168-53	25319-25320	±	_	
168-54	25320-25324	17.7	_	
168-55	25325-25326	N	_	
168-56	25326-25327	/	_	
168-57	25327-25328	A	_	
168-58	25331-25338	Smoking	_	
168-59	25339-25345	status	_	
168-60	25346-25347	(	_	
168-61	25347-25350	cig	_	
168-62	25350-25351	/	_	
168-63	25351-25354	day	_	
168-64	25354-25355	)	_	
168-65	25356-25359	1.7	_	
168-66	25359-25360	±	_	
168-67	25360-25363	3.1	_	
168-68	25364-25367	2.3	_	
168-69	25367-25368	±	_	
168-70	25368-25371	2.4	_	
168-71	25372-25376	0.55	_	
168-72	25379-25383	BPRS	_	
168-73	25384-25390	scorec	_	
168-74	25391-25395	23.1	_	
168-75	25395-25396	±	_	
168-76	25396-25399	3.4	_	
168-77	25400-25404	38.1	_	
168-78	25404-25405	±	_	
168-79	25405-25408	8.4	_	
168-80	25409-25410	<	_	
168-81	25410-25417	0.00001	_	
168-82	25420-25431	Medicationd	_	
168-83	25432-25433	N	_	
168-84	25433-25434	/	_	
168-85	25434-25435	A	_	
168-86	25436-25440	93.9	_	
168-87	25440-25441	±	_	
168-88	25441-25446	130.7	_	
168-89	25447-25448	N	_	
168-90	25448-25449	/	_	
168-91	25449-25450	A	_	
168-92	25453-25463	MoCAescore	_	
168-93	25464-25468	25.5	_	
168-94	25468-25469	±	_	
168-95	25469-25472	3.0	_	
168-96	25473-25477	22.8	_	
168-97	25477-25478	±	_	
168-98	25478-25481	3.8	_	
168-99	25482-25486	0.04	_	
168-100	25490-25491	P	_	
168-101	25492-25498	values	_	
168-102	25499-25503	from	_	
168-103	25504-25514	two-sample	_	
168-104	25515-25522	t-tests	_	
168-105	25523-25530	between	_	
168-106	25531-25534	the	_	
168-107	25535-25538	two	_	
168-108	25539-25545	groups	_	
168-109	25546-25549	for	_	
168-110	25550-25553	age	_	
168-111	25553-25554	,	_	
168-112	25555-25562	smoking	_	
168-113	25563-25569	status	_	
168-114	25569-25570	,	_	
168-115	25571-25575	BPRS	_	
168-116	25576-25579	and	_	
168-117	25580-25584	MoCA	_	
168-118	25585-25591	scores	_	
168-119	25591-25592	;	_	
168-120	25593-25595	or	_	
168-121	25596-25600	from	_	
168-122	25601-25603	χ2	_	
168-123	25603-25604	-	_	
168-124	25604-25608	test	_	
168-125	25609-25612	for	_	
168-126	25613-25616	the	_	
168-127	25617-25628	categorical	_	
168-128	25629-25637	variable	_	
168-129	25638-25641	sex	_	
168-130	25641-25642	.	_	
168-131	25643-25647	mean	_	
168-132	25648-25649	±	_	
168-133	25650-25658	standard	_	
168-134	25659-25668	deviation	_	
168-135	25669-25674	Brief	_	
168-136	25675-25686	Psychiatric	_	
168-137	25687-25693	Rating	_	
168-138	25694-25699	Scale	_	
168-139	25700-25701	(	_	
168-140	25701-25705	BPRS	_	
168-141	25705-25706	)	_	
168-142	25706-25707	;	_	
168-143	25708-25714	please	_	
168-144	25715-25718	see	_	
168-145	25719-25726	Methods	_	
168-146	25727-25734	section	_	
168-147	25735-25738	for	_	
168-148	25739-25749	references	_	
168-149	25749-25750	.	_	

#Text=Medication reported with derived chlorpromazine equivalent dose in dose-year (milligram).
169-1	25751-25761	Medication	_	
169-2	25762-25770	reported	_	
169-3	25771-25775	with	_	
169-4	25776-25783	derived	_	
169-5	25784-25798	chlorpromazine	_	
169-6	25799-25809	equivalent	_	
169-7	25810-25814	dose	_	
169-8	25815-25817	in	_	
169-9	25818-25827	dose-year	_	
169-10	25828-25829	(	_	
169-11	25829-25838	milligram	_	
169-12	25838-25839	)	_	
169-13	25839-25840	.	_	

#Text=More detailed information about medication doses and types are reported in Supplemental Table S1.
170-1	25841-25845	More	_	
170-2	25846-25854	detailed	_	
170-3	25855-25866	information	_	
170-4	25867-25872	about	_	
170-5	25873-25883	medication	_	
170-6	25884-25889	doses	_	
170-7	25890-25893	and	_	
170-8	25894-25899	types	_	
170-9	25900-25903	are	_	
170-10	25904-25912	reported	_	
170-11	25913-25915	in	_	
170-12	25916-25928	Supplemental	_	
170-13	25929-25934	Table	_	
170-14	25935-25937	S1	_	
170-15	25937-25938	.	_	

#Text=Current chlorpromazine (CPZ) equivalents were used as a proxy for lifetime antipsychotic exposure.
171-1	25939-25946	Current	_	
171-2	25947-25961	chlorpromazine	_	
171-3	25962-25963	(	_	
171-4	25963-25966	CPZ	_	
171-5	25966-25967	)	_	
171-6	25968-25979	equivalents	_	
171-7	25980-25984	were	_	
171-8	25985-25989	used	_	
171-9	25990-25992	as	_	
171-10	25993-25994	a	_	
171-11	25995-26000	proxy	_	
171-12	26001-26004	for	_	
171-13	26005-26013	lifetime	_	
171-14	26014-26027	antipsychotic	_	
171-15	26028-26036	exposure	_	
171-16	26036-26037	.	_	

#Text=Montreal Cognitive Assessment (MoCA); please see Methods section for references.
172-1	26038-26046	Montreal	_	
172-2	26047-26056	Cognitive	_	
172-3	26057-26067	Assessment	_	
172-4	26068-26069	(	_	
172-5	26069-26073	MoCA	_	
172-6	26073-26074	)	_	
172-7	26074-26075	;	_	
172-8	26076-26082	please	_	
172-9	26083-26086	see	_	
172-10	26087-26094	Methods	_	
172-11	26095-26102	section	_	
172-12	26103-26106	for	_	
172-13	26107-26117	references	_	
172-14	26117-26118	.	_	

#Text=Hyper-connectivity (schizophrenia > control) between thalamic sub-regions and various brain regions in schizophrenia patients compared to controls.
173-1	26119-26137	Hyper-connectivity	_	
173-2	26138-26139	(	_	
173-3	26139-26152	schizophrenia	_	
173-4	26153-26154	>	_	
173-5	26155-26162	control	_	
173-6	26162-26163	)	_	
173-7	26164-26171	between	_	
173-8	26172-26180	thalamic	_	
173-9	26181-26192	sub-regions	_	
173-10	26193-26196	and	_	
173-11	26197-26204	various	_	
173-12	26205-26210	brain	_	
173-13	26211-26218	regions	_	
173-14	26219-26221	in	_	
173-15	26222-26235	schizophrenia	_	
173-16	26236-26244	patients	_	
173-17	26245-26253	compared	_	
173-18	26254-26256	to	_	
173-19	26257-26265	controls	_	
173-20	26265-26266	.	_	

#Text=Functional connectivity (z)\t\t\t\t\t \t\t\t\tschizophrenia\tcontrol\t\tCluster Peak d(mm, MNI)\t\t\t \tRegiona\tHemisphere\tCluster Sizeb\tmean\tstd\tmean\tstd\tEffect Sizec\tX\tV\tz\tPeak T\tAdjusted P Value\t \tSub-region 1 (connection to primary motor)\t\t\t\t\t\t\t\t \tPrecentral\tR\t120\t0.096\t0.059\t−0.046\t0.077\t2.15\t−42\t−8\t46\t5.03\tle-5\t \tPrecentral\tL\t97\t0.043\t0.036\t−0.062\t0.057\t2.29\t34\t−4\t50\t4.47\t0.001\t \tParacentral_Lobule\tL\t60\t0.082\t0.065\t−0.047\t0.066\t2.04\t10\t−30\t62\t4.36\t0.004\t \tPanetal_Sup\tL\t50\t0.016\t0.063\t−0.066\t0.056\t1.43\t24\t−64\t48\t5.44\t0.001\t \tPostcentral\tR\t140\t0.069\t0.054\t−0.056\t0.075\t1.99\t−38\t−30\t50\t4.83\tle-5\t \tPostcentral\tL\t112\t0.055\t0.042\t−0.063\t0.055\t2.50\t22\t−46\t56\t5.01\t0.007\t \tPrecuneus\tL\t55\t0.043\t0.035\t−0.059\t0.043\t2.70\t6\t−64\t54\t4.53\t0.002\t \tSupp_Motor_Area\tR\t71\t0.092\t0.063\t−0.041\t0.055\t2.33\t−8\t−22\t62\t4.02\tle-5\t \tSupp_Motor_Area\tL\t87\t0.100\t0.066\t−0.035\t0.066\t2.12\t8\t−16\t56\t5.07\t0.003\t \tTemporal Mid\tR\t95\t0.036\t0.064\t−0.093\t0.051\t2.31\t−42\t−66\t0\t4.50\t0.007\t \tTempo ral_Su P\tR\t82\t0.053\t0.045\t−0.043\t0.075\t1.61\t−52\t−36\t8\t5.08\t0.001\t \tSub-region 2 ( connection to sensory)\t\t\t\t\t\t\t\t\t \tPostcentral\tR\t150\t0.072\t0.054\t−0.055\t0.069\t2.13\t−52\t−8\t36\t5.25\t0.001\t \tPostcentral\tL\t194\t0.048\t0.041\t−0.070\t0.067\t2.20\t50\t−10\t20\t4.71\tle-5\t \tSupraMargina 1\tR\t23\t0.054\t0.063\t−0.051\t0.065\t1.70\t−38\t−32\t40\t3.93\tle-5\t \tSupraMargina 1\tL\t52\t0.029\t0.027\t−0.048\t0.062\t1.67\t52\t−26\t14\t4.05\t0.002\t \tParacentral_Lobule\tL\t74\t0.073\t0.058\t−0.053\t0.073\t1.98\t10\t−30\t60\t5.71\t0.009\t \tPrecentral\tR\t170\t0.100\t0.065\t−0.047\t0.082\t2.06\t−42\t4\t30\t4.66\t0.005\t \tPrecentral\tL\t130\t0.036\t0.033\t−0.062\t0.065\t1.97\t52\t4\t28\t4.86\t0.001\t \tSupp_Motor_Area\tR\t161\t0.090\t0.058\t−0.034\t0.070\t2.00\t−12\t14\t46\t5.57\t0.001\t \tSupp_Motor_Area\tL\t122\t0.088\t0.058\t−0.034\t0.071\t1.95\t8\t−14\t48\t4.18\t0.001\t \tTemporal Mid\tL\t178\t0.014\t0.024\t−0.074\t0.054\t2.19\t58\t−16\tI8\t4.60\tle-5\t \tTemporal_SuP\tL\t144\t0.047\t0.045\t−0.064\t0.083\t1.73\t50\t−28\t12\t4.99\t0.001\t \tSub-region 3 ( connection to occtpital)\t\t\t\t\t\t\t\t\t \tPostcentral\tR\t153\t0.073\t0.050\t−0.040\t0.085\t1.68\t−52\t−4\t30\t4.15\t0.001\t \tPiecentrai\tR\t128\t0.090\t0.056\t−0.039\t0.085\t1.86\t−48\t−8\t38\t4.88\t0.007\t \tTemporal_Sup\tR\t92\t0.042\t0.041\t−0.024\t0.096\t0.93\t−54\t−10\t12\t4.46\t0.009\t \tSub-region 4 ( connection to prefrontal)\t\t\t\t\t\t\t\t\t \tPostcentral\tR\t81\t0.060\t0.046\t−0.042\t0.074\t1.72\t−26\t−42\t56\t4.40\tle-5\t \tPostcentral\tL\t55\t0.037\t0.041\t−0.063\t0.068\t1.85\t20\t−32\t58\t4.04\tle-5\t \tPrecentral\tR\t94\t0.090\tO.O80\t−0.036\t0.070\t1.74\t−50\t4\t34\t5.03\tle-5\t \tPrecentral\tL\t40\t0.025\t0.036\t−0.076\t0.069\t1.90\t56\t0\t34\t4.71\tle-5\t \tSupp_Motor_Area\tR\t36\t0.054\t0.079\t−0.033\t0.053\t1.34\t−12\t0\t52\t3.91\t0.002\t \tTemporal Mid\tL\t37\t0.008\t0.038\t−0.071\t0.057\t1.35\t52\t−48\t6\t5.41\t0.002\t \tTemporal Mid\tR\t27\t0.025\t0.051\t−0.052\t0.044\t1.68\t−52\t−64\t6\t3.17\tle-5\t \tSub-region 5 ( connection to premotor)\t\t\t\t\t\t\t\t\t \tPrecentral\tR\t169\t0.099\t0.061\t−0.050\t0.082\t2.14\t−44\t2\t38\t5.15\tle-5\t \tPrecentral\tL\t153\t0.039\t0.030\t−0.071\t0.061\t2.37\t26\t−18\t64\t4.58\t0.003\t \tSupp_Motor_Area\tR\t123\t0.098\t0.068\t−0.037\t0.063\t2.14\t−10\t−16\t60\t5.64\tle-5\t \tSupp_Motor_Area\tL\t121\t0.100\t0.064\t−0.033\t0.063\t2.17\t10\t−18\t60\t5.61\tle-5\t \tParacentral_Lobule\tL\t80\tO.O80\t0.060\t−0.051\t0.063\t2.21\t6\t−22\t58\t5.11\t0.002\t \tPostcentral\tR\t146\tO.O82\t0.055\t−0.062\t0.082\t2.14\t−30\t−36\t68\t4.10\tle-5\t \tPostcentral\tL\t166\t0.053\t0.041\t−0.066\t0.061\t2.38\t24\t−34\t56\t5.23\t0.004\t \tTemporal Mid\tR\t128\t0.031\t0.052\t−0.094\t0.048\t2.59\t−52\t−58\t0\t5.11\t0.005\t \tSub-region 6 ( connection to posterior parietal)\t\t\t\t\t\t\t\t \tParacentral_Lobule\tL\t39\t0.076\t0.05 5\t−0.065\t0.080\t2.13\t10\t−30\t60\t4.48\t0.003\t \tPanetal_Inf\tR\t33\t0.048\t0.06 9\t−0.087\t0.065\t2.09\t−32\t−46\t52\t4.27\t0.007\t \tPostcential\tR\t256\t0.090\t0.06 5\t−0.052\t0.085\t1.95\t−52\t−8\t36\t6.13\tle-5\t \tPostcentral\tL\t286\t0.044\t0.04 5\t−0.070\t0.074\t1.93\t46\t−18\t34\t5.32\t0.003\t \tPrecuneus\tL\t52\t0.046\t0.05 0\t−0.062\t0.036\t2.57\t20\t−50\t2\t4.20\tle-5\t \tPrecentral\tR\t289\t0.102\t0.07 2\t−0.047\t0.086\t1.95\t−48\t−6\t28\t7.08\tle-5\t \tPrecentral\tL\t101\t0.040\t0.03 3\t−0.075\t0.067\t2.26\t50\t0\t40\t4.20\t0.008\t \tSupp_Motor_Area\tR\t101\t0.096\t0.06 0\t−0.038\t0.061\t2.30\t−10\t−22\t64\t5.53\t0.002\t \tTemporal Mid\tR\t85\t0.027\t0.04 4\t−0.089\t0.039\t2.90\t−52\t−66\t.2\t4.13\t0.001\t \tSub-region 7 ( connection to temporal)\t\t\t\t\t\t\t\t\t \tTemporal Mid\tL\t37\t0.001\t0.04 6\t−0.069\t0.065\t1.29\t58\t−44\t.2\t3.14\t0.003\t \tTemporal_Sup\tL\t31\t0.020\t0.05 1\t−0.038\t0.078\t0.91\t46\t−40\t12\t3.80\t0.030\t \tPostcentral\tR\t63\t0.042\t0.04 7\t−0.034\t0.064\t1.40\t−26\t−42\t56\t4.61\t0.001\t \tPostcentral\tL\t37\t0.038\t0.04 4\t−0.060\t0.069\t1.76\t38\t−34\t54\t3.70\tle-5\t \tPrecentral\tR\t35\t0.077\t0.08 1\t−0.035\t0.075\t1.49\t−28\t−26\t52\t3.89\t0.001\t \tPrecentral\tL\t30\t0.017\t0.02 8\t−0.056\t0.079\t1.28\t48\t−2\t28\t4.08\t0.005\t \t
#Text=The brain regions were labeled according to the IBASPM 116 atlas (please see Methods for references).
174-1	26270-26280	Functional	_	
174-2	26281-26293	connectivity	_	
174-3	26294-26295	(	_	
174-4	26295-26296	z	_	
174-5	26296-26297	)	_	
174-6	26307-26320	schizophrenia	_	
174-7	26321-26328	control	_	
174-8	26330-26337	Cluster	_	
174-9	26338-26342	Peak	_	
174-10	26343-26344	d	_	
174-11	26344-26345	(	_	
174-12	26345-26347	mm	_	
174-13	26347-26348	,	_	
174-14	26349-26352	MNI	_	
174-15	26352-26353	)	_	
174-16	26358-26365	Regiona	_	
174-17	26366-26376	Hemisphere	_	
174-18	26377-26384	Cluster	_	
174-19	26385-26390	Sizeb	_	
174-20	26391-26395	mean	_	
174-21	26396-26399	std	_	
174-22	26400-26404	mean	_	
174-23	26405-26408	std	_	
174-24	26409-26415	Effect	_	
174-25	26416-26421	Sizec	_	
174-26	26422-26423	X	_	
174-27	26424-26425	V	_	
174-28	26426-26427	z	_	
174-29	26428-26432	Peak	_	
174-30	26433-26434	T	_	
174-31	26435-26443	Adjusted	_	
174-32	26444-26445	P	_	
174-33	26446-26451	Value	_	
174-34	26454-26464	Sub-region	_	
174-35	26465-26466	1	_	
174-36	26467-26468	(	_	
174-37	26468-26478	connection	_	
174-38	26479-26481	to	_	
174-39	26482-26489	primary	_	
174-40	26490-26495	motor	_	
174-41	26495-26496	)	_	
174-42	26506-26516	Precentral	_	
174-43	26517-26518	R	_	
174-44	26519-26522	120	_	
174-45	26523-26528	0.096	_	
174-46	26529-26534	0.059	_	
174-47	26535-26536	−	_	
174-48	26536-26541	0.046	_	
174-49	26542-26547	0.077	_	
174-50	26548-26552	2.15	_	
174-51	26553-26554	−	_	
174-52	26554-26556	42	_	
174-53	26557-26558	−	_	
174-54	26558-26559	8	_	
174-55	26560-26562	46	_	
174-56	26563-26567	5.03	_	
174-57	26568-26570	le	_	
174-58	26570-26571	-	_	
174-59	26571-26572	5	_	
174-60	26575-26585	Precentral	_	
174-61	26586-26587	L	_	
174-62	26588-26590	97	_	
174-63	26591-26596	0.043	_	
174-64	26597-26602	0.036	_	
174-65	26603-26604	−	_	
174-66	26604-26609	0.062	_	
174-67	26610-26615	0.057	_	
174-68	26616-26620	2.29	_	
174-69	26621-26623	34	_	
174-70	26624-26625	−	_	
174-71	26625-26626	4	_	
174-72	26627-26629	50	_	
174-73	26630-26634	4.47	_	
174-74	26635-26640	0.001	_	
174-75	26643-26661	Paracentral_Lobule	_	
174-76	26662-26663	L	_	
174-77	26664-26666	60	_	
174-78	26667-26672	0.082	_	
174-79	26673-26678	0.065	_	
174-80	26679-26680	−	_	
174-81	26680-26685	0.047	_	
174-82	26686-26691	0.066	_	
174-83	26692-26696	2.04	_	
174-84	26697-26699	10	_	
174-85	26700-26701	−	_	
174-86	26701-26703	30	_	
174-87	26704-26706	62	_	
174-88	26707-26711	4.36	_	
174-89	26712-26717	0.004	_	
174-90	26720-26731	Panetal_Sup	_	
174-91	26732-26733	L	_	
174-92	26734-26736	50	_	
174-93	26737-26742	0.016	_	
174-94	26743-26748	0.063	_	
174-95	26749-26750	−	_	
174-96	26750-26755	0.066	_	
174-97	26756-26761	0.056	_	
174-98	26762-26766	1.43	_	
174-99	26767-26769	24	_	
174-100	26770-26771	−	_	
174-101	26771-26773	64	_	
174-102	26774-26776	48	_	
174-103	26777-26781	5.44	_	
174-104	26782-26787	0.001	_	
174-105	26790-26801	Postcentral	_	
174-106	26802-26803	R	_	
174-107	26804-26807	140	_	
174-108	26808-26813	0.069	_	
174-109	26814-26819	0.054	_	
174-110	26820-26821	−	_	
174-111	26821-26826	0.056	_	
174-112	26827-26832	0.075	_	
174-113	26833-26837	1.99	_	
174-114	26838-26839	−	_	
174-115	26839-26841	38	_	
174-116	26842-26843	−	_	
174-117	26843-26845	30	_	
174-118	26846-26848	50	_	
174-119	26849-26853	4.83	_	
174-120	26854-26856	le	_	
174-121	26856-26857	-	_	
174-122	26857-26858	5	_	
174-123	26861-26872	Postcentral	_	
174-124	26873-26874	L	_	
174-125	26875-26878	112	_	
174-126	26879-26884	0.055	_	
174-127	26885-26890	0.042	_	
174-128	26891-26892	−	_	
174-129	26892-26897	0.063	_	
174-130	26898-26903	0.055	_	
174-131	26904-26908	2.50	_	
174-132	26909-26911	22	_	
174-133	26912-26913	−	_	
174-134	26913-26915	46	_	
174-135	26916-26918	56	_	
174-136	26919-26923	5.01	_	
174-137	26924-26929	0.007	_	
174-138	26932-26941	Precuneus	_	
174-139	26942-26943	L	_	
174-140	26944-26946	55	_	
174-141	26947-26952	0.043	_	
174-142	26953-26958	0.035	_	
174-143	26959-26960	−	_	
174-144	26960-26965	0.059	_	
174-145	26966-26971	0.043	_	
174-146	26972-26976	2.70	_	
174-147	26977-26978	6	_	
174-148	26979-26980	−	_	
174-149	26980-26982	64	_	
174-150	26983-26985	54	_	
174-151	26986-26990	4.53	_	
174-152	26991-26996	0.002	_	
174-153	26999-27014	Supp_Motor_Area	_	
174-154	27015-27016	R	_	
174-155	27017-27019	71	_	
174-156	27020-27025	0.092	_	
174-157	27026-27031	0.063	_	
174-158	27032-27033	−	_	
174-159	27033-27038	0.041	_	
174-160	27039-27044	0.055	_	
174-161	27045-27049	2.33	_	
174-162	27050-27051	−	_	
174-163	27051-27052	8	_	
174-164	27053-27054	−	_	
174-165	27054-27056	22	_	
174-166	27057-27059	62	_	
174-167	27060-27064	4.02	_	
174-168	27065-27067	le	_	
174-169	27067-27068	-	_	
174-170	27068-27069	5	_	
174-171	27072-27087	Supp_Motor_Area	_	
174-172	27088-27089	L	_	
174-173	27090-27092	87	_	
174-174	27093-27098	0.100	_	
174-175	27099-27104	0.066	_	
174-176	27105-27106	−	_	
174-177	27106-27111	0.035	_	
174-178	27112-27117	0.066	_	
174-179	27118-27122	2.12	_	
174-180	27123-27124	8	_	
174-181	27125-27126	−	_	
174-182	27126-27128	16	_	
174-183	27129-27131	56	_	
174-184	27132-27136	5.07	_	
174-185	27137-27142	0.003	_	
174-186	27145-27153	Temporal	_	
174-187	27154-27157	Mid	_	
174-188	27158-27159	R	_	
174-189	27160-27162	95	_	
174-190	27163-27168	0.036	_	
174-191	27169-27174	0.064	_	
174-192	27175-27176	−	_	
174-193	27176-27181	0.093	_	
174-194	27182-27187	0.051	_	
174-195	27188-27192	2.31	_	
174-196	27193-27194	−	_	
174-197	27194-27196	42	_	
174-198	27197-27198	−	_	
174-199	27198-27200	66	_	
174-200	27201-27202	0	_	
174-201	27203-27207	4.50	_	
174-202	27208-27213	0.007	_	
174-203	27216-27221	Tempo	_	
174-204	27222-27228	ral_Su	_	
174-205	27229-27230	P	_	
174-206	27231-27232	R	_	
174-207	27233-27235	82	_	
174-208	27236-27241	0.053	_	
174-209	27242-27247	0.045	_	
174-210	27248-27249	−	_	
174-211	27249-27254	0.043	_	
174-212	27255-27260	0.075	_	
174-213	27261-27265	1.61	_	
174-214	27266-27267	−	_	
174-215	27267-27269	52	_	
174-216	27270-27271	−	_	
174-217	27271-27273	36	_	
174-218	27274-27275	8	_	
174-219	27276-27280	5.08	_	
174-220	27281-27286	0.001	_	
174-221	27289-27299	Sub-region	_	
174-222	27300-27301	2	_	
174-223	27302-27303	(	_	
174-224	27304-27314	connection	_	
174-225	27315-27317	to	_	
174-226	27318-27325	sensory	_	
174-227	27325-27326	)	_	
174-228	27337-27348	Postcentral	_	
174-229	27349-27350	R	_	
174-230	27351-27354	150	_	
174-231	27355-27360	0.072	_	
174-232	27361-27366	0.054	_	
174-233	27367-27368	−	_	
174-234	27368-27373	0.055	_	
174-235	27374-27379	0.069	_	
174-236	27380-27384	2.13	_	
174-237	27385-27386	−	_	
174-238	27386-27388	52	_	
174-239	27389-27390	−	_	
174-240	27390-27391	8	_	
174-241	27392-27394	36	_	
174-242	27395-27399	5.25	_	
174-243	27400-27405	0.001	_	
174-244	27408-27419	Postcentral	_	
174-245	27420-27421	L	_	
174-246	27422-27425	194	_	
174-247	27426-27431	0.048	_	
174-248	27432-27437	0.041	_	
174-249	27438-27439	−	_	
174-250	27439-27444	0.070	_	
174-251	27445-27450	0.067	_	
174-252	27451-27455	2.20	_	
174-253	27456-27458	50	_	
174-254	27459-27460	−	_	
174-255	27460-27462	10	_	
174-256	27463-27465	20	_	
174-257	27466-27470	4.71	_	
174-258	27471-27473	le	_	
174-259	27473-27474	-	_	
174-260	27474-27475	5	_	
174-261	27478-27490	SupraMargina	_	
174-262	27491-27492	1	_	
174-263	27493-27494	R	_	
174-264	27495-27497	23	_	
174-265	27498-27503	0.054	_	
174-266	27504-27509	0.063	_	
174-267	27510-27511	−	_	
174-268	27511-27516	0.051	_	
174-269	27517-27522	0.065	_	
174-270	27523-27527	1.70	_	
174-271	27528-27529	−	_	
174-272	27529-27531	38	_	
174-273	27532-27533	−	_	
174-274	27533-27535	32	_	
174-275	27536-27538	40	_	
174-276	27539-27543	3.93	_	
174-277	27544-27546	le	_	
174-278	27546-27547	-	_	
174-279	27547-27548	5	_	
174-280	27551-27563	SupraMargina	_	
174-281	27564-27565	1	_	
174-282	27566-27567	L	_	
174-283	27568-27570	52	_	
174-284	27571-27576	0.029	_	
174-285	27577-27582	0.027	_	
174-286	27583-27584	−	_	
174-287	27584-27589	0.048	_	
174-288	27590-27595	0.062	_	
174-289	27596-27600	1.67	_	
174-290	27601-27603	52	_	
174-291	27604-27605	−	_	
174-292	27605-27607	26	_	
174-293	27608-27610	14	_	
174-294	27611-27615	4.05	_	
174-295	27616-27621	0.002	_	
174-296	27624-27642	Paracentral_Lobule	_	
174-297	27643-27644	L	_	
174-298	27645-27647	74	_	
174-299	27648-27653	0.073	_	
174-300	27654-27659	0.058	_	
174-301	27660-27661	−	_	
174-302	27661-27666	0.053	_	
174-303	27667-27672	0.073	_	
174-304	27673-27677	1.98	_	
174-305	27678-27680	10	_	
174-306	27681-27682	−	_	
174-307	27682-27684	30	_	
174-308	27685-27687	60	_	
174-309	27688-27692	5.71	_	
174-310	27693-27698	0.009	_	
174-311	27701-27711	Precentral	_	
174-312	27712-27713	R	_	
174-313	27714-27717	170	_	
174-314	27718-27723	0.100	_	
174-315	27724-27729	0.065	_	
174-316	27730-27731	−	_	
174-317	27731-27736	0.047	_	
174-318	27737-27742	0.082	_	
174-319	27743-27747	2.06	_	
174-320	27748-27749	−	_	
174-321	27749-27751	42	_	
174-322	27752-27753	4	_	
174-323	27754-27756	30	_	
174-324	27757-27761	4.66	_	
174-325	27762-27767	0.005	_	
174-326	27770-27780	Precentral	_	
174-327	27781-27782	L	_	
174-328	27783-27786	130	_	
174-329	27787-27792	0.036	_	
174-330	27793-27798	0.033	_	
174-331	27799-27800	−	_	
174-332	27800-27805	0.062	_	
174-333	27806-27811	0.065	_	
174-334	27812-27816	1.97	_	
174-335	27817-27819	52	_	
174-336	27820-27821	4	_	
174-337	27822-27824	28	_	
174-338	27825-27829	4.86	_	
174-339	27830-27835	0.001	_	
174-340	27838-27853	Supp_Motor_Area	_	
174-341	27854-27855	R	_	
174-342	27856-27859	161	_	
174-343	27860-27865	0.090	_	
174-344	27866-27871	0.058	_	
174-345	27872-27873	−	_	
174-346	27873-27878	0.034	_	
174-347	27879-27884	0.070	_	
174-348	27885-27889	2.00	_	
174-349	27890-27891	−	_	
174-350	27891-27893	12	_	
174-351	27894-27896	14	_	
174-352	27897-27899	46	_	
174-353	27900-27904	5.57	_	
174-354	27905-27910	0.001	_	
174-355	27913-27928	Supp_Motor_Area	_	
174-356	27929-27930	L	_	
174-357	27931-27934	122	_	
174-358	27935-27940	0.088	_	
174-359	27941-27946	0.058	_	
174-360	27947-27948	−	_	
174-361	27948-27953	0.034	_	
174-362	27954-27959	0.071	_	
174-363	27960-27964	1.95	_	
174-364	27965-27966	8	_	
174-365	27967-27968	−	_	
174-366	27968-27970	14	_	
174-367	27971-27973	48	_	
174-368	27974-27978	4.18	_	
174-369	27979-27984	0.001	_	
174-370	27987-27995	Temporal	_	
174-371	27996-27999	Mid	_	
174-372	28000-28001	L	_	
174-373	28002-28005	178	_	
174-374	28006-28011	0.014	_	
174-375	28012-28017	0.024	_	
174-376	28018-28019	−	_	
174-377	28019-28024	0.074	_	
174-378	28025-28030	0.054	_	
174-379	28031-28035	2.19	_	
174-380	28036-28038	58	_	
174-381	28039-28040	−	_	
174-382	28040-28042	16	_	
174-383	28043-28045	I8	_	
174-384	28046-28050	4.60	_	
174-385	28051-28053	le	_	
174-386	28053-28054	-	_	
174-387	28054-28055	5	_	
174-388	28058-28070	Temporal_SuP	_	
174-389	28071-28072	L	_	
174-390	28073-28076	144	_	
174-391	28077-28082	0.047	_	
174-392	28083-28088	0.045	_	
174-393	28089-28090	−	_	
174-394	28090-28095	0.064	_	
174-395	28096-28101	0.083	_	
174-396	28102-28106	1.73	_	
174-397	28107-28109	50	_	
174-398	28110-28111	−	_	
174-399	28111-28113	28	_	
174-400	28114-28116	12	_	
174-401	28117-28121	4.99	_	
174-402	28122-28127	0.001	_	
174-403	28130-28140	Sub-region	_	
174-404	28141-28142	3	_	
174-405	28143-28144	(	_	
174-406	28145-28155	connection	_	
174-407	28156-28158	to	_	
174-408	28159-28168	occtpital	_	
174-409	28168-28169	)	_	
174-410	28180-28191	Postcentral	_	
174-411	28192-28193	R	_	
174-412	28194-28197	153	_	
174-413	28198-28203	0.073	_	
174-414	28204-28209	0.050	_	
174-415	28210-28211	−	_	
174-416	28211-28216	0.040	_	
174-417	28217-28222	0.085	_	
174-418	28223-28227	1.68	_	
174-419	28228-28229	−	_	
174-420	28229-28231	52	_	
174-421	28232-28233	−	_	
174-422	28233-28234	4	_	
174-423	28235-28237	30	_	
174-424	28238-28242	4.15	_	
174-425	28243-28248	0.001	_	
174-426	28251-28261	Piecentrai	_	
174-427	28262-28263	R	_	
174-428	28264-28267	128	_	
174-429	28268-28273	0.090	_	
174-430	28274-28279	0.056	_	
174-431	28280-28281	−	_	
174-432	28281-28286	0.039	_	
174-433	28287-28292	0.085	_	
174-434	28293-28297	1.86	_	
174-435	28298-28299	−	_	
174-436	28299-28301	48	_	
174-437	28302-28303	−	_	
174-438	28303-28304	8	_	
174-439	28305-28307	38	_	
174-440	28308-28312	4.88	_	
174-441	28313-28318	0.007	_	
174-442	28321-28333	Temporal_Sup	_	
174-443	28334-28335	R	_	
174-444	28336-28338	92	_	
174-445	28339-28344	0.042	_	
174-446	28345-28350	0.041	_	
174-447	28351-28352	−	_	
174-448	28352-28357	0.024	_	
174-449	28358-28363	0.096	_	
174-450	28364-28368	0.93	_	
174-451	28369-28370	−	_	
174-452	28370-28372	54	_	
174-453	28373-28374	−	_	
174-454	28374-28376	10	_	
174-455	28377-28379	12	_	
174-456	28380-28384	4.46	_	
174-457	28385-28390	0.009	_	
174-458	28393-28403	Sub-region	_	
174-459	28404-28405	4	_	
174-460	28406-28407	(	_	
174-461	28408-28418	connection	_	
174-462	28419-28421	to	_	
174-463	28422-28432	prefrontal	_	
174-464	28432-28433	)	_	
174-465	28444-28455	Postcentral	_	
174-466	28456-28457	R	_	
174-467	28458-28460	81	_	
174-468	28461-28466	0.060	_	
174-469	28467-28472	0.046	_	
174-470	28473-28474	−	_	
174-471	28474-28479	0.042	_	
174-472	28480-28485	0.074	_	
174-473	28486-28490	1.72	_	
174-474	28491-28492	−	_	
174-475	28492-28494	26	_	
174-476	28495-28496	−	_	
174-477	28496-28498	42	_	
174-478	28499-28501	56	_	
174-479	28502-28506	4.40	_	
174-480	28507-28509	le	_	
174-481	28509-28510	-	_	
174-482	28510-28511	5	_	
174-483	28514-28525	Postcentral	_	
174-484	28526-28527	L	_	
174-485	28528-28530	55	_	
174-486	28531-28536	0.037	_	
174-487	28537-28542	0.041	_	
174-488	28543-28544	−	_	
174-489	28544-28549	0.063	_	
174-490	28550-28555	0.068	_	
174-491	28556-28560	1.85	_	
174-492	28561-28563	20	_	
174-493	28564-28565	−	_	
174-494	28565-28567	32	_	
174-495	28568-28570	58	_	
174-496	28571-28575	4.04	_	
174-497	28576-28578	le	_	
174-498	28578-28579	-	_	
174-499	28579-28580	5	_	
174-500	28583-28593	Precentral	_	
174-501	28594-28595	R	_	
174-502	28596-28598	94	_	
174-503	28599-28604	0.090	_	
174-504	28605-28610	O.O80	_	
174-505	28611-28612	−	_	
174-506	28612-28617	0.036	_	
174-507	28618-28623	0.070	_	
174-508	28624-28628	1.74	_	
174-509	28629-28630	−	_	
174-510	28630-28632	50	_	
174-511	28633-28634	4	_	
174-512	28635-28637	34	_	
174-513	28638-28642	5.03	_	
174-514	28643-28645	le	_	
174-515	28645-28646	-	_	
174-516	28646-28647	5	_	
174-517	28650-28660	Precentral	_	
174-518	28661-28662	L	_	
174-519	28663-28665	40	_	
174-520	28666-28671	0.025	_	
174-521	28672-28677	0.036	_	
174-522	28678-28679	−	_	
174-523	28679-28684	0.076	_	
174-524	28685-28690	0.069	_	
174-525	28691-28695	1.90	_	
174-526	28696-28698	56	_	
174-527	28699-28700	0	_	
174-528	28701-28703	34	_	
174-529	28704-28708	4.71	_	
174-530	28709-28711	le	_	
174-531	28711-28712	-	_	
174-532	28712-28713	5	_	
174-533	28716-28731	Supp_Motor_Area	_	
174-534	28732-28733	R	_	
174-535	28734-28736	36	_	
174-536	28737-28742	0.054	_	
174-537	28743-28748	0.079	_	
174-538	28749-28750	−	_	
174-539	28750-28755	0.033	_	
174-540	28756-28761	0.053	_	
174-541	28762-28766	1.34	_	
174-542	28767-28768	−	_	
174-543	28768-28770	12	_	
174-544	28771-28772	0	_	
174-545	28773-28775	52	_	
174-546	28776-28780	3.91	_	
174-547	28781-28786	0.002	_	
174-548	28789-28797	Temporal	_	
174-549	28798-28801	Mid	_	
174-550	28802-28803	L	_	
174-551	28804-28806	37	_	
174-552	28807-28812	0.008	_	
174-553	28813-28818	0.038	_	
174-554	28819-28820	−	_	
174-555	28820-28825	0.071	_	
174-556	28826-28831	0.057	_	
174-557	28832-28836	1.35	_	
174-558	28837-28839	52	_	
174-559	28840-28841	−	_	
174-560	28841-28843	48	_	
174-561	28844-28845	6	_	
174-562	28846-28850	5.41	_	
174-563	28851-28856	0.002	_	
174-564	28859-28867	Temporal	_	
174-565	28868-28871	Mid	_	
174-566	28872-28873	R	_	
174-567	28874-28876	27	_	
174-568	28877-28882	0.025	_	
174-569	28883-28888	0.051	_	
174-570	28889-28890	−	_	
174-571	28890-28895	0.052	_	
174-572	28896-28901	0.044	_	
174-573	28902-28906	1.68	_	
174-574	28907-28908	−	_	
174-575	28908-28910	52	_	
174-576	28911-28912	−	_	
174-577	28912-28914	64	_	
174-578	28915-28916	6	_	
174-579	28917-28921	3.17	_	
174-580	28922-28924	le	_	
174-581	28924-28925	-	_	
174-582	28925-28926	5	_	
174-583	28929-28939	Sub-region	_	
174-584	28940-28941	5	_	
174-585	28942-28943	(	_	
174-586	28944-28954	connection	_	
174-587	28955-28957	to	_	
174-588	28958-28966	premotor	_	
174-589	28966-28967	)	_	
174-590	28978-28988	Precentral	_	
174-591	28989-28990	R	_	
174-592	28991-28994	169	_	
174-593	28995-29000	0.099	_	
174-594	29001-29006	0.061	_	
174-595	29007-29008	−	_	
174-596	29008-29013	0.050	_	
174-597	29014-29019	0.082	_	
174-598	29020-29024	2.14	_	
174-599	29025-29026	−	_	
174-600	29026-29028	44	_	
174-601	29029-29030	2	_	
174-602	29031-29033	38	_	
174-603	29034-29038	5.15	_	
174-604	29039-29041	le	_	
174-605	29041-29042	-	_	
174-606	29042-29043	5	_	
174-607	29046-29056	Precentral	_	
174-608	29057-29058	L	_	
174-609	29059-29062	153	_	
174-610	29063-29068	0.039	_	
174-611	29069-29074	0.030	_	
174-612	29075-29076	−	_	
174-613	29076-29081	0.071	_	
174-614	29082-29087	0.061	_	
174-615	29088-29092	2.37	_	
174-616	29093-29095	26	_	
174-617	29096-29097	−	_	
174-618	29097-29099	18	_	
174-619	29100-29102	64	_	
174-620	29103-29107	4.58	_	
174-621	29108-29113	0.003	_	
174-622	29116-29131	Supp_Motor_Area	_	
174-623	29132-29133	R	_	
174-624	29134-29137	123	_	
174-625	29138-29143	0.098	_	
174-626	29144-29149	0.068	_	
174-627	29150-29151	−	_	
174-628	29151-29156	0.037	_	
174-629	29157-29162	0.063	_	
174-630	29163-29167	2.14	_	
174-631	29168-29169	−	_	
174-632	29169-29171	10	_	
174-633	29172-29173	−	_	
174-634	29173-29175	16	_	
174-635	29176-29178	60	_	
174-636	29179-29183	5.64	_	
174-637	29184-29186	le	_	
174-638	29186-29187	-	_	
174-639	29187-29188	5	_	
174-640	29191-29206	Supp_Motor_Area	_	
174-641	29207-29208	L	_	
174-642	29209-29212	121	_	
174-643	29213-29218	0.100	_	
174-644	29219-29224	0.064	_	
174-645	29225-29226	−	_	
174-646	29226-29231	0.033	_	
174-647	29232-29237	0.063	_	
174-648	29238-29242	2.17	_	
174-649	29243-29245	10	_	
174-650	29246-29247	−	_	
174-651	29247-29249	18	_	
174-652	29250-29252	60	_	
174-653	29253-29257	5.61	_	
174-654	29258-29260	le	_	
174-655	29260-29261	-	_	
174-656	29261-29262	5	_	
174-657	29265-29283	Paracentral_Lobule	_	
174-658	29284-29285	L	_	
174-659	29286-29288	80	_	
174-660	29289-29294	O.O80	_	
174-661	29295-29300	0.060	_	
174-662	29301-29302	−	_	
174-663	29302-29307	0.051	_	
174-664	29308-29313	0.063	_	
174-665	29314-29318	2.21	_	
174-666	29319-29320	6	_	
174-667	29321-29322	−	_	
174-668	29322-29324	22	_	
174-669	29325-29327	58	_	
174-670	29328-29332	5.11	_	
174-671	29333-29338	0.002	_	
174-672	29341-29352	Postcentral	_	
174-673	29353-29354	R	_	
174-674	29355-29358	146	_	
174-675	29359-29364	O.O82	_	
174-676	29365-29370	0.055	_	
174-677	29371-29372	−	_	
174-678	29372-29377	0.062	_	
174-679	29378-29383	0.082	_	
174-680	29384-29388	2.14	_	
174-681	29389-29390	−	_	
174-682	29390-29392	30	_	
174-683	29393-29394	−	_	
174-684	29394-29396	36	_	
174-685	29397-29399	68	_	
174-686	29400-29404	4.10	_	
174-687	29405-29407	le	_	
174-688	29407-29408	-	_	
174-689	29408-29409	5	_	
174-690	29412-29423	Postcentral	_	
174-691	29424-29425	L	_	
174-692	29426-29429	166	_	
174-693	29430-29435	0.053	_	
174-694	29436-29441	0.041	_	
174-695	29442-29443	−	_	
174-696	29443-29448	0.066	_	
174-697	29449-29454	0.061	_	
174-698	29455-29459	2.38	_	
174-699	29460-29462	24	_	
174-700	29463-29464	−	_	
174-701	29464-29466	34	_	
174-702	29467-29469	56	_	
174-703	29470-29474	5.23	_	
174-704	29475-29480	0.004	_	
174-705	29483-29491	Temporal	_	
174-706	29492-29495	Mid	_	
174-707	29496-29497	R	_	
174-708	29498-29501	128	_	
174-709	29502-29507	0.031	_	
174-710	29508-29513	0.052	_	
174-711	29514-29515	−	_	
174-712	29515-29520	0.094	_	
174-713	29521-29526	0.048	_	
174-714	29527-29531	2.59	_	
174-715	29532-29533	−	_	
174-716	29533-29535	52	_	
174-717	29536-29537	−	_	
174-718	29537-29539	58	_	
174-719	29540-29541	0	_	
174-720	29542-29546	5.11	_	
174-721	29547-29552	0.005	_	
174-722	29555-29565	Sub-region	_	
174-723	29566-29567	6	_	
174-724	29568-29569	(	_	
174-725	29570-29580	connection	_	
174-726	29581-29583	to	_	
174-727	29584-29593	posterior	_	
174-728	29594-29602	parietal	_	
174-729	29602-29603	)	_	
174-730	29613-29631	Paracentral_Lobule	_	
174-731	29632-29633	L	_	
174-732	29634-29636	39	_	
174-733	29637-29642	0.076	_	
174-734	29643-29647	0.05	_	
174-735	29648-29649	5	_	
174-736	29650-29651	−	_	
174-737	29651-29656	0.065	_	
174-738	29657-29662	0.080	_	
174-739	29663-29667	2.13	_	
174-740	29668-29670	10	_	
174-741	29671-29672	−	_	
174-742	29672-29674	30	_	
174-743	29675-29677	60	_	
174-744	29678-29682	4.48	_	
174-745	29683-29688	0.003	_	
174-746	29691-29702	Panetal_Inf	_	
174-747	29703-29704	R	_	
174-748	29705-29707	33	_	
174-749	29708-29713	0.048	_	
174-750	29714-29718	0.06	_	
174-751	29719-29720	9	_	
174-752	29721-29722	−	_	
174-753	29722-29727	0.087	_	
174-754	29728-29733	0.065	_	
174-755	29734-29738	2.09	_	
174-756	29739-29740	−	_	
174-757	29740-29742	32	_	
174-758	29743-29744	−	_	
174-759	29744-29746	46	_	
174-760	29747-29749	52	_	
174-761	29750-29754	4.27	_	
174-762	29755-29760	0.007	_	
174-763	29763-29774	Postcential	_	
174-764	29775-29776	R	_	
174-765	29777-29780	256	_	
174-766	29781-29786	0.090	_	
174-767	29787-29791	0.06	_	
174-768	29792-29793	5	_	
174-769	29794-29795	−	_	
174-770	29795-29800	0.052	_	
174-771	29801-29806	0.085	_	
174-772	29807-29811	1.95	_	
174-773	29812-29813	−	_	
174-774	29813-29815	52	_	
174-775	29816-29817	−	_	
174-776	29817-29818	8	_	
174-777	29819-29821	36	_	
174-778	29822-29826	6.13	_	
174-779	29827-29829	le	_	
174-780	29829-29830	-	_	
174-781	29830-29831	5	_	
174-782	29834-29845	Postcentral	_	
174-783	29846-29847	L	_	
174-784	29848-29851	286	_	
174-785	29852-29857	0.044	_	
174-786	29858-29862	0.04	_	
174-787	29863-29864	5	_	
174-788	29865-29866	−	_	
174-789	29866-29871	0.070	_	
174-790	29872-29877	0.074	_	
174-791	29878-29882	1.93	_	
174-792	29883-29885	46	_	
174-793	29886-29887	−	_	
174-794	29887-29889	18	_	
174-795	29890-29892	34	_	
174-796	29893-29897	5.32	_	
174-797	29898-29903	0.003	_	
174-798	29906-29915	Precuneus	_	
174-799	29916-29917	L	_	
174-800	29918-29920	52	_	
174-801	29921-29926	0.046	_	
174-802	29927-29931	0.05	_	
174-803	29932-29933	0	_	
174-804	29934-29935	−	_	
174-805	29935-29940	0.062	_	
174-806	29941-29946	0.036	_	
174-807	29947-29951	2.57	_	
174-808	29952-29954	20	_	
174-809	29955-29956	−	_	
174-810	29956-29958	50	_	
174-811	29959-29960	2	_	
174-812	29961-29965	4.20	_	
174-813	29966-29968	le	_	
174-814	29968-29969	-	_	
174-815	29969-29970	5	_	
174-816	29973-29983	Precentral	_	
174-817	29984-29985	R	_	
174-818	29986-29989	289	_	
174-819	29990-29995	0.102	_	
174-820	29996-30000	0.07	_	
174-821	30001-30002	2	_	
174-822	30003-30004	−	_	
174-823	30004-30009	0.047	_	
174-824	30010-30015	0.086	_	
174-825	30016-30020	1.95	_	
174-826	30021-30022	−	_	
174-827	30022-30024	48	_	
174-828	30025-30026	−	_	
174-829	30026-30027	6	_	
174-830	30028-30030	28	_	
174-831	30031-30035	7.08	_	
174-832	30036-30038	le	_	
174-833	30038-30039	-	_	
174-834	30039-30040	5	_	
174-835	30043-30053	Precentral	_	
174-836	30054-30055	L	_	
174-837	30056-30059	101	_	
174-838	30060-30065	0.040	_	
174-839	30066-30070	0.03	_	
174-840	30071-30072	3	_	
174-841	30073-30074	−	_	
174-842	30074-30079	0.075	_	
174-843	30080-30085	0.067	_	
174-844	30086-30090	2.26	_	
174-845	30091-30093	50	_	
174-846	30094-30095	0	_	
174-847	30096-30098	40	_	
174-848	30099-30103	4.20	_	
174-849	30104-30109	0.008	_	
174-850	30112-30127	Supp_Motor_Area	_	
174-851	30128-30129	R	_	
174-852	30130-30133	101	_	
174-853	30134-30139	0.096	_	
174-854	30140-30144	0.06	_	
174-855	30145-30146	0	_	
174-856	30147-30148	−	_	
174-857	30148-30153	0.038	_	
174-858	30154-30159	0.061	_	
174-859	30160-30164	2.30	_	
174-860	30165-30166	−	_	
174-861	30166-30168	10	_	
174-862	30169-30170	−	_	
174-863	30170-30172	22	_	
174-864	30173-30175	64	_	
174-865	30176-30180	5.53	_	
174-866	30181-30186	0.002	_	
174-867	30189-30197	Temporal	_	
174-868	30198-30201	Mid	_	
174-869	30202-30203	R	_	
174-870	30204-30206	85	_	
174-871	30207-30212	0.027	_	
174-872	30213-30217	0.04	_	
174-873	30218-30219	4	_	
174-874	30220-30221	−	_	
174-875	30221-30226	0.089	_	
174-876	30227-30232	0.039	_	
174-877	30233-30237	2.90	_	
174-878	30238-30239	−	_	
174-879	30239-30241	52	_	
174-880	30242-30243	−	_	
174-881	30243-30245	66	_	
174-882	30246-30248	.2	_	
174-883	30249-30253	4.13	_	
174-884	30254-30259	0.001	_	
174-885	30262-30272	Sub-region	_	
174-886	30273-30274	7	_	
174-887	30275-30276	(	_	
174-888	30277-30287	connection	_	
174-889	30288-30290	to	_	
174-890	30291-30299	temporal	_	
174-891	30299-30300	)	_	
174-892	30311-30319	Temporal	_	
174-893	30320-30323	Mid	_	
174-894	30324-30325	L	_	
174-895	30326-30328	37	_	
174-896	30329-30334	0.001	_	
174-897	30335-30339	0.04	_	
174-898	30340-30341	6	_	
174-899	30342-30343	−	_	
174-900	30343-30348	0.069	_	
174-901	30349-30354	0.065	_	
174-902	30355-30359	1.29	_	
174-903	30360-30362	58	_	
174-904	30363-30364	−	_	
174-905	30364-30366	44	_	
174-906	30367-30369	.2	_	
174-907	30370-30374	3.14	_	
174-908	30375-30380	0.003	_	
174-909	30383-30395	Temporal_Sup	_	
174-910	30396-30397	L	_	
174-911	30398-30400	31	_	
174-912	30401-30406	0.020	_	
174-913	30407-30411	0.05	_	
174-914	30412-30413	1	_	
174-915	30414-30415	−	_	
174-916	30415-30420	0.038	_	
174-917	30421-30426	0.078	_	
174-918	30427-30431	0.91	_	
174-919	30432-30434	46	_	
174-920	30435-30436	−	_	
174-921	30436-30438	40	_	
174-922	30439-30441	12	_	
174-923	30442-30446	3.80	_	
174-924	30447-30452	0.030	_	
174-925	30455-30466	Postcentral	_	
174-926	30467-30468	R	_	
174-927	30469-30471	63	_	
174-928	30472-30477	0.042	_	
174-929	30478-30482	0.04	_	
174-930	30483-30484	7	_	
174-931	30485-30486	−	_	
174-932	30486-30491	0.034	_	
174-933	30492-30497	0.064	_	
174-934	30498-30502	1.40	_	
174-935	30503-30504	−	_	
174-936	30504-30506	26	_	
174-937	30507-30508	−	_	
174-938	30508-30510	42	_	
174-939	30511-30513	56	_	
174-940	30514-30518	4.61	_	
174-941	30519-30524	0.001	_	
174-942	30527-30538	Postcentral	_	
174-943	30539-30540	L	_	
174-944	30541-30543	37	_	
174-945	30544-30549	0.038	_	
174-946	30550-30554	0.04	_	
174-947	30555-30556	4	_	
174-948	30557-30558	−	_	
174-949	30558-30563	0.060	_	
174-950	30564-30569	0.069	_	
174-951	30570-30574	1.76	_	
174-952	30575-30577	38	_	
174-953	30578-30579	−	_	
174-954	30579-30581	34	_	
174-955	30582-30584	54	_	
174-956	30585-30589	3.70	_	
174-957	30590-30592	le	_	
174-958	30592-30593	-	_	
174-959	30593-30594	5	_	
174-960	30597-30607	Precentral	_	
174-961	30608-30609	R	_	
174-962	30610-30612	35	_	
174-963	30613-30618	0.077	_	
174-964	30619-30623	0.08	_	
174-965	30624-30625	1	_	
174-966	30626-30627	−	_	
174-967	30627-30632	0.035	_	
174-968	30633-30638	0.075	_	
174-969	30639-30643	1.49	_	
174-970	30644-30645	−	_	
174-971	30645-30647	28	_	
174-972	30648-30649	−	_	
174-973	30649-30651	26	_	
174-974	30652-30654	52	_	
174-975	30655-30659	3.89	_	
174-976	30660-30665	0.001	_	
174-977	30668-30678	Precentral	_	
174-978	30679-30680	L	_	
174-979	30681-30683	30	_	
174-980	30684-30689	0.017	_	
174-981	30690-30694	0.02	_	
174-982	30695-30696	8	_	
174-983	30697-30698	−	_	
174-984	30698-30703	0.056	_	
174-985	30704-30709	0.079	_	
174-986	30710-30714	1.28	_	
174-987	30715-30717	48	_	
174-988	30718-30719	−	_	
174-989	30719-30720	2	_	
174-990	30721-30723	28	_	
174-991	30724-30728	4.08	_	
174-992	30729-30734	0.005	_	
174-993	30738-30741	The	_	
174-994	30742-30747	brain	_	
174-995	30748-30755	regions	_	
174-996	30756-30760	were	_	
174-997	30761-30768	labeled	_	
174-998	30769-30778	according	_	
174-999	30779-30781	to	_	
174-1000	30782-30785	the	_	
174-1001	30786-30792	IBASPM	_	
174-1002	30793-30796	116	_	
174-1003	30797-30802	atlas	_	
174-1004	30803-30804	(	_	
174-1005	30804-30810	please	_	
174-1006	30811-30814	see	_	
174-1007	30815-30822	Methods	_	
174-1008	30823-30826	for	_	
174-1009	30827-30837	references	_	
174-1010	30837-30838	)	_	
174-1011	30838-30839	.	_	

#Text=Number of voxels that show significant group difference in this region.
175-1	30840-30846	Number	_	
175-2	30847-30849	of	_	
175-3	30850-30856	voxels	_	
175-4	30857-30861	that	_	
175-5	30862-30866	show	_	
175-6	30867-30878	significant	_	
175-7	30879-30884	group	_	
175-8	30885-30895	difference	_	
175-9	30896-30898	in	_	
175-10	30899-30903	this	_	
175-11	30904-30910	region	_	
175-12	30910-30911	.	_	

#Text=Effect size was estimated with Cohen’s d.
176-1	30912-30918	Effect	_	
176-2	30919-30923	size	_	
176-3	30924-30927	was	_	
176-4	30928-30937	estimated	_	
176-5	30938-30942	with	_	
176-6	30943-30948	Cohen	_	
176-7	30948-30949	’	_	
176-8	30949-30950	s	_	
176-9	30951-30952	d	_	
176-10	30952-30953	.	_	

#Text=Location of the voxel with the maximum (peak) T-score in the cluster in the MNI space.
177-1	30954-30962	Location	_	
177-2	30963-30965	of	_	
177-3	30966-30969	the	_	
177-4	30970-30975	voxel	_	
177-5	30976-30980	with	_	
177-6	30981-30984	the	_	
177-7	30985-30992	maximum	_	
177-8	30993-30994	(	_	
177-9	30994-30998	peak	_	
177-10	30998-30999	)	_	
177-11	31000-31007	T-score	_	
177-12	31008-31010	in	_	
177-13	31011-31014	the	_	
177-14	31015-31022	cluster	_	
177-15	31023-31025	in	_	
177-16	31026-31029	the	_	
177-17	31030-31033	MNI	_	
177-18	31034-31039	space	_	
177-19	31039-31040	.	_	

#Text=Shaded regions indicate non-primary targets of each seed (sub-thalamic region from the atlas). std: inter-subject standard deviation.
178-1	31041-31047	Shaded	_	
178-2	31048-31055	regions	_	
178-3	31056-31064	indicate	_	
178-4	31065-31076	non-primary	_	
178-5	31077-31084	targets	_	
178-6	31085-31087	of	_	
178-7	31088-31092	each	_	
178-8	31093-31097	seed	_	
178-9	31098-31099	(	_	
178-10	31099-31111	sub-thalamic	_	
178-11	31112-31118	region	_	
178-12	31119-31123	from	_	
178-13	31124-31127	the	_	
178-14	31128-31133	atlas	_	
178-15	31133-31134	)	_	
178-16	31134-31135	.	_	
178-17	31136-31139	std	_	
178-18	31139-31140	:	_	
178-19	31141-31154	inter-subject	_	
178-20	31155-31163	standard	_	
178-21	31164-31173	deviation	_	
178-22	31173-31174	.	_	

#Text=Hypo-connectivity (schizophrenia < control) between thalamic sub-regions and various brain regions in schizophrenia patients compared to controls.
179-1	31175-31192	Hypo-connectivity	_	
179-2	31193-31194	(	_	
179-3	31194-31207	schizophrenia	_	
179-4	31208-31209	<	_	
179-5	31210-31217	control	_	
179-6	31217-31218	)	_	
179-7	31219-31226	between	_	
179-8	31227-31235	thalamic	_	
179-9	31236-31247	sub-regions	_	
179-10	31248-31251	and	_	
179-11	31252-31259	various	_	
179-12	31260-31265	brain	_	
179-13	31266-31273	regions	_	
179-14	31274-31276	in	_	
179-15	31277-31290	schizophrenia	_	
179-16	31291-31299	patients	_	
179-17	31300-31308	compared	_	
179-18	31309-31311	to	_	
179-19	31312-31320	controls	_	
179-20	31320-31321	.	_	

#Text=Functional connectivity (z)\t\t\t\t\t \t\t\t\tschizophrenia\tcontrol\t\tCluster Peak d(mm, MNI)\t\t\t \tRegiona\tHemisphere\tCluster Sizeb\tmean\tstd\tmean\tstd\tEffect Sizec\tX\tV\tz\tPeak T\tAdjusted P Value\t \tSub-region 1 (connection to primary motor)\t\t\t\t\t\t\t\t \tCaudate\tL\t133\t−0.023\t0.077\t0.108\t0.057\t−2.01\t10\t12\t18\t4.65\t0.002\t \tSub-region 2 ( cormecrion to sensory )\t\t\t\t\t\t\t\t\t \tFrontal_Sup\tR\t48\t−0.059\t0.029\t0.039\t0.035\t−3.16\t−16\t26\t54\t3.92\t0.003\t \tFrontal_Sup\tL\t28\t−0.037\t0.039\t0.047\t0.041\t−2.18\t12\t32\t54\t4.00\t0.003\t \tSub-region 3 ( connection to occipital)\t\t\t\t\t\t\t\t\t \tCerebelum 8\tL\t71\t−0.020\t0.038\t0.032\t0.057\t−1.11\t42\t−54\t−52\t4.05\t0.003\t \tCerebelum 9\tL\t52\t−0.021\t0.048\t0.048\t0.077\t−1.12\t12\t−52\t−50\t4.18\t0.002\t \tSub-region 4 ( connection to prefrontal)\t\t\t\t\t\t\t\t\t \tFrontal_Mid\tL\t78\t−0.065\t0.074\t0.032\t0.056\t−1.53\t4\t17\t36\t3.90\t0.003\t \tFrontal_Inf_Tri\tL\t55\t−0.066\t0.067\t0.033\t0.081\t−1.38\t48\t46\t12\t2.87\t0.003\t \tFrontal_Inf_Oper\tL\t52\t−0.024\t0.076\t0.044\t0.076\t−0.93\t60\t12\t22\t2.81\t0.003\t \tCaudate\tL\t92\t−0.043\t0.053\t0.101\t0.076\t−2.28\t4\t18\t−4\t4.13\t0.003\t \tCmzulate Post\tR\t37\t−0.025\t0.063\t0.094\t0.072\t−1.3\t−4\t−40\t22\t4.28\t0.003\t \tSub-region 5 ( connection to premotor)\t\t\t\t\t\t\t\t\t \tFrontal_Sup\tL\t33\t−0.043\t0.050\t0.048\t0.042\t−2.05\t14\t50\t38\t4.33\t0.003\t \tCaudate\tL\t120\t−0.033\t0.067\t0.106\t0.060\t−2.27\t18\t12\t20\t3.88\t0.002\t \tSub-region 6 ( cormecrion to posterior parietal)\t\t\t\t\t\t\t\t \tFrontal Sup\tR\t82\t−0.062\t0.034\t0.045\t0.038\t−3.07\t−22\t54\t10\t4.89\t0.002\t \tFrontal Mid\tR\t64\t−0.066\t0.036\t0.028\t0.033\t−2.72\t−30\t50\t4\t4.38\t0.002\t \tCaudate\tL\t67\t−0.045\t0.062\t0.102\t0.068\t−2.34\t18\t10\t20\t5.29\t0.002\t \tCingulate_Mid\tR\t37\t−0.039\t0.044\t0.057\t0.047\t−2.19\t−2\t−32\t46\t3.39\t0.002\t \tSub-region 7 ( connection to temporal)\t\t\t\t\t\t\t\t\t \tCinzulate_Post\tR\t33\t0.002\t0.069\t0.108\t0.097\t−1.31\t−10\t−40\t18\t4.25\t0.002\t \t
#Text=The brain regions were labeled according to the IBASPM 116 atlas (please see Methods for references).
180-1	31325-31335	Functional	_	
180-2	31336-31348	connectivity	_	
180-3	31349-31350	(	_	
180-4	31350-31351	z	_	
180-5	31351-31352	)	_	
180-6	31362-31375	schizophrenia	_	
180-7	31376-31383	control	_	
180-8	31385-31392	Cluster	_	
180-9	31393-31397	Peak	_	
180-10	31398-31399	d	_	
180-11	31399-31400	(	_	
180-12	31400-31402	mm	_	
180-13	31402-31403	,	_	
180-14	31404-31407	MNI	_	
180-15	31407-31408	)	_	
180-16	31413-31420	Regiona	_	
180-17	31421-31431	Hemisphere	_	
180-18	31432-31439	Cluster	_	
180-19	31440-31445	Sizeb	_	
180-20	31446-31450	mean	_	
180-21	31451-31454	std	_	
180-22	31455-31459	mean	_	
180-23	31460-31463	std	_	
180-24	31464-31470	Effect	_	
180-25	31471-31476	Sizec	_	
180-26	31477-31478	X	_	
180-27	31479-31480	V	_	
180-28	31481-31482	z	_	
180-29	31483-31487	Peak	_	
180-30	31488-31489	T	_	
180-31	31490-31498	Adjusted	_	
180-32	31499-31500	P	_	
180-33	31501-31506	Value	_	
180-34	31509-31519	Sub-region	_	
180-35	31520-31521	1	_	
180-36	31522-31523	(	_	
180-37	31523-31533	connection	_	
180-38	31534-31536	to	_	
180-39	31537-31544	primary	_	
180-40	31545-31550	motor	_	
180-41	31550-31551	)	_	
180-42	31561-31568	Caudate	_	
180-43	31569-31570	L	_	
180-44	31571-31574	133	_	
180-45	31575-31576	−	_	
180-46	31576-31581	0.023	_	
180-47	31582-31587	0.077	_	
180-48	31588-31593	0.108	_	
180-49	31594-31599	0.057	_	
180-50	31600-31601	−	_	
180-51	31601-31605	2.01	_	
180-52	31606-31608	10	_	
180-53	31609-31611	12	_	
180-54	31612-31614	18	_	
180-55	31615-31619	4.65	_	
180-56	31620-31625	0.002	_	
180-57	31628-31638	Sub-region	_	
180-58	31639-31640	2	_	
180-59	31641-31642	(	_	
180-60	31643-31653	cormecrion	_	
180-61	31654-31656	to	_	
180-62	31657-31664	sensory	_	
180-63	31665-31666	)	_	
180-64	31677-31688	Frontal_Sup	_	
180-65	31689-31690	R	_	
180-66	31691-31693	48	_	
180-67	31694-31695	−	_	
180-68	31695-31700	0.059	_	
180-69	31701-31706	0.029	_	
180-70	31707-31712	0.039	_	
180-71	31713-31718	0.035	_	
180-72	31719-31720	−	_	
180-73	31720-31724	3.16	_	
180-74	31725-31726	−	_	
180-75	31726-31728	16	_	
180-76	31729-31731	26	_	
180-77	31732-31734	54	_	
180-78	31735-31739	3.92	_	
180-79	31740-31745	0.003	_	
180-80	31748-31759	Frontal_Sup	_	
180-81	31760-31761	L	_	
180-82	31762-31764	28	_	
180-83	31765-31766	−	_	
180-84	31766-31771	0.037	_	
180-85	31772-31777	0.039	_	
180-86	31778-31783	0.047	_	
180-87	31784-31789	0.041	_	
180-88	31790-31791	−	_	
180-89	31791-31795	2.18	_	
180-90	31796-31798	12	_	
180-91	31799-31801	32	_	
180-92	31802-31804	54	_	
180-93	31805-31809	4.00	_	
180-94	31810-31815	0.003	_	
180-95	31818-31828	Sub-region	_	
180-96	31829-31830	3	_	
180-97	31831-31832	(	_	
180-98	31833-31843	connection	_	
180-99	31844-31846	to	_	
180-100	31847-31856	occipital	_	
180-101	31856-31857	)	_	
180-102	31868-31877	Cerebelum	_	
180-103	31878-31879	8	_	
180-104	31880-31881	L	_	
180-105	31882-31884	71	_	
180-106	31885-31886	−	_	
180-107	31886-31891	0.020	_	
180-108	31892-31897	0.038	_	
180-109	31898-31903	0.032	_	
180-110	31904-31909	0.057	_	
180-111	31910-31911	−	_	
180-112	31911-31915	1.11	_	
180-113	31916-31918	42	_	
180-114	31919-31920	−	_	
180-115	31920-31922	54	_	
180-116	31923-31924	−	_	
180-117	31924-31926	52	_	
180-118	31927-31931	4.05	_	
180-119	31932-31937	0.003	_	
180-120	31940-31949	Cerebelum	_	
180-121	31950-31951	9	_	
180-122	31952-31953	L	_	
180-123	31954-31956	52	_	
180-124	31957-31958	−	_	
180-125	31958-31963	0.021	_	
180-126	31964-31969	0.048	_	
180-127	31970-31975	0.048	_	
180-128	31976-31981	0.077	_	
180-129	31982-31983	−	_	
180-130	31983-31987	1.12	_	
180-131	31988-31990	12	_	
180-132	31991-31992	−	_	
180-133	31992-31994	52	_	
180-134	31995-31996	−	_	
180-135	31996-31998	50	_	
180-136	31999-32003	4.18	_	
180-137	32004-32009	0.002	_	
180-138	32012-32022	Sub-region	_	
180-139	32023-32024	4	_	
180-140	32025-32026	(	_	
180-141	32027-32037	connection	_	
180-142	32038-32040	to	_	
180-143	32041-32051	prefrontal	_	
180-144	32051-32052	)	_	
180-145	32063-32074	Frontal_Mid	_	
180-146	32075-32076	L	_	
180-147	32077-32079	78	_	
180-148	32080-32081	−	_	
180-149	32081-32086	0.065	_	
180-150	32087-32092	0.074	_	
180-151	32093-32098	0.032	_	
180-152	32099-32104	0.056	_	
180-153	32105-32106	−	_	
180-154	32106-32110	1.53	_	
180-155	32111-32112	4	_	
180-156	32113-32115	17	_	
180-157	32116-32118	36	_	
180-158	32119-32123	3.90	_	
180-159	32124-32129	0.003	_	
180-160	32132-32147	Frontal_Inf_Tri	_	
180-161	32148-32149	L	_	
180-162	32150-32152	55	_	
180-163	32153-32154	−	_	
180-164	32154-32159	0.066	_	
180-165	32160-32165	0.067	_	
180-166	32166-32171	0.033	_	
180-167	32172-32177	0.081	_	
180-168	32178-32179	−	_	
180-169	32179-32183	1.38	_	
180-170	32184-32186	48	_	
180-171	32187-32189	46	_	
180-172	32190-32192	12	_	
180-173	32193-32197	2.87	_	
180-174	32198-32203	0.003	_	
180-175	32206-32222	Frontal_Inf_Oper	_	
180-176	32223-32224	L	_	
180-177	32225-32227	52	_	
180-178	32228-32229	−	_	
180-179	32229-32234	0.024	_	
180-180	32235-32240	0.076	_	
180-181	32241-32246	0.044	_	
180-182	32247-32252	0.076	_	
180-183	32253-32254	−	_	
180-184	32254-32258	0.93	_	
180-185	32259-32261	60	_	
180-186	32262-32264	12	_	
180-187	32265-32267	22	_	
180-188	32268-32272	2.81	_	
180-189	32273-32278	0.003	_	
180-190	32281-32288	Caudate	_	
180-191	32289-32290	L	_	
180-192	32291-32293	92	_	
180-193	32294-32295	−	_	
180-194	32295-32300	0.043	_	
180-195	32301-32306	0.053	_	
180-196	32307-32312	0.101	_	
180-197	32313-32318	0.076	_	
180-198	32319-32320	−	_	
180-199	32320-32324	2.28	_	
180-200	32325-32326	4	_	
180-201	32327-32329	18	_	
180-202	32330-32331	−	_	
180-203	32331-32332	4	_	
180-204	32333-32337	4.13	_	
180-205	32338-32343	0.003	_	
180-206	32346-32354	Cmzulate	_	
180-207	32355-32359	Post	_	
180-208	32360-32361	R	_	
180-209	32362-32364	37	_	
180-210	32365-32366	−	_	
180-211	32366-32371	0.025	_	
180-212	32372-32377	0.063	_	
180-213	32378-32383	0.094	_	
180-214	32384-32389	0.072	_	
180-215	32390-32391	−	_	
180-216	32391-32394	1.3	_	
180-217	32395-32396	−	_	
180-218	32396-32397	4	_	
180-219	32398-32399	−	_	
180-220	32399-32401	40	_	
180-221	32402-32404	22	_	
180-222	32405-32409	4.28	_	
180-223	32410-32415	0.003	_	
180-224	32418-32428	Sub-region	_	
180-225	32429-32430	5	_	
180-226	32431-32432	(	_	
180-227	32433-32443	connection	_	
180-228	32444-32446	to	_	
180-229	32447-32455	premotor	_	
180-230	32455-32456	)	_	
180-231	32467-32478	Frontal_Sup	_	
180-232	32479-32480	L	_	
180-233	32481-32483	33	_	
180-234	32484-32485	−	_	
180-235	32485-32490	0.043	_	
180-236	32491-32496	0.050	_	
180-237	32497-32502	0.048	_	
180-238	32503-32508	0.042	_	
180-239	32509-32510	−	_	
180-240	32510-32514	2.05	_	
180-241	32515-32517	14	_	
180-242	32518-32520	50	_	
180-243	32521-32523	38	_	
180-244	32524-32528	4.33	_	
180-245	32529-32534	0.003	_	
180-246	32537-32544	Caudate	_	
180-247	32545-32546	L	_	
180-248	32547-32550	120	_	
180-249	32551-32552	−	_	
180-250	32552-32557	0.033	_	
180-251	32558-32563	0.067	_	
180-252	32564-32569	0.106	_	
180-253	32570-32575	0.060	_	
180-254	32576-32577	−	_	
180-255	32577-32581	2.27	_	
180-256	32582-32584	18	_	
180-257	32585-32587	12	_	
180-258	32588-32590	20	_	
180-259	32591-32595	3.88	_	
180-260	32596-32601	0.002	_	
180-261	32604-32614	Sub-region	_	
180-262	32615-32616	6	_	
180-263	32617-32618	(	_	
180-264	32619-32629	cormecrion	_	
180-265	32630-32632	to	_	
180-266	32633-32642	posterior	_	
180-267	32643-32651	parietal	_	
180-268	32651-32652	)	_	
180-269	32662-32669	Frontal	_	
180-270	32670-32673	Sup	_	
180-271	32674-32675	R	_	
180-272	32676-32678	82	_	
180-273	32679-32680	−	_	
180-274	32680-32685	0.062	_	
180-275	32686-32691	0.034	_	
180-276	32692-32697	0.045	_	
180-277	32698-32703	0.038	_	
180-278	32704-32705	−	_	
180-279	32705-32709	3.07	_	
180-280	32710-32711	−	_	
180-281	32711-32713	22	_	
180-282	32714-32716	54	_	
180-283	32717-32719	10	_	
180-284	32720-32724	4.89	_	
180-285	32725-32730	0.002	_	
180-286	32733-32740	Frontal	_	
180-287	32741-32744	Mid	_	
180-288	32745-32746	R	_	
180-289	32747-32749	64	_	
180-290	32750-32751	−	_	
180-291	32751-32756	0.066	_	
180-292	32757-32762	0.036	_	
180-293	32763-32768	0.028	_	
180-294	32769-32774	0.033	_	
180-295	32775-32776	−	_	
180-296	32776-32780	2.72	_	
180-297	32781-32782	−	_	
180-298	32782-32784	30	_	
180-299	32785-32787	50	_	
180-300	32788-32789	4	_	
180-301	32790-32794	4.38	_	
180-302	32795-32800	0.002	_	
180-303	32803-32810	Caudate	_	
180-304	32811-32812	L	_	
180-305	32813-32815	67	_	
180-306	32816-32817	−	_	
180-307	32817-32822	0.045	_	
180-308	32823-32828	0.062	_	
180-309	32829-32834	0.102	_	
180-310	32835-32840	0.068	_	
180-311	32841-32842	−	_	
180-312	32842-32846	2.34	_	
180-313	32847-32849	18	_	
180-314	32850-32852	10	_	
180-315	32853-32855	20	_	
180-316	32856-32860	5.29	_	
180-317	32861-32866	0.002	_	
180-318	32869-32882	Cingulate_Mid	_	
180-319	32883-32884	R	_	
180-320	32885-32887	37	_	
180-321	32888-32889	−	_	
180-322	32889-32894	0.039	_	
180-323	32895-32900	0.044	_	
180-324	32901-32906	0.057	_	
180-325	32907-32912	0.047	_	
180-326	32913-32914	−	_	
180-327	32914-32918	2.19	_	
180-328	32919-32920	−	_	
180-329	32920-32921	2	_	
180-330	32922-32923	−	_	
180-331	32923-32925	32	_	
180-332	32926-32928	46	_	
180-333	32929-32933	3.39	_	
180-334	32934-32939	0.002	_	
180-335	32942-32952	Sub-region	_	
180-336	32953-32954	7	_	
180-337	32955-32956	(	_	
180-338	32957-32967	connection	_	
180-339	32968-32970	to	_	
180-340	32971-32979	temporal	_	
180-341	32979-32980	)	_	
180-342	32991-33005	Cinzulate_Post	_	
180-343	33006-33007	R	_	
180-344	33008-33010	33	_	
180-345	33011-33016	0.002	_	
180-346	33017-33022	0.069	_	
180-347	33023-33028	0.108	_	
180-348	33029-33034	0.097	_	
180-349	33035-33036	−	_	
180-350	33036-33040	1.31	_	
180-351	33041-33042	−	_	
180-352	33042-33044	10	_	
180-353	33045-33046	−	_	
180-354	33046-33048	40	_	
180-355	33049-33051	18	_	
180-356	33052-33056	4.25	_	
180-357	33057-33062	0.002	_	
180-358	33066-33069	The	_	
180-359	33070-33075	brain	_	
180-360	33076-33083	regions	_	
180-361	33084-33088	were	_	
180-362	33089-33096	labeled	_	
180-363	33097-33106	according	_	
180-364	33107-33109	to	_	
180-365	33110-33113	the	_	
180-366	33114-33120	IBASPM	_	
180-367	33121-33124	116	_	
180-368	33125-33130	atlas	_	
180-369	33131-33132	(	_	
180-370	33132-33138	please	_	
180-371	33139-33142	see	_	
180-372	33143-33150	Methods	_	
180-373	33151-33154	for	_	
180-374	33155-33165	references	_	
180-375	33165-33166	)	_	
180-376	33166-33167	.	_	

#Text=Number of voxels that show significant group difference in this region.
181-1	33168-33174	Number	_	
181-2	33175-33177	of	_	
181-3	33178-33184	voxels	_	
181-4	33185-33189	that	_	
181-5	33190-33194	show	_	
181-6	33195-33206	significant	_	
181-7	33207-33212	group	_	
181-8	33213-33223	difference	_	
181-9	33224-33226	in	_	
181-10	33227-33231	this	_	
181-11	33232-33238	region	_	
181-12	33238-33239	.	_	

#Text=Effect size was estimated with Cohen’s d.
182-1	33240-33246	Effect	_	
182-2	33247-33251	size	_	
182-3	33252-33255	was	_	
182-4	33256-33265	estimated	_	
182-5	33266-33270	with	_	
182-6	33271-33276	Cohen	_	
182-7	33276-33277	’	_	
182-8	33277-33278	s	_	
182-9	33279-33280	d	_	
182-10	33280-33281	.	_	

#Text=Location of the voxel with the maximum (peak) T-score in the cluster in the MNI space.
183-1	33282-33290	Location	_	
183-2	33291-33293	of	_	
183-3	33294-33297	the	_	
183-4	33298-33303	voxel	_	
183-5	33304-33308	with	_	
183-6	33309-33312	the	_	
183-7	33313-33320	maximum	_	
183-8	33321-33322	(	_	
183-9	33322-33326	peak	_	
183-10	33326-33327	)	_	
183-11	33328-33335	T-score	_	
183-12	33336-33338	in	_	
183-13	33339-33342	the	_	
183-14	33343-33350	cluster	_	
183-15	33351-33353	in	_	
183-16	33354-33357	the	_	
183-17	33358-33361	MNI	_	
183-18	33362-33367	space	_	
183-19	33367-33368	.	_	

#Text=Shaded regions indicate non-primary targets of each seed (sub-thalamic region from the atlas). std: inter-subject standard deviation.
184-1	33369-33375	Shaded	_	
184-2	33376-33383	regions	_	
184-3	33384-33392	indicate	_	
184-4	33393-33404	non-primary	_	
184-5	33405-33412	targets	_	
184-6	33413-33415	of	_	
184-7	33416-33420	each	_	
184-8	33421-33425	seed	_	
184-9	33426-33427	(	_	
184-10	33427-33439	sub-thalamic	_	
184-11	33440-33446	region	_	
184-12	33447-33451	from	_	
184-13	33452-33455	the	_	
184-14	33456-33461	atlas	_	
184-15	33461-33462	)	_	
184-16	33462-33463	.	_	
184-17	33464-33467	std	_	
184-18	33467-33468	:	_	
184-19	33469-33482	inter-subject	_	
184-20	33483-33491	standard	_	
184-21	33492-33501	deviation	_	
184-22	33501-33502	.	_	
